<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004109.pub2" GROUP_ID="AIRWAYS" ID="952802090410530729" MERGED_FROM="" MODIFIED="2008-07-25 18:57:30 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;30 Dec 2003&lt;br&gt;Final look by CJC. &lt;br&gt;Great! Ready for submission.&lt;br&gt;__________________________________&lt;br&gt;17.12.03&lt;br&gt;Dear Chris,&lt;/p&gt;&lt;p&gt;I am happy with the clarification of moderate dose.&lt;br&gt;We have added a couple of sentences(in red) in both the methods and the discussion to clarify the lack of significance and changed the wording of the first conclusion:&lt;/p&gt;&lt;p&gt;METHODS, ANALYSIS: Equivalence between doses was considered to be present when the 95% confidence limit for the effect size was within the limits of clinical significance for the outcome of interest. These values were: PEF 50L/min; FEV1 200ml or 10% predicted.&lt;br&gt;DISCUSSION: There was no heterogeneity amongst the studies and the confidence intervals were relatively tight. For the key outcome of PEF, the criteria for equivalence was met for each dose comparison.&lt;br&gt;CONCLUSION: The results of this review support initiating ICS at a constant moderate dose.&lt;/p&gt;&lt;p&gt;Many thanks&lt;br&gt;Heather&lt;/p&gt;&lt;p&gt;&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;12.12.2003&lt;br&gt;Dear Heather,&lt;br&gt;We are on to final touches now! There are a couple of useful suggestions from the peer reviewer:&lt;/p&gt;&lt;p&gt;Methods.&lt;br&gt;&amp;quot;High dose is defined as &amp;gt; 400 mcg/day FP or &amp;gt; 800 mcg/day BUD/BDP. This indicates that 800 BUD is high dose. In the moderate category, the BUD/BDP dosage is stated as 400-800 mcg/day. It could be clarified that this is up to 800 and does not include 800. Some of the national guidelines state &amp;quot;up to&amp;quot; 800 for clarification. &amp;quot;&lt;/p&gt;&lt;p&gt;I have changed medium dose to make this even clearer (see text in red). &lt;/p&gt;&lt;p&gt;b) Moderate dose - Adults: from 200 up to (but not including) 400 mcg/day FP or  from 400 up to (but not including) 800 mcg/day BUD or BDP.&lt;br&gt;                                 - Children: from 100 up to (but not including) 200 mcg/day FP or  from 200 up to (but not including) 400 mcg/day BUD or BDP.&lt;/p&gt;&lt;p&gt;Discussion and conclusions:&lt;br&gt;1. There could be more clarity about whether significant differences between doses have been excluded (by tight confidence intervals) or whether there is not enough data to be sure.&lt;/p&gt;&lt;p&gt;2. The back titration issue may be confusing to readers. The review does not deal with the general issue of cutting down to the minimum effective dose of ICS once patients are controlled.  It is starting high and then cutting down in initiall treatment that is being considered. The first sentence of the conclusion seemed to mitigate against any cutting down. Could you clarify that this just addresses starting doses? I have highlighted this line in red.&lt;/p&gt;&lt;p&gt;Thanks,&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;24.10.03&lt;br&gt;Dear Heather,&lt;br&gt;I am quite happy with this now. The revised wording is clearer and this can now go forward for copy editing and peer review.&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;14.10.03&lt;br&gt;Dear Chris,&lt;br&gt;We have changed the wording again to be the fold difference in dose that was compared, not fold change. We have also removed the sentence referring to clinicians adjusting the dose.  Our  reasoning for this comparison stems from the Australian asthma mangagement guidelines Step 5 (p27, 1998):&lt;/p&gt;&lt;p&gt;PEF                                                    Symptoms                                         Advice&lt;br&gt;PEF 60-80% of                               Increased or at onset of               resume or &lt;br&gt;usual best                                        upper respiratory                         double dose &lt;br&gt;                                                            tract infection                               of preventer&lt;/p&gt;&lt;p&gt;&lt;br&gt;This is common practice in Australia. It suggests a therapeutic principle that it is the relative dose that is important not the absolute dose in mcg. We tested this in the situation of intial ICS dosing. If still unclear, please suggest what you would be happy with.&lt;/p&gt;&lt;p&gt;We have also added a sentence to the discussion to clarify our final sentence.&lt;/p&gt;&lt;p&gt;Many thanks&lt;br&gt;Heather&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;3.10.2003&lt;br&gt;Dear Heather,&lt;br&gt;Thanks for making the changes I asked for. It is very helpful that you have left your changes in red! I have put them back to black but have let a few red bits for you to look at (see below).&lt;br&gt;This looks good. I have left the section on Fold Changes in Red as  I am not comfortable with this still (sorry). I have obtained a copy of the Gershman paper to try to understand the issues better here. The study compares 100 and 1000mcg of FP in parallel.  This is included in High v Lo dose and Fold change outcomes. There is not any CHANGE in dose in this paper so I cannot see how it applies to a clinician considering change in dose in stable asthma.  The comparison is around USE of doses at different ratios. I may be stupid here but what is the question this outcome seeks to answer and do the trials permit this? I think you are taking the opportunity to cut the data in a different way (rather than high moderate and low) and this is fine.  It is the application to clinicians changing dose that I am unhappy about. Can you discuss this with Peter and see if there is a different form of words around this.&lt;br&gt;Finally I have put the final sentence of the discussion in red as it reads as if you disagree with step down of ICS for controlled asthma and I am SURE this is not what you had in mind.&lt;br&gt;Cheers,&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;__________________________________________________________&lt;/p&gt;&lt;p&gt;&lt;br&gt;1.10.03&lt;br&gt;Dear Chris&lt;br&gt;Thankyou for your comments. We have made the recommmended changes and I have answered your queries below in capitals. I have also change 3#3 to WMD&lt;br&gt;Heather&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;Editing by CJC 12/9/2003&lt;/p&gt;&lt;p&gt;Authors' Contribution - fine&lt;/p&gt;&lt;p&gt;Objectives - efficacy is being tested in RCTs rather than effectiveness&lt;/p&gt;&lt;p&gt;References - fine&lt;/p&gt;&lt;p&gt;Table of included studies - What are the washout times in the parallel trials??? I am only familiar with this in cross-overs.&lt;br&gt;ONE STUDY (LORENTZSON) HAD A WASHOUT FOR SUBJECTS ON ORAL BETA AGONIST PRIOR TO COMMENCEMENT.  ANOTHER 3 STUDIES WERE EITHER FOLLOWED UP FOR 3 MONTHS OR HAD A PLACEBO OR FP RUNOUT FOR BOTH TREATMENT GROUPS. TO MAKE THIS CLEARER I HAVE REMOVED THE WASHOUT PHASE FOR THE PARALLEL STUDIES AND INCLUDED THESE DETAILS IN 'OTHER'&lt;br&gt;&amp;gt;&amp;gt;&amp;gt;Thanks&lt;/p&gt;&lt;p&gt;Metaview Labels - fine. Does the title of 1#8 mean proportion of patients whose asthma was adequately controlled? Could the title be made a little clearer? in 2#1 the children have a higher FEV1 than the adults (is this % predicted?) YES. In general it would be very helpful to have the units of the outcome in the title for the reader (puffs per day, litres per minute etc). I do not understand the meaning of fold change in dose in comparison five - is there another form of words that would be clearer?&lt;br&gt;WE HAVE REPHRASED OUR EXPLANATIOON FOR FOLD CHANGE DOSE (IN RED IN THE FOLD CHANGE COMPARISON). TITLES FOR THE META- ANALYSES HAVE BEEN CLARIFED SHOWING UNIT OF MEASUREMENT&lt;br&gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;Thanks&lt;/p&gt;&lt;p&gt;&lt;br&gt;Synopsis - Minor changes only. Back-titration will not make sense to consumers.&lt;/p&gt;&lt;p&gt;Abstract - Please add date of last search. ADDED&lt;/p&gt;&lt;p&gt;Please see other minor changes in red.&lt;/p&gt;&lt;p&gt;Methods: fine&lt;/p&gt;&lt;p&gt;Results: &amp;quot;There was no heterogeneity present but some inconsistency was present (I2 = 26%) between studies for daytime beta agonist use.&amp;quot; I have changed low to some for this reported I square result. OK&lt;br&gt;&amp;quot;When these results were pooled there was no significant difference in withdrawals due to adverse events for constant ICS compared to step down ICS.&amp;quot; Non significant increase altered to no significant difference. OK&lt;br&gt;&amp;quot;Studies using FP and BUD, all &amp;gt; 12 weeks duration showed no significant difference between high and moderate dose ICS, while the study using BDP, &amp;lt; 12 weeks duration, significantly favoured high dose ICS. &amp;quot; &lt;br&gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;I have highlighted this in red as it is not valid to compare trials according to whether they reach statistical significance or not. Compared to each other the CIs overlap and without testing I am sure that these sub-group differences are NOT significant. I suggest a re-write indicating no difference between drugs or cut this out completely............&lt;br&gt;THIS HAS BEEN REMOVED&lt;/p&gt;&lt;p&gt;Morning Peak Flow (high v mod)&lt;br&gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;As Litres per second are not commonly used I would convert the mean and SD for the Majima trial to litres per min (multiply all by 60) and report as WMD.&lt;br&gt;DONE&lt;/p&gt;&lt;p&gt;I have changed non significant difference to no significant difference.&lt;br&gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;&amp;gt;Same problem as a above with the BUD FP comparisons....... ?remove.&lt;br&gt;REMOVED&lt;/p&gt;&lt;p&gt;Moderate v Low Dose&lt;br&gt;&amp;quot;Morning PEF l/min change from baseline (adults): WMD 11.14 (95% CI 1.34 to 20.93)&lt;br&gt;When examined by individual ICS and device the improvement did not show any significant difference between FP and BUD.&lt;br&gt;Morning PEF l/min change from baseline (BUD): WMD 10.69 (95% CI -2.78 to 24.16)&lt;br&gt;Morning PEF l/min change from baseline (FP): WMD 11.63 (95% CI -2.64 to 25.91)&amp;quot;&lt;br&gt;I have reworded this - it is not appropriate to assess whether each drug reaches significance as the power will drop due to smaller group sizes! OK&lt;br&gt;&amp;gt;&amp;gt;&amp;gt;&amp;quot;When examined by ICS the pooled result of the two FP studies maintained its significance but there was no difference for the study conducted using BUD.&lt;br&gt;Symptom score (night waking) BUD: SMD 0.0 (95%CI -0.47 to 0.47). Symptom score (night waking) FP: SMD -0.39 (95%CI -0.66 to -0.12). &amp;quot;&lt;br&gt;Same problem as above - ?remove this.&lt;br&gt;REMOVED&lt;/p&gt;&lt;p&gt;PS I have changed no difference to no significant difference throughout.&lt;/p&gt;&lt;p&gt;Discussion : fine&lt;/p&gt;&lt;p&gt;Contentious issues &lt;/p&gt;&lt;p&gt;Spellchecked: not yet.&lt;/p&gt;&lt;p&gt;Next action: Heather this is an excellent review but needs a little tidying up (especially in relation to subgroup comparison reporting).  Please get back to me if you are not clear about my concerns.&lt;br&gt;Chris.&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: #High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children&lt;br&gt;Old title: #High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children (WITH CHRIS  151003)&lt;br&gt;Old title: =High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children (PEER REVIEW COMMENTS WITH CHRIS 011203)&lt;br&gt;Old title: #High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children&lt;br&gt;Old title: =High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children (WITH CHRIS 221203)&lt;br&gt;Old title: #High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children (WITH CHRIS  151003)&lt;/p&gt;" NOTES_MODIFIED="2008-07-25 17:55:54 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="HVL-AST" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-07-25 18:57:30 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children</TITLE>
<CONTACT MODIFIED="2008-07-25 18:57:30 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="4647" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Gibson</LAST_NAME><EMAIL_1>Peter.Gibson@hnehealth.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory and Sleep Medicine</DEPARTMENT><ORGANISATION>John Hunter Hospital</ORGANISATION><ADDRESS_2>Locked Bag 1</ADDRESS_2><CITY>Hunter Mail Centre</CITY><ZIP>2310</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 498555766</PHONE_1><FAX_1>+ 61 2 49855850</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-07-25 18:57:30 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="12480" ROLE="AUTHOR"><FIRST_NAME>Heather</FIRST_NAME><LAST_NAME>Powell</LAST_NAME><POSITION>Research Data Manager</POSITION><EMAIL_1>Heather.Powell@hnehealth.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory &amp; Sleep Medicine</DEPARTMENT><ORGANISATION>John Hunter Hospital</ORGANISATION><ADDRESS_2>Locked Bag 1</ADDRESS_2><CITY>Hunter Region Mail Centre</CITY><ZIP>2310</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>02 49213446</PHONE_1></ADDRESS></PERSON><PERSON ID="4647" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Gibson</LAST_NAME><EMAIL_1>Peter.Gibson@hnehealth.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory and Sleep Medicine</DEPARTMENT><ORGANISATION>John Hunter Hospital</ORGANISATION><ADDRESS_2>Locked Bag 1</ADDRESS_2><CITY>Hunter Mail Centre</CITY><ZIP>2310</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 498555766</PHONE_1><FAX_1>+ 61 2 49855850</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-25 18:57:30 +0200" MODIFIED_BY="Toby Lasserson">
<UP_TO_DATE>
<DATE DAY="20" MONTH="8" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="8" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="25" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="8" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Cooperative Research Centre for Asthma</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Garfield Weston Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-25 17:49:24 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-07-25 17:35:30 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-25 17:35:30 +0100" MODIFIED_BY="Toby J Lasserson">High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children</TITLE>
<SUMMARY_BODY MODIFIED="2008-07-25 17:35:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Guidelines vary in their recommendations for the initial dose of inhaled corticosteroid (ICS) for asthma. This review compared initial ICS doses for asthma . The results showed that commencing with a moderate dose ICS is as effective as commencing with a high dose ICS and then reducing the dose whilst monitoring symptoms. These results also show that initial moderate dose ICS maybe more effective than initial low dose ICS. No extra benefit was gained by doubling or quadrupling the starting ICS dose. People with asthma should start their treatment with low to moderate doses of ICS.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-25 17:35:32 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>Inhaled corticosteroids (ICS) form the basis of maintenance therapy in asthma and their efficacy is well established. However, the optimal starting dose of ICS is not clearly established. Recent reviews demonstrate a relatively flat efficacy curve for ICS and increasing side effects with increasing ICS doses. High doses are frequently prescribed and there are now reports of significant side effects occurring with high dose ICS use. These issues demonstrate the need to establish the optimal starting dose of ICS in asthma.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To establish the optimal starting dose of ICS by evaluating the efficacy of initial high dose ICS with low dose ICS in subjects with asthma, not currently on ICS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Airways Group trials register and reference lists of articles.Date of last search: January 2003<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of two different doses of the same ICS in adults and children with asthma with no concomitant ICS or OCS.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trial quality was assessed and data were extracted independently by two reviewers. Study authors were contacted for confirmation. Trials were analysed according to the following ICS dose comparisons: step down vs constant dose ICS (n=7); high vs moderate (n=11); high vs low (n=9); moderate vs low (n=11); fold change in dose (all studies). </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-07-25 17:35:32 +0100" MODIFIED_BY="Toby J Lasserson">
<P>31 papers reporting the results of 26 trials were included in the review. For studies that compared a step down approach to a constant moderate/low ICS dose, there were no significant differences in lung function, symptoms, rescue medications or asthma control between the two treatment approaches. Significant but clinically small improvements in percent predicted FEV1 ( WMD 5.32, 95% CI 0.65 to 9.99) and non significant improvements in the change in morning PEF were found for high dose ICS compared to moderate dose ICS. There were no significant differences in efficacy between high and low dose ICS. For moderate dose ICS, compared to low dose ICS, there were significant improvements in the change in morning PEF l/min from baseline (WMD 11.14, 95% CI 1.34 to 20.93) and nocturnal symptoms (SMD -0.29, 95% CI -0.53 to -0.06 ) . Commencing ICS at double or quadruple a base moderate or low dose had no greater effect than commencing with the base dose. Several studies reported greater improvement in airway hyperresponsiveness for high dose ICS.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>For patients with asthma who require ICS, commencing with a moderate dose ICS is equivalent to commencing with a high dose ICS and down-titrating. The small significant benefits of commencing with a high ICS dose are not of sufficient clinical benefit to warrant its use when compared to moderate or low dose ICS. Initial moderate ICS dose appears to be more effective than initial low ICS dose. High dose ICS may be more effective than moderate or low dose ICS for airway hyperresponsiveness. There is no benefit in doubling or quadrupling ICS in subjects with stable asthma.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-25 17:49:24 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND>
<P>The use of inhaled corticosteroids (ICS) is very effective in reducing mortality and morbidity from asthma (<LINK REF="REF-Suissa-2001" TYPE="REFERENCE">Suissa 2001</LINK>). Inhaled corticosteroids form the basis of maintenance therapy in asthma (<LINK REF="REF-NAC-2002" TYPE="REFERENCE">NAC 2002</LINK>; <LINK REF="REF-NIH-2002" TYPE="REFERENCE">NIH 2002</LINK>), and target the airway inflammatory process that is a key pathophysiological characteristic of asthma (<LINK REF="REF-Barnes-1998" TYPE="REFERENCE">Barnes 1998</LINK>). Systematic reviews of randomised controlled trials of inhaled corticosteroid use have established their efficacy as maintenance treatment of asthma (<LINK REF="REF-Adams-2002" TYPE="REFERENCE">Adams 2002</LINK>; <LINK REF="REF-Adams-2002-_x0028_b_x0029_" TYPE="REFERENCE">Adams 2002 (b)</LINK>; <LINK REF="REF-Adams-2002-_x0028_c_x0029_" TYPE="REFERENCE">Adams 2002 (c)</LINK>). However, the optimal starting dose of ICS is not clearly established.</P>
<P>A systematic review has shown that, with increasing doses of inhaled corticosteroids, there is an increase in side effects (<LINK REF="REF-Adams-2002" TYPE="REFERENCE">Adams 2002</LINK>). Reviews also demonstrate that there is a relatively flat efficacy curve for inhaled corticosteroid use where greater than 90% of the benefit is achieved at low doses (e.g. fluticasone propionate 250 mcg/day) (<LINK REF="REF-Holt-2001" TYPE="REFERENCE">Holt 2001</LINK>; <LINK REF="REF-Adams-2002" TYPE="REFERENCE">Adams 2002</LINK>; <LINK REF="REF-Powell-2003" TYPE="REFERENCE">Powell 2003</LINK>). Very high doses of inhaled corticosteroids are frequently prescribed in clinical practice (<LINK REF="REF-Black-2000" TYPE="REFERENCE">Black 2000</LINK>) and there are now reports of significant side-effects occurring with high dose inhaled corticosteroid use (<LINK REF="REF-Todd-2002" TYPE="REFERENCE">Todd 2002</LINK>). These issues demonstrate the need to establish the optimal starting dose of inhaled corticosteroid in asthma.</P>
<P>The Global Initiative against Asthma (GINA) guidelines for asthma management recommend a wide range of starting doses, between 200 to 1000 mcg beclomethasone-equivalent per day (<LINK REF="REF-NIH-2002" TYPE="REFERENCE">NIH 2002</LINK>). Some guidelines recommend starting with a high dose of inhaled corticosteroid and then back-titrating the dose (step down) (<LINK REF="REF-NAC-2002" TYPE="REFERENCE">NAC 2002</LINK>). In contrast, other guidelines either do not specify a starting dose (<LINK REF="REF-NIH-2002" TYPE="REFERENCE">NIH 2002</LINK>) or recommend starting with moderate to low doses of inhaled corticosteroid (<LINK REF="REF-BTS_x002f_SIGN-2003" TYPE="REFERENCE">BTS/SIGN 2003</LINK>; <LINK REF="REF-NZGG-2003" TYPE="REFERENCE">NZGG 2003</LINK>). Randomised controlled trials have compared the effect of starting with high dose inhaled corticosteroid, with some studies then back titrating, or starting with low dose inhaled corticosteroid. This review aims to assess the efficacy of initial inhaled corticosteroid doses for the treatment of asthma.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this systematic review is to establish the optimal starting dose of inhaled corticosteroid by evaluating the efficacy of constant high dose, constant moderate dose, constant low dose, and initial high dose inhaled corticosteroid followed by low dose inhaled corticosteroids (step down) in subjects with asthma, not currently treated with inhaled corticosteroids.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-25 17:39:25 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Prospective randomised controlled trials only were eligible for inclusion in the review. Trials using either a parallel or crossover design and double, single or unblinded studies were considered.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults and children with non-oral steroid dependent asthma (defined by doctor's diagnosis, objective lung function or according to American Thoracic Society guidelines).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Interventions that compared two different doses of the same inhaled corticosteroid with no concomitant oral or inhaled corticosteroid therapy, and no recent use of inhaled corticosteroids (at least 1 month) were permitted. Treatment duration was required to be a minimum of 4 weeks. Delivery may be by metered dose inhaler (pMDI) with or without a valved holding device (spacer), dry powder inhaler (DPI) or nebuliser.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The following outcomes were evaluated: asthma symptoms, lung function, exacerbations, unscheduled visits to the doctor, ER visits, hospitalisation, airway hyperresponsiveness, asthma control.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-25 17:37:01 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-07-25 17:37:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Cochrane Airways Group's register derived from MEDLINE, EMBASE, CINAHL, hand searched respiratory journals and meeting abstracts. The register was searched using the following terms: </P>
<P>(asthma OR wheez*) AND (step* OR high* dose OR low* dose) AND (inhaled corticoster* OR beclometh* OR triamcin* OR flutic* OR budes* OR betameth* OR flunis* OR cicles* OR momet*)</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-25 17:36:49 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Full text versions of the relevant papers were obtained, and their bibliographic lists hand searched for additional articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-25 17:39:25 +0100" MODIFIED_BY="Toby J Lasserson">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2008-07-25 17:37:41 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The full text version of each potentially relevant article was obtained for assessment by two independent reviewers to establish whether it met the inclusion criteria. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-25 17:39:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Two authors extracted data from the studies independently. Study investigators were contacted to verify and provide further information about methodological approaches and outcomes data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-25 17:38:05 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Study quality was assessed independently and scored by two reviewers using two instruments. The first, the Jadad system (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>), allows for a score between 0 and 5 with higher scores indicating a better description of the study. The Jadad system measures the clarity of the description of: randomisation (1 point, 2 points if well described and appropriate), blinding (1point, 2 points if well described and appropriate) and treatment of withdrawals and dropouts (1 point). One point is deducted if the method of randomisation or blinding is inappropriate. Studies were further assessed, using the Cochrane method, as "Adequate", "Inadequate" or "Unclear" according to the actual methods used for randomisation and concealment of allocation. In this assessment, if studies are either not truly randomised (e.g. alternated) or if allocation to treatment or control groups is not truly blinded, studies are considered "inadequate". If the author does not fully state these methods, the study is characterised as "unclear" until the author is contacted and clarification can be made.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-25 17:39:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Outcomes were analysed as continuous and/or dichotomous variables, using standard statistical techniques.<BR/>i) For continuous outcomes, the weighted mean difference or standardised mean difference with 95% confidence intervals was calculated as appropriate.</P>
<P>ii) For dichotomous outcomes, the relative risk was calculated with 95% confidence interval.<BR/>Heterogeneity was examined using a Chi-squared test and reasons for heterogeneity explored where appropriate.<BR/>Equivalence between doses was considered to be present when the 95% confidence limit for the effect size was within the limits of clinical significance for the outcome of interest. These values were: PEF 50L/min; FEV1 200ml or 10% predicted.</P>
<P>Five primary comparisons were made. These were determined by the strength of the ICS dose and the type of intervention - step down or constant dose being compared. ICS dose was classified according to British Thoracic Society guidelines (<LINK REF="REF-BTS_x002f_SIGN-2003" TYPE="REFERENCE">BTS/SIGN 2003</LINK>) as:<BR/>a) High dose - Adults: <U>&gt;</U> 400 mcg/day of fluticasone propionate (FP) or <U>&gt;</U> 800 mcg/day budesonide (BUD) or beclomethasone (BDP)<BR/>- Children:<U>&gt;</U> 200 mcg/day FP or <U>&gt;</U> 400 mcg/day BUD or 400 mcg BDP.<BR/>b) Moderate dose - Adults: from 200 up to (but not including) 400 mcg/day FP or from 400 up to (but not including) 800 mcg/day BUD or BDP.<BR/>- Children: from 100 up to (but not including) 200 mcg/day FP or from 200 up to (but not including) 400 mcg/day BUD or BDP.<BR/>c) Low dose - &lt; 200 mcg/day FP or &lt; 400 mcg/day BUD or BDP.<BR/>- Children: &lt; 100 mcg/day FP or &lt; 200 mcg/day BUD or BDP.</P>
<P>The primary comparisons were:<BR/>1) Step Down vs Constant ICS Dose<BR/>2) High vs Moderate ICS Dose<BR/>3) High vs Low ICS Dose<BR/>4) Moderate vs Low ICS Dose<BR/>5) Fold difference in ICS dose: two or four fold increased ICS vs base ICS dose</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-07-25 17:38:14 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Outcomes were analysed according to:<BR/>i) Delivery device (nebuliser / pMDI / DPI)<BR/>ii) Age (infants / children / adults)<BR/>iii) Design (parallel / crossover)<BR/>iv) Duration of treatment (&lt;= 12 weeks / &gt; 12 weeks)<BR/>v) ICS type</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-25 17:49:24 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-07-25 17:40:26 +0100" MODIFIED_BY="Toby J Lasserson">
<P>31 publications describing 26 RCTs met the inclusion criteria for the review. Full details of the studies are provided in the characteristics of the included studies table. Disagreement on eligibility for inclusion was resolved by consensus. Agreement was 94%, kappa 0.88.</P>
<SUBSECTION>
<HEADING LEVEL="5">PARTICIPANT CHARACTERISTICS</HEADING>
<P>Twenty studies had a multicentre design. Three of these were conducted in general practice, one in a medical centre and eight in outpatient clinics. The remaining eight multicentre trials did not state where they were conducted. Two trials were conducted as single centre outpatient trials and the remaining four did not state where the trial was conducted.</P>
<P>Participants in seven studies were ICS naive. In four studies the inclusion criteria included no current ICS use and 15 studies excluded potential participants who had used ICS in the previous 4 weeks to six months prior to commencement of the study. One trial (<LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK>) allowed participants to use intranasal ICS.</P>
<P>The majority of studies were conducted in adults (n = 17) with five studies conducted in children (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>; <LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>; <LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>) and four in infants (<LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK>; <LINK REF="STD-Bisgaard-1999" TYPE="STUDY">Bisgaard 1999</LINK>; <LINK REF="STD-Volovitz-1998" TYPE="STUDY">Volovitz 1998</LINK>; <LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">INTERVENTION</HEADING>
<P>The majority of studies (n = 15) were comparisons of BUD dose. Seven studies compared different doses of FP, three studies compared beclomethasone (BDP) doses and one study incorporated both BDP and FP comparisons (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). In six studies, three arms of three doses of the same ICS were compared (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>; <LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>; <LINK REF="STD-Sheffer-1996" TYPE="STUDY">Sheffer 1996</LINK>; <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>). Two studies included a third treatment arm of another asthma medication. This included theophylline (<LINK REF="STD-Pedersen-1996" TYPE="STUDY">Pedersen 1996</LINK>) and salbutamol (<LINK REF="STD-Majima-1993" TYPE="STUDY">Majima 1993</LINK>). A placebo arm as well as dose comparison was included in 15 studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">DESIGN</HEADING>
<P>Parallel group design was used in 24 studies. One of these studies, (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>), had one arm each using FP in one and BDP in the other. These ICS doses were increased every six weeks for 18 weeks, and then a three week run out period on high dose FP. This study was not included in any meta analysis due to the differing study design. The two remaining studies were of crossover design (<LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>). These two studies had three arms with three four week treatment periods. <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK> incorporated a two week run in before commencement of the intervention. Neither of these studies used a washout between treatment periods. These two studies (<LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>) did not provide sufficient data to be included in any meta analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">DOSE</HEADING>
<P>Seven studies incorporated a step down versus constant ICS dose. Six of these used BUD, 800-1600 mcg/day reducing to 200 mcg/day compared to a constant dose of 200-400 mcg /day for the four adult trials (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>; <LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>; <LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>) and nebulised BUD 2 mg reducing to 0.5 mg vs 0.5 mg in the infant studies (<LINK REF="STD-Volovitz-1998" TYPE="STUDY">Volovitz 1998</LINK>; <LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>). One study compared FP 1000 mcg/day reducing to 100 mcg /day vs 200 mcg/day (<LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>).</P>
<P>Eleven studies compared high dose versus moderate dose ICS. Three of these studies used the step down approach and measured outcomes prior to stepping down ICS (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>). High vs low dose ICS were compared in nine studies, two of these using the step down approach and measuring outcomes prior to step down (<LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>; <LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>). Moderate vs low dose ICS were compared in 11 trials. This included one trial that included two low dose ICS arms (<LINK REF="STD-Sheffer-1996" TYPE="STUDY">Sheffer 1996</LINK>). Four studies included three arms comparing high, moderate and low dose ICS (<LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>; <LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>;<LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>; <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). One study compared low, medium and high dose ICS in increasing doses (step up) (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). The comparison of two low ICS doses was made in two studies (<LINK REF="STD-Hampel-2000" TYPE="STUDY">Hampel 2000</LINK>; <LINK REF="STD-Sheffer-1996" TYPE="STUDY">Sheffer 1996</LINK>).</P>
<P>Full details of the dose comparisons are described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">DURATION</HEADING>
<P>Treatment periods ranged from a minimum of four weeks through to 24 months. The 24 month trial (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>) had an initial treatment period of 12 weeks with some participants continuing for 24 months. Outcome data was collected at 12 weeks. The majority of studies (n = 18) were conducted over a four to 12 week period. Another two studies had a duration of 16 weeks (<LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>; <LINK REF="STD-O_x0027_Byrne-1996" TYPE="STUDY">O'Byrne 1996</LINK>), one study of 18 weeks ( <LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>) and three studies of 24 weeks (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK>; <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). Two studies were conducted over nine and 12 months (<LINK REF="STD-Pedersen-1996" TYPE="STUDY">Pedersen 1996</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">DEVICES</HEADING>
<P>A dry powder inhaler (DPI) was used to deliver ICS in nine studies. Twelve studies used a metered dose inhaler (pMDI) with six of these also using a spacer device. A nebuliser was used in two of the infant studies(<LINK REF="STD-Volovitz-1998" TYPE="STUDY">Volovitz 1998</LINK>; <LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>). Three studies did not state the method of ICS delivery.</P>
<P/>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ASTHMA SEVERITY</HEADING>
<P>Asthma severity was determined from the study reports using percent predicted FEV1 stated as an inclusion criteria or the mean percent predicted FEV1 of participating subjects. Asthma severity was defined according to Australian Asthma Management Guidelines (<LINK REF="REF-NAC-2002" TYPE="REFERENCE">NAC 2002</LINK>) as mild: FEV1 &gt; 80% predicted, moderate: FEV1 60-80% predicted and severe: FEV1 &lt;60% predicted. The majority of studies included participants with mild to moderate asthma (n = 8). Mild asthma was represented in four studies, moderate asthma in four studies and four studies included participants with moderate to severe asthma (<LINK REF="STD-Bisgaard-1999" TYPE="STUDY">Bisgaard 1999</LINK>; <LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>; <LINK REF="STD-Sheffer-1996" TYPE="STUDY">Sheffer 1996</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>). In six studies the level of asthma severity was unable to be determined. In three studies this was due to reporting mean FEV1 instead of percent predicted, one study reported entry criteria of symptoms present a minimum of six days per month (<LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>), <LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK> included participants with recurrent wheeze, and one study's entry criteria were wheezing more than 40% of the days in the past three months (<LINK REF="STD-Volovitz-1998" TYPE="STUDY">Volovitz 1998</LINK>). In one study (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>) 1% of participants had severe asthma.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Methodological quality was good for the majority of studies. All the included trials were randomised controlled trials with 22 of them double blinded. Two trials did not specify the type of blinding (<LINK REF="STD-Majima-1993" TYPE="STUDY">Majima 1993</LINK>; <LINK REF="STD-Hampel-2000" TYPE="STUDY">Hampel 2000</LINK>), one trial was 'open label' (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>) and one single blind (<LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK>). Using the Jadad system, 81% of the studies scored three or higher, with four trials scoring two and one trial with a score of one (<LINK REF="STD-Majima-1993" TYPE="STUDY">Majima 1993</LINK>). It is possible that this trial was of higher quality but due to the limitations of translation this could not be determined. Quality assessed by the Cochrane method was unclear for 15 studies with 11 trials adequately reporting the method of allocation concealment.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-25 17:49:24 +0100" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="5">STEP DOWN VERSUS CONSTANT ICS DOSE</HEADING>
<P>In seven studies initial high dose ICS that was subsequently stepped down was compared to a constant ICS dose. 1396 participants were randomised and in six studies 844 participants completed the study. One study (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>) reported a withdrawal rate of 33% due to adverse events, worsening asthma and non-compliance (55% of withdrawals). The total duration of treatment varied from 10 weeks (<LINK REF="STD-Volovitz-1998" TYPE="STUDY">Volovitz 1998</LINK>) to 12 months (<LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>). The duration of high dose ICS prior to step down was one week (<LINK REF="STD-Volovitz-1998" TYPE="STUDY">Volovitz 1998</LINK>), three weeks (<LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>), four weeks (<LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>; <LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>; <LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>), six weeks (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>) and two months (<LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>). In two studies, ICS dose was only reduced if participants fitted predefined criteria for dose reduction (<LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>) or their asthma was controlled (<LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>). Two studies, at step down, reduced the dose from b.i.d to a once daily dose (<LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>; <LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>). The step down ICS dose was reduced to a lower dose than the constant ICS dose in two studies (<LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>) and reduced to the same dose as the constant dose comparison in the remaining five studies. Four studies were conducted in adults, one in children and two in infants. Where appropriate, subgroup analyses were conducted for age, ICS type, device (if stated) and duration.<BR/>These seven studies reported the following results:</P>
<SUBSECTION>
<HEADING LEVEL="6">Lung Function</HEADING>
<P>FEV1, measured as percent predicted, was reported in four studies(<LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>; <LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>; <LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>), however there was insufficient data provided to perform a meta analysis. All four studies reported no significant difference between the treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Peak Flow (PEF)</HEADING>
<P>Five studies reported morning PEF, three as l/min (<LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>; <LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>) and two as change from baseline (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>). There was no significant difference in morning PEF for step down ICS dose compared to a constant ICS dose. This non-significance extended to both adults, children and ICS type separately for morning PEF l/min. There was no heterogeneity present. All studies included in these meta analyses were conducted for &gt; 12 weeks and used either DPI or did not state the method of delivery (<LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>).<BR/>Morning PEF l/min (adults and children): WMD -0.91 (95%CI -26.13 to 24.30)<BR/>Morning PEF l/min change from baseline (adults): WMD 0.83 (95%CI -8.6 to 10.26)<BR/>
<BR/>No significant difference between treatment groups for evening PEF l/min was reported in one study (<LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Symptoms</HEADING>
<P>All seven studies reported symptoms. Overall, there was no significant difference between the two treatment approaches. Symptoms improved for both treatment groups with no significant difference between the groups in three studies (<LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>; <LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>). Symptoms were measured as a score in the remaining four studies. All four studies used a score of 0-3 where no symptoms equalled a score of zero and severe symptoms a score of three. <LINK REF="STD-Volovitz-1998" TYPE="STUDY">Volovitz 1998</LINK> reported a reduction in symptoms for both treatment groups that was greater for the step down group particularly for wheeze. Day and night symptom scores were reported in three studies, one as a mean score (<LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>) and two as diary card symptom score change from baseline (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>). No significant difference between treatment groups in day and night symptoms was reported and no significant heterogeneity present with the pooled results. Both studies included in these meta analyses were conducted in adults using BUD via a DPI for &gt; 12 weeks.<BR/>Diary card symptom score (day) change from baseline (adults): WMD -0.07 (95% CI -0.16 to 0.03)<BR/>Diary card symptom score (night) change from baseline (adults): WMD 0.06 (95% CI -0.04 to 0.15)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rescue <I>m</I>edications</HEADING>
<P>Rescue medication use was measured in five trials. Three trials reported a reduction in beta agonist use for both treatment groups (<LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>; <LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>; <LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>). Day and night beta agonist use was reported separately in two trials, both in adults using BUD via a DPI for &gt; 12 weeks, as the change from baseline in mean puffs per day or night (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>). Meta analyses were able to be performed for these two outcomes. There was no significant difference for the change in nighttime or daytime beta agonist use. There was no heterogeneity present but some inconsistency was present (I<SUP>2 </SUP>= 26%) between studies for daytime beta agonist use.<BR/>Rescue medications (day) change from baseline (adults): WMD -0.18 (95% CI -0.45 to 0.08)<BR/>Rescue medications (night) change from baseline (adults): WMD -0.04 (95% CI -0.13 to 0.05)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse events</HEADING>
<P>Adverse events were recorded as the number of participants who withdrew due to an adverse event in two studies in adults (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>). When these results were pooled there was no significant difference in withdrawals due to adverse events for constant ICS compared to step down ICS. There was no heterogeneity present. Both studies included in the meta analysis were conducted in adults using BUD via a DPI for &gt; 12 weeks.<BR/>Withdrawal due to adverse event (adults): RR 1.54 (95% CI 0.73 to 3.24)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Asthma control</HEADING>
<P>There was no reported difference in time taken to achieve control of asthma for step down or constant dose ICS in infants (<LINK REF="STD-Wennergren-1996" TYPE="STUDY">Wennergren 1996</LINK>) or adults (<LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>). Two studies in adults using BUD via a DPI for &gt; 12 weeks, reported the number of participants achieving asthma control (<LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>; <LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>). There was no significant difference and no heterogeneity present for these pooled results.<BR/>Asthma control (adults): RR 1.0 (95% CI 0.87 to 1.16)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Airway <I>h</I>yperresponsiveness</HEADING>
<P>In a study in children <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK> reported an improvement in airway hyperresponsiveness for both stepdown and constant ICS groups. This was higher for the step down ICS at four months but there was no significant difference between the dose groups in airway hyperresponsiveness at completion of the study after 12 months.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HIGH VERSUS MODERATE ICS DOSE</HEADING>
<P>High dose ICS were compared to moderate dose ICS in 11 studies. 1749 participants were randomised with 10 studies reporting 1294 participants completing the studies. Three studies that were included in the step down comparison have also been included in this comparison using outcome data collected prior to stepping down the high dose ICS at four, six and eight weeks respectively (<LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>; <LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>; <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK>). The remaining eight studies were between six weeks and nine months duration.</P>
<P>Three studies had three dosage arms of high, moderate and low dose ICS (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>). The high and moderate ICS dose comparisons were used in this analysis. A parallel design was used in nine studies, crossover design of three four week treatment periods in one study (<LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>) and a step up design of two ICS in another (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). Subgroup analysis was conducted for age, ICS type, device(if stated) and duration of study.</P>
<P>
<I>Lung Function</I>
<BR/>FEV1 was reported in eight studies as litres, percent predicted and litres change from baseline. No significant difference between high and moderate dose ICS was reported in four studies (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>; <LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>). Four studies reporting percent predicted FEV1 provided sufficient data to be pooled using a WMD. There was a significant improvement in FEV1 in favour of the high dose group with no statistical heterogeneity.<BR/>FEV1 % predicted (All): WMD 5.32 (95% CI 0.65 to 9.99)<BR/>When analysed by age this remained significant for adults but there was no significant difference between high and moderate dose ICS for children. The pooled sample sizes were small: adults = 55, children = 75.<BR/>FEV1 % predicted (adults): WMD 10.34 (95% CI 2.45 to 18.24)<BR/>FEV1 % predicted (children): WMD 2.61 (95% CI -3.18 to 8.4)<BR/>

</P>
<SUBSECTION>
<HEADING LEVEL="6">Morning Peak Flow</HEADING>
<P>Four studies reported morning PEF as l/min.There was no significant difference between treatment groups in morning PEF reported in one study (<LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK>) and a significant improvement for all treatment groups with difference between treatment groups not stated in an other study (<LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>). No significant difference was found when the results of two studies, both using a DPI and &lt; 12 weeks duration were pooled. This was consistent for age and ICS type. There was no heterogeneity.<BR/>Morning PEF (All): WMD 7.91 (95% CI -16.17 to 32.0)</P>
<P>Morning PEF was reported as the change in l/min from baseline in five studies conducted in adults. When these studies were pooled there was no significant difference between the treatment groups in favour of high dose ICS. No heterogeneity was present. These results remained non significant when analysed by device and duration of the study. 
<BR/>
Morning PEF l/min change from baseline (All): WMD 5.72 (95% CI -1.56 to 13.0)
<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Evening Peak Flow</HEADING>
<P>Four studies reported evening PEF as l/min (n=2) and l/min change from baseline (n=2). No significant difference between treatment groups was reported in all four studies. A significant test for trend suggesting a dose response relationship was reported in one study (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Symptoms</HEADING>
<P>Symptoms were reported in seven studies as both day and night symptoms, proportion of participants reporting symptoms, symptom score and symptom score change from baseline. <LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK> reported significant dose-response relationships for symptom scores. Symptoms reduced for both treatment groups in four studies with no significant difference between treatment groups in two studies (<LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>; <LINK REF="STD-O_x0027_Byrne-1996" TYPE="STUDY">O'Byrne 1996</LINK>) and significance not stated in two studies (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>
<I>; </I>
<LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>). There was no significant difference in two studies, conducted in adults using BUD via a DPI for 12 weeks or less, when the results were pooled. Both studies used the same 0-3 scale. No heterogeneity was present.<I>
<BR/>
</I>Symptom score (day ) change from baseline: WMD 0.02 (95% CI -0.06 to 0.11)<BR/>Symptom score (night) change from baseline: WMD 0.02 (95% CI -0.06 to 0.10)<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rescue <I>m</I>edications</HEADING>
<P>Five studies reported the use of rescue medication. Two studies, both in adults using BUD for 12 weeks or less, reported beta agonist use as the change in puffs per day or night from baseline (<LINK REF="STD-Campbell--1998" TYPE="STUDY">Campbell 1998</LINK>
<I>; </I>
<LINK REF="STD-Chanez-2001" TYPE="STUDY">Chanez 2001</LINK>). The pooled results showed no significant difference between treatment groups for day or night rescue medication use and no heterogeneity.<I>
<BR/>
</I>Rescue medications (day) change from baseline: WMD -0.11(95% CI -0.39 to 0.17)<BR/>Rescue medications (night) change from baseline: WMD -0.03(95% CI -0.12 to 0.05)</P>
<P>The remaining three studies reported reductions in rescue medication use for both treatment groups with no significant difference between groups in one study (<LINK REF="STD-Pedersen-1996" TYPE="STUDY">Pedersen 1996</LINK>) and significance not stated in two studies (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>).</P>
<P>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Airway hyperresponsiveness</HEADING>
<P>Airway hyperresponsiveness was measured in five studies either as PC20 or after exercise challenge. There was insufficient data provided to perform a meta analysis. In the three studies conducted in children, (<LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>) reported a significant difference between high and moderate dose BUD in fall in FEV1% after exercise in favour of the high dose group (p&lt;0.0001). <LINK REF="STD-Visser-2001" TYPE="STUDY">Visser 2001</LINK> reported an improvement in AHR for both FP treatment groups that was significantly higher for the high dose group at four months. In a study of FP conducted in children by <LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK> PD20 was higher for the high dose group at 24 weeks but not significant and AHR (exercise) was significantly reduced for both FP groups.</P>
<P>In the remaining two studies conducted in adults using FP and BDP ( <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>) and BUD ( <LINK REF="STD-Pedersen-1996" TYPE="STUDY">Pedersen 1996</LINK>), no significant differences between high and moderate dose ICS for AHR were reported at completion of the study. However in the study using BUD, although non significant, the improvement was greater in the high dose group.</P>
<P>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse Events</HEADING>
<P>Withdrawal Due to Adverse Event<I>
<BR/>
</I>Two studies ( <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>; <LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>) conducted in adults reported the number of participants who withdrew due to an adverse event. There was no significant difference between high or moderate BUD or FP and no heterogeneity. Both studies were less than 12 weeks duration and used a DPI for delivery of ICS.<BR/>Withdrawal due to adverse event (adults): RR 0.59 (95%CI 0.14 to 2.43)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Oral Candidiasis</HEADING>
<P>In the two studies reporting oral candidiasis <LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK> reported no cases in either treatment group and there was no significant difference in oral candidiasis between high and moderate FP in the study conducted by <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Inflammatory markers</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Blood Eosinophils</HEADING>
<P>Blood eosinophils decreased for both high and moderate dose BUD in one study ( <LINK REF="STD-Pedersen-1996" TYPE="STUDY">Pedersen 1996</LINK>). These decreases were more rapid in the high dose group than the moderate dose group despite there being no significant difference between treatment groups at the end of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Serum ECP</HEADING>
<P>Two studies reported the results of high and moderate ICS dose on serum ECP. No significant changes were reported for either FP group in a study conducted in children ( <LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK>). ECP reduced after 9 months on low dose BUD and after 1 month on high dose BUD (<LINK REF="STD-Pedersen-1996" TYPE="STUDY">Pedersen 1996</LINK>).</P>
<P>

</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HIGH VERSUS LOW ICS DOSE</HEADING>
<P>In nine studies high dose ICS was compared to low dose ICS. Three of these studies included a third arm of moderate dose ICS which was analysed in the previous comparison (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>). One study using the step down approach reported outcomes prior to step down (<LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>). 1136 participants were randomised with eight studies reporting 730 completing. Parallel design was used in six studies in adults, two studies in infants and children used a crossover design (<LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>), and one adult study stepped up medication every six weeks (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). Duration ranged from four to 24 weeks. Results were analysed by age, ICS type, device and duration.</P>
<SUBSECTION>
<HEADING LEVEL="6">Lung Function</HEADING>
<P>Six studies reported FEV1 as percent predicted FEV1, litres or change from baseline. Two studies in adults of 12 weeks or less duration, reporting FEV1 as percent predicted and in litres were pooled in a meta analysis. There were no significant differences in FEV1 between high dose ICS and low dose ICS and no statistical heterogeneity was present. This was consistent when analysed by ICS type, device and duration of study.<BR/>FEV1 (All):SMD -0.20 (95% CI -0.55 to 0.16)</P>
<P>No significant differences between treatment groups were reported in the remaining four studies for FEV1 (<LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>; <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>), or FEV1 change from baseline (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Morning Peak Flow</HEADING>
<P>Morning peak flow was measured in five studies as l/min. Morning PEF was not significantly different between high and low ICS dose (<LINK REF="STD-Tukiainen--2000" TYPE="STUDY">Tukiainen 2000</LINK>) and improvements for both treatment groups were reported in another study (<LINK REF="STD-Pirozynski-1996" TYPE="STUDY">Pirozynski 1996</LINK>). When the results of two studies conducted in adults, and less than 12 weeks duration, were pooled in a meta analysis there was no significant difference in morning PEF. This was consistent for both ICS type and device with no statistical heterogeneity.<BR/>Morning PEF (All): WMD -18.05 (95% CI -56.04 to 19.95)</P>
<P>Two studies reported morning PEF l/min as the change from baseline. Both studies were conducted in adults using BUD via a DPI and for less than 12 weeks. When these results were pooled there was no significant improvement in morning PEF in favour of high dose BUD. Statistical heterogeneity was not present, however there was moderate inconsistency between the studies.<BR/>Morning PEF change from baseline (adults): WMD 12.0 (95% CI -1.50 to 25.51). Chi<SUP>2</SUP> =2.06, p=0.15, I<SUP>2 </SUP>= 51.6%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Evening Peak Flow</HEADING>
<P>Evening PEF was reported in two studies as l/min (<LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>; <LINK REF="STD-Tukiainen--2000" TYPE="STUDY">Tukiainen 2000</LINK>) and change from baseline (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>). No significant difference between treatment groups was reported by all four studies. <LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK> reported a significant test for trend suggesting a dose response relationship.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Symptoms</HEADING>
<P>Seven studies reported symptoms both as day and night symptoms and symptom score . Symptoms reduced for both treatment groups with no significant difference between groups in five studies (<LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK>; <LINK REF="STD-Gershman-2000" TYPE="STUDY">Gershman 2000</LINK>; <LINK REF="STD-Tukiainen--2000" TYPE="STUDY">Tukiainen 2000</LINK>; <LINK REF="STD-van-der-Molen--1998" TYPE="STUDY">van der Molen 1998</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>) and reduced in two studies with significance not stated (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rescue medications</HEADING>
<P>The use of rescue medications was reported in five studies. There was no significant difference in beta agonist use (puffs/day) in adults and no heterogeneity present when the results of two studies of 12 weeks or less and reporting rescue medication use were pooled. Significant heterogeneity ws not present but there was moderate inconsistency between the two studies.<BR/>Rescue Medications: WMD -0.04 (95%CI -0.65 to 0.56). Chi<SUP>2</SUP> =2.36, p=0.12, I<SUP>2</SUP> =57.6%.<BR/>When analysed by ICS type there was a non significant trend for less rescue medication use in the high dose treatment group for the study conducted using FP via a pMDI and no significant difference between BUD treatment groups.</P>
<P>The three remaining studies (<LINK REF="STD-Bisgaard-1993" TYPE="STUDY">Bisgaard 1993</LINK>; <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>) reported reductions in rescue medication use with both treatments, and significance not stated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Airway hyperresponsiveness</HEADING>
<P>Four studies measured airway hyperresponsiveness either as PC20 or after exercise challenge. There was insufficient data provided to perform a meta analysis. In the study conducted in children, <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK> reported a significant difference between high and low dose BUD in fall in FEV1% after exercise in favour of the high dose group (p&lt;0.001).</P>
<P>In the remaining three studies conducted in adults the study using FP (<LINK REF="STD-Gershman-2000" TYPE="STUDY">Gershman 2000</LINK>) reported no significant differences between high and low dose ICS for AHR. <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>, using both BDP and FP reported a maximum change in PC20 at low dose FP and at moderate dose BDP with significance between high and low dose ICS not stated. In a study of BUD <LINK REF="STD-Tukiainen--2000" TYPE="STUDY">Tukiainen 2000</LINK> reported, although non significant, an improvement that was greater in the high dose group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse events</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Withdrawal Due to Adverse Event</HEADING>
<P>Two studies (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>) conducted in adults reported the number of participants who withdrew due to an adverse event. There was no significant difference between high or low BUD or FP. Significant heterogeneity was not present but there was low to moderate inconsistency between the studies. Both studies were less than 12 weeks duration and used a DPI for delivery of ICS.<BR/>Withdrawal due to adverse event (adults): RR 0.56 (95%CI 0.14 to 2.33).Chi2 =1.61, p=0.20, I<SUP>2</SUP> =38.0%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Oral Candidiasis</HEADING>
<P>There was no significant difference in oral candidiasis between high and low dose FP in one study (<LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Inflammatory markers</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Blood Eosinophils</HEADING>
<P>
<LINK REF="STD-Tukiainen--2000" TYPE="STUDY">Tukiainen 2000</LINK> reported a significantly greater decrease in blood eosinophils for the high dose BUD group compared to the low dose group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Serum ECP</HEADING>
<P>Two studies reported the results of high and moderate ICS dose on serum ECP. Serum ECP decreased significantly for the high dose BUD group with no change for the low dose group in one study (<LINK REF="STD-Tukiainen--2000" TYPE="STUDY">Tukiainen 2000</LINK>). <LINK REF="STD-Gershman-2000" TYPE="STUDY">Gershman 2000</LINK> reported significant decreases for both FP groups but no significant differences between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Sputum Eosinophils</HEADING>
<P>
<LINK REF="STD-Gershman-2000" TYPE="STUDY">Gershman 2000</LINK> reported a significant reduction in sputum eosinophils after 14 days treatment for both high and low FP groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">MODERATE VERSUS LOW ICS DOSE</HEADING>
<P>1971 participants were randomised in 11 studies to moderate or low dose ICS with 1743 completing the studies. Seven studies were conducted in adults, three in children and one in infants. The duration of treatment was from four to 24 weeks. Four studies included in the high vs moderate ICS dose comparison that had a third arm of low dose ICS were able to be analysed in this comparison (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>; <LINK REF="STD-Wasserman-1996" TYPE="STUDY">Wasserman 1996</LINK>; <LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). One study was a crossover design (<LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>) and one study of two treatments stepped up therapy every six weeks (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>). Results were analysed by age, ICS type, device and duration.</P>
<SUBSECTION>
<HEADING LEVEL="6">Lung Function</HEADING>
<P>FEV1 was reported as the change from baseline in litres or percent predicted in six studies. There was no significant difference in moderate or low dose ICS for FEV1 change from baseline when analysed by age, ICS type, device or duration in the five studies that were pooled for this analysis. There was no heterogeneity.<BR/>FEV1 change from baseline (adults &amp; children): SMD 0.11 (-0.06 to 0.28)</P>
<P>One study (<LINK REF="STD-Szefler-2002" TYPE="STUDY">Szefler 2002</LINK>) reported FEV1 (L) reaching a maximum at moderate dose BDP and at low dose FP.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Morning PEF</HEADING>
<P>Three studies in children reported PEF l/min. Two of these studies (<LINK REF="STD-Nayak-2002" TYPE="STUDY">Nayak 2002</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>) did not state the difference between the treatment groups but compared them to a placebo arm. <LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK> reported no significant difference between the treatment groups for PEF. There was a significant improvement in PEF l/min change from baseline in favour of a moderate ICS dose for the five studies in adults, all less than 12 weeks duration, that were pooled for this analysis. No heterogeneity was present.<BR/>Morning PEF l/min change from baseline (adults): WMD 11.14 (95% CI 1.34 to 20.93)<BR/>When examined by individual ICS and device the improvement did not show any significant difference between FP and BUD.<BR/>Morning PEF l/min change from baseline (BUD): WMD 10.69 (95% CI -2.78 to 24.16)<BR/>Morning PEF l/min change from baseline (FP): WMD 11.63 (95% CI -2.64 to 25.91)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Evening PEF</HEADING>
<P>There was no significant difference in evening PEF l/min change from baseline between moderate and low dose ICS as reported in three adult studies of less than 12 weeks duration. This was consistent for device with no heterogeneity.<BR/>Evening PEF l/min change from baseline (adults): WMD 4.30 (95%CI -6.16 to 14.75)<BR/>When analysed by ICS type there was a non significant trend for improvement in evening PEF for FP but not BUD.<BR/>Evening PEF l/min change from baseline (BUD): WMD -0.52 (95%CI -13.55 to 12.51)<BR/>Evening PEF l/min change from baseline (FP): WMD 13.0 (95%CI -4.52 to 30.52)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">PEF Diurnal Variation</HEADING>
<P>PEF diurnal variation was measured in two studies in adults with BUD using a DPI and less than 12 weeks duration as l/min (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>) and percent (<LINK REF="STD-Jatakanon-1999" TYPE="STUDY">Jatakanon 1999</LINK>) change from baseline. The improvement in favour of moderate dose ICS was not significant and showed no heterogeneity.<BR/>PEF diurnal variation change from baseline (adults): SMD -0.28 (95%CI -0.63 to 0.07)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Symptoms</HEADING>
<P>Symptoms were reported in nine studies. <LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK> reported significant dose-response relationships for symptom scores. No significant differences were reported for moderate compared to low dose ICS for symptom scores (<LINK REF="STD-Noonan-1998" TYPE="STUDY">Noonan 1998</LINK>), diary card symptoms (<LINK REF="STD-Bisgaard-1999" TYPE="STUDY">Bisgaard 1999</LINK>), mean symptom free days (<LINK REF="STD-Miyamoto-2000" TYPE="STUDY">Miyamoto 2000</LINK>) and symptom score change from baseline (<LINK REF="STD-Lorentzson-1990" TYPE="STUDY">Lorentzson 1990</LINK>). Symptoms were reduced for all treatment groups in two studies (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>; <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK>). Two studies in adults using the same 0-3 scale reported symptom score change from baseline(<LINK REF="STD-Noonan-1998" TYPE="STUDY">Noonan 1998</LINK>; <LINK REF="STD-Jatakanon-1999" TYPE="STUDY">Jatakanon 1999</LINK>). There was no significant difference in reduction in symptom score when these results were pooled, however significant heterogeneity and high inconsistency were present.<BR/>Symptom Score change from baseline (adults):WMD -0.04 (95%CI -0.21 to 0.13).<BR/>When examined by ICS type there was a significant improvement in symptom score from baseline for moderate dose BUD using a DPI (<LINK REF="STD-Jatakanon-1999" TYPE="STUDY">Jatakanon 1999</LINK>) and no significant difference between moderate and low dose FP using a pMDI (<LINK REF="STD-Noonan-1998" TYPE="STUDY">Noonan 1998</LINK>). Both studies were of less than 12 weeks duration.</P>
<P>There was a significant reduction of symptoms (night waking) from baseline in favour of moderate dose ICS when the results of three studies, two using the same 0 to 3 scaled symptom score and one study reporting as mean number of awakenings were pooled. There was no heterogeneity. All three studies were conducted in adults using a pMDI and less than 12 weeks duration.<BR/>Symptom score (night waking): SMD -0.29 (95%CI -0.53 to -0.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rescue Medication</HEADING>
<P>Rescue medications were measured as the change in number of puffs from baseline in five studies. <LINK REF="STD-Lorentzson-1990" TYPE="STUDY">Lorentzson 1990</LINK> reported no significant difference between moderate and low dose BUD for reduction in day or night beta agonist use compared to baseline. When the results of the remaining four studies were pooled the reduction in beta agonist use for moderate dose ICS was not significant. This was consistent for age, ICS type and device with no heterogeneity. The studies were all less than 12 weeks in duration.<BR/>Rescue Medications change from baseline (adults &amp; children): WMD -0.35 (95% CI -0.98 to 0.28)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Airway <I>h</I>yperresponsiveness</HEADING>
<P>There were no significant differences between moderate and low dose ICS for PD20 in three studies (<LINK REF="STD-Jatakanon-1999" TYPE="STUDY">Jatakanon 1999</LINK>; <LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>; <LINK REF="STD-Noonan-1998" TYPE="STUDY">Noonan 1998</LINK>). However <LINK REF="STD-Jatakanon-1999" TYPE="STUDY">Jatakanon 1999</LINK> reported a trend in favour of increasing BUD doses and <LINK REF="STD-Noonan-1998" TYPE="STUDY">Noonan 1998</LINK> reported this to be non significantly greater for the moderate dose group. <LINK REF="STD-Pedersen-1995" TYPE="STUDY">Pedersen 1995</LINK> reported significant differences in favour of the moderate dose BUD group for AHR post exercise challenge.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse events</HEADING>
<P>There were no significant differences and no heterogeneity between moderate and low dose ICS for the seven studies that reported this outcome either as withdrawal due to adverse event or as adverse events. This was consistent for age, ICS type, device and duration of study.<BR/>Withdrawal due to adverse event (all): RR 1.0 (95% CI 0.41 to 2.46)<BR/>Adverse events (all): RR 1.04 (95% CI 0.93 to 1.17)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Oral Candidiasis</HEADING>
<P>Two studies using FP reported the incidence of oral candidiasis, one in adults(<LINK REF="STD-Sheffer-1996" TYPE="STUDY">Sheffer 1996</LINK>) and one in infants (<LINK REF="STD-Bisgaard-1999" TYPE="STUDY">Bisgaard 1999</LINK>). There was no significant difference between moderate and low dose ICS when these results were pooled. Statistical heterogeneity was present and there was high inconsistency between the two studies.<BR/>Oral candidiasis (adults &amp; infants): RR 0.90 (95% CI 0.34 to 2.39), Chi<SUP>2</SUP> =3.91, p=0.05, I<SUP>2</SUP> =74.4%.<BR/>This was consistent for both device and duration of the study. When analysed by age, there were non significantly fewer reporting of oral candidiasis in the low dose ICS group for adults and the moderate dose ICS group for infants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Exacerbations</HEADING>
<P>Exacerbations were reported in two studies with no significant difference between moderate and low dose ICS for children or infants. This was consistent for ICS type, device and duration of study. No statistical heterogeneity was present.<BR/>Exacerbations (children &amp; infants): RR 0.82 (95% CI 0.47 to 1.43)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Plasma Cortisol</HEADING>
<P>A non significant proportion of participants randomised to low dose ICS were reported to have a plasma cortisol level below the reference range in two studies conducted in adults and children. No heterogeneity was present and no significant difference in subgroup analysis.<BR/>Plasma cortisol below reference range (adults &amp; children): RR 0.62 (95% CI 0.30 to 1.27)<I>
<BR/>
</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Other Outcomes</HEADING>
<P>No significant differences between treatment groups were reported for serum eosinophils or ECP in one study in children (<LINK REF="STD-Jonasson-1998" TYPE="STUDY">Jonasson 1998</LINK>). In a study in adults <LINK REF="STD-Jatakanon-1999" TYPE="STUDY">Jatakanon 1999</LINK> reported significant reductions in sputum eosinophils and exhaled nitrous oxide with no significant difference between the treatment groups.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">FOLD DIFFERENCE IN ICS DOSE</HEADING>
<P>ICS dose can also be examined as a fold increase over the comparator. We therefore included an analysis examining fold difference in ICS dose. All included studies were analysed according to the fold difference in ICS dose compared to the ICS dose used in the control group. Studies were classified using either a two fold ICS dose increase (n=9), a four fold increase or greater (n=11) or both two and four fold ICS dose increases, when compared to the ICS dose used by the control group (n=5). One study compared a three fold increase in ICS (<LINK REF="STD-Hofstra--2000" TYPE="STUDY">Hofstra 2000</LINK>). For the studies using the step down approach the outcomes reported prior to step down were used. The following are the results of the pooled analyses.</P>
<SUBSECTION>
<HEADING LEVEL="6">Lung Function</HEADING>
<P>Five studies measuring FEV1 as l/min or percent predicted were pooled using the SMD. There was no significant difference in FEV1 between the base ICS dose and a four fold increased ICS dose in four studies. No heterogeneity was present and there was low inconsistency between the studies.<BR/>FEV1 (&gt;= 4 Fold): SMD 0.04 (95% CI -0.23 to 0.31).</P>
<P>FEV1 reported as the change from baseline was not significantly greater for both a four fold increase in ICS (n=3) and a two fold increase in ICS dose (n=5). No heterogeneity was present, however there was moderate inconsistency between the four fold studies.<BR/>FEV1 change from baseline (&gt;= 4 Fold): SMD 0.18 (95% CI -0.08 to 0.43). Chi<SUP>2</SUP> = 4.08, p = 0.13, I<SUP>2</SUP> = 51.0%.<BR/>FEV1 change from baseline (2 Fold): SMD 0.14 (95% CI -0.01 to 0.29).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Morning Peak Flow</HEADING>
<P>Four studies reported morning PEF as l/min or l/second. There was no significant difference in morning PEF between a four fold increased ICS dose(n=3) or a two fold increased ICS dose (n=1) and the base dose. No heterogeneity was present.<BR/>Morning PEF (&gt;= 4 Fold): SMD -0.03 (95% CI -0.36 to 0.29)<BR/>Morning PEF (2 Fold): SMD -0.51 (95% CI -1.67 to 0.65).<BR/>There was a significant improvement in the change in morning PEF from baseline favouring both the four fold (n=5) and two fold (n=8) increased dose. There was no heterogeneity.<BR/>Morning PEF change from baseline (&gt;= 4 Fold): WMD 10.21(95% CI 1.75 to 18.67)<BR/>Morning PEF change from baseline (2 Fold): WMD 6.8 (95% CI 0.75 to 12.84).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Evening Peak Flow</HEADING>
<P>Evening PEF was reported as the change from baseline. In the one study that compared a four fold increase in ICS dose there was a non significant improvement in favour of the four fold dose. There was no significant difference in improvement in evening PEF from baseline between the two fold increased dose and the base dose when the results of four studies were pooled. Heterogeneity was not present.<BR/>Evening PEF change from baseline (&gt;= 4 Fold): SMD 15.0 (95% CI -6.39 to 36.39)<BR/>Evening PEF change from baseline (2 Fold): SMD 2.37 (95% CI -5.78 to 10.53).<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">PEF Diurnal Variation</HEADING>
<P>In the three studies measuring this outcome the improvement in PEF diurnal variation in favour of both a four fold and a two fold increase in ICS compared to the base dose was not significant.<BR/>PEF Diurnal Variation (&gt;= 4 Fold): SMD -0.32 (95% CI -0.66 to 0.03)<BR/>PEF Diurnal Variation (2 Fold): SMD -0.21 (95% CI -0.59 to 0.16).<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Symptoms</HEADING>
<P>Symptoms were reported as the change in both day and night symptoms scores from baseline. There was no difference in improvement in daytime symptom score between a two fold increased ICS dose and the base ICS dose in the pooled result of two studies. In a single study comparing a four fold increased ICS dose there was a non significant improvement in favour of the base ICS dose.<BR/>Symptom score (day ) change from baseline (&gt;= 4 fold): WMD 0.11 (95%CI -0.08 to 0.30)<BR/>Symptom score (day ) change from baseline ( 2 fold): WMD 0.0 (95%CI -0.09 to 0.09)<BR/>There was an improvement in night time symptom score for all treatment groups with no significant difference between a two fold increase and a base dose (n=4) and a non significant difference in favour of a four fold increase (n=2), however heterogeneity was present in the four fold analysis.<BR/>Symptom score (night) change from baseline (&gt;= 4 fold): SMD -0.17 (95% -0.38 CI to 0.05), Chi<SUP>2</SUP> =3.42, p=0.06, <I>I<SUP>2</SUP>
</I> =71%<BR/>Symptom score (night) change from baseline (2 fold): SMD -0.02 (95% CI -0.15 to 0.11)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rescue <I>m</I>edications</HEADING>
<P>Rescue medication use reported as the change from baseline of either the number of puffs or puffs per day, was no different for either a four fold ICS dose (n=2) or two fold ICS dose (n=4) compared to a base ICS dose and no heterogeneity.<I>
<BR/>
</I>Rescue medications change from baseline (&gt;= 4 fold): SMD -0.11 (95%CI -0.42 to 0.19)<BR/>Rescue medications change from baseline (2 fold): SMD -0.01 (95%CI -0.16 to 0.15)<BR/>This lack of a difference was also evident when rescue medications were measured as day and night use change from baseline.<BR/>Rescue medications (day) change from baseline (&gt;= 4 fold): WMD -0.10 (95%CI -0.37 to 0.57)<BR/>Rescue medications (day) change from baseline (2 fold): WMD -0.21 (95%CI -0.55 to 0.14)<BR/>Rescue medications (night)change from baseline (&gt;= 4 fold): WMD -0.10(95%CI -0.42 to 0.22)<BR/>Rescue medications (night) change from baseline (2 fold): WMD -0.03 (95%CI -0.11 to 0.06)<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse events</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Withdrawal Due to Adverse Event</HEADING>
<P>There was no significant difference in the risk of withdrawing due to an adverse event between a four fold increased ICS (n=2) or a two fold increased ICS (n=5) compared to base ICS dose and no statistical heterogeneity. However low to moderate inconsistency was present for the two four fold studies.<BR/>Withdrawal due to adverse event (&gt;= 4 fold): RR 0.56 (95% CI 0.14 to 2.33), Chi<SUP>2</SUP> = 1.61, p = 0.2, I<SUP>2</SUP> = 38.0%.<BR/>Withdrawal due to adverse event (2 fold): RR 1.09 (95% CI 0.49 to 2.42)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Oral Candidiasis</HEADING>
<P>There was no significant difference in incidences of oral candidiasis in the pooled results of four studies comparing a two fold ICS increase to a base dose and the two studies comparing a four fold increase in ICS dose and no heterogeneity. There was low inconsistency between the four fold studies and the two fold studies.<BR/>Oral Candidiasis (&gt;= 4 fold): RR 2.30 (95% CI 0.68 to 7.83), Chi<SUP>2</SUP> = 1.46, p = 0.23, I<SUP>2</SUP> = 31.4%<BR/>Oral Candidiasis (2 fold): RR 0.66 (95% CI 0.27 to 1.64), Chi<SUP>2</SUP> = 2.28, p = 0.32, I<SUP>2</SUP> = 12.1%</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Plasma Cortisol</HEADING>
<P>A non significant greater proportion of participants were reported to have a plasma cortisol level below the reference range in the base dose groups for both the four fold and the two fold comparisons.<BR/>Plasma Cortisol below ref range (&gt;=4 fold): RR 0.63 (95%CI 0.18 to 2.14)<BR/>Plasma Cortisol below ref range (2 fold): RR 0.62 (95%CI 0.30 to 1.27)</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This systematic review evaluated the results of 26 RCTs that compared initial ICS doses in asthma. We evaluated the effects of starting ICS at a high dose, plus or minus a subsequent step down, to commencing with a moderate or low dose ICS. In light of differing guideline recommendations, and the frequent prescription of high dose ICS with subsequent significant side effects, it is important to establish the optimal starting dose for ICS in asthma. </P>
<P>The overall results of the studies suggest that there is no significant difference between initial ICS doses for most asthma outcomes. It has previously been established that low to moderate ICS doses are highly effective for asthma (<LINK REF="REF-Adams-2002" TYPE="REFERENCE">Adams 2002</LINK>; <LINK REF="REF-Powell-2003" TYPE="REFERENCE">Powell 2003</LINK>). We have extended these observations to examine the efficacy of differing ICS doses as initial therapy for asthma. In most of the studies included in this review efficacy was shown in both treatment arms for the majority of outcomes. There was no clear benefit for starting at a high ICS dose. There was no heterogeneity amongst the studies and the confidence intervals were relatively tight. For the key outcome of PEF, the criteria for equivalence was met for each dose comparison.This did not differ when analysed by drug type, delivery device or duration of the study. There may be a benefit for airway hyperresponsiveness, and this outcome is discussed separately below.</P>
<P>The practice of starting with high dose ICS to gain control of asthma and then stepping down to a moderate or low maintenance dose is recommended in some asthma management guidelines (<LINK REF="REF-NAC-2002" TYPE="REFERENCE">NAC 2002</LINK>). When we reviewed the seven studies that compared this practice to a constant moderate or low ICS dose we found no significant benefit on lung function, symptoms, rescue medications or asthma control. There were some non significant effects in favour of a step down dose for both rescue medication use and symptoms during the day but this was not maintained at night. These results suggest that constant ICS doses have similar clinical efficacy to the more complex regimen of high ICS doses followed by a step down.</P>
<P>In reviewing the 11 studies that compared a constant high dose ICS to a moderate dose ICS no significant differences were found between commencing with high or moderate dose ICS for most asthma outcomes. There was a statistically significant difference for adults favouring high dose ICS for FEV1. The pooled sample size for the FEV1 analysis was small (55 adults), and the effect was not seen in children. Furthermore, the effect was not consistently seen in other measures of lung function, or in other dose comparisons. This small benefit in lung function needs to be considered against the risks of increased side effects with the use of constant high dose ICS (<LINK REF="REF-Adams-2002" TYPE="REFERENCE">Adams 2002</LINK>; <LINK REF="REF-Powell-2003" TYPE="REFERENCE">Powell 2003</LINK>).</P>
<P>For the nine studies that compared a constant high dose ICS to a low dose ICS no significant differences were found in asthma outcomes. There was a clinically small and non significant improvement in change in morning PEF from baseline. Due to differences in reporting most outcomes only two studies were able to be included in the meta analyses. However all the studies reported improvements for both low and high dose ICS groups.</P>
<P>For moderate dose ICS there was a significant improvement in the change in morning PEF from baseline and nocturnal symptoms in comparison to low dose ICS. There were also non significant improvements in FEV1, PEF diurnal variation, and the reduction of rescue medication use from baseline suggesting a superior effect for moderate dose ICS. </P>
<P>Many of the subjects entering the studies were required to have symptomatic asthma with features of poor asthma control. Clinicians frequently consider dose adjustment by a two fold or four fold increase in dose under these circumstances. We therefore performed an analysis that compared the efficacy of a baseline dose to a two or four fold increased dose. When we reviewed all the included studies as to whether they compared a two or four fold increase in ICS we found no greater benefit for either. The change in morning PEF from baseline was the only outcome to show a significant improvement for either a two or four fold increased ICS dose compared to a moderate or low base dose. Any other improvements were non significant and, in the majority of outcomes, equivalent for a two or four fold increase in dose. For several outcomes these increases in dose were equivalent to the base dose. There was no significant difference for a four fold increase in ICS for FEV1, morning PEF or rescue medication use. This would suggest that there is no extra benefit gained by quadrupling the ICS dose. There was also no extra benefit for doubling ICS for evening PEF, symptom score (day or night), rescue medication use or withdrawal due to adverse events.<BR/>
<BR/>Several studies reported a possible dose response relationship for airway hyperresponsiveness. In the one stepdown study that measured this outcome in children there was a significant improvement for the high dose group prior to stepping down ICS dose which was not maintained once the dose was stepped down. Another study, also in children, reported significant differences between high moderate and low dose ICS after exercise challenge. These differences were significant for the higher dose for all possible comparisons. Non significant improvements in AHR for high dose ICS were also reported when compared to moderate dose ICS in children (n=1), adults (n=1) and to low dose in adults in another study. no significant difference in AHR between treatment groups was reported in four studies, three comparing moderate to low dose ICS (one study reported a trend in favour of increasing doses) and one comparing high to low dose ICS. The study incorporating a step up design did not report the significance between treatment groups but stated a maximum improvement in AHR was achieved at low dose FP and moderate dose BDP.</P>
<P>International guidelines for initial ICS therapy vary in their recommendations. The Australian Asthma Management Guidelines (AAMP) (<LINK REF="REF-NAC-2002" TYPE="REFERENCE">NAC 2002</LINK>) recommend for adults with moderate persistent asthma commencing ICS at a dose of 800 mcg BDP equivalent per day (high dose) to gain rapid control of symptoms and then reducing this dose once controlled to the minimum required to maintain control. Whilst the Global Initiative for Asthma (GINA) (<LINK REF="REF-NIH-2002" TYPE="REFERENCE">NIH 2002</LINK>) recommend less than or equal to 500 mcg BDP equivalent (moderate dose) for mild persistent asthma and a wide range of initial ICS for moderate persistent asthma ranging from 200-1000 mcg BDP equivalent (low to high dose). Similarly, they recommend stepping down ICS once asthma is controlled to 500 mcg BDP equivalent. The British Thoracic Society (<LINK REF="REF-BTS_x002f_SIGN-2003" TYPE="REFERENCE">BTS/SIGN 2003</LINK>) guidelines recommend starting with an ICS dose of 400 mcg BDP equivalent per day (moderate dose) but also recommend a range according to severity of 200-800 mcg/day, then titrating down to the lowest effective dose to maintain control. This review examined initial starting ICS doses. We did not examine back-titration of maintenance ICS doses in controlled asthma. The results of this review support initiating asthma therapy with low to moderate doses of ICS at a constant dose.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The results of this review support initiating ICS at a constant moderate dose.</P>
<P>Commencing inhaled corticosteroids at a constant moderate or low dose is equally efficacious to commencing at a high dose and then down titrating.</P>
<P>The small significant benefits of commencing with a high ICS dose are not of sufficient clinical benefit to warrant its use when compared to moderate or low dose ICS.</P>
<P>Initial moderate ICS dose appears to be more effective than initial low ICS dose.</P>
<P>High dose ICS may be more effective than moderate or low dose ICS for airway hyperresponsiveness.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further research could examine the effects of initial ICS dose on other asthma outcomes such as airway hyperresponsiveness, longitudinal decline in lung function, and asthma pathology.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank the Cochrane Airways Review Group for their assistance with this review with data base searches, obtaining studies, translations and statistical assistance: Toby Lasserson, Karen Blackhall, Jo Picot and Chris Cates.</P>
<P>We would also like to thank the following authors for providing information regarding their studies: Dr B Volovitz, Dr WB Hofstra, Dr MJ Visser and Dr O Selroos for Dr Miyamoto.</P>
<P>We would like to thank the Cooperative Research Centre for Asthma for financial support.<BR/>

<BR/>
We would like to thank Claire Allen for comments on the synopsis for this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Nil</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>
<BR/>Powell H - protocol design, inclusion/exclusion, quality assessment, data extraction, analysis, interpretation and writing<BR/>Gibson PG - conception, protocol design, inclusion/exclusion, quality assessment, data extraction, analysis and interpretation, writing and editing.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-25 17:55:54 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES MODIFIED="2008-07-25 17:55:54 +0100" MODIFIED_BY="Toby J Lasserson">
<INCLUDED_STUDIES MODIFIED="2008-07-25 17:55:54 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="PUB" ID="STD-Bisgaard-1993" NAME="Bisgaard 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bisgaard H</AU>
<TI>Systemic activity of inhaled topical steroid in toddlers studied by knemometry</TI>
<SO>Acta Paediatr</SO>
<YR>1993</YR>
<VL>82</VL>
<PG>1066-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bisgaard-1999" NAME="Bisgaard 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bisgaard H, Gillies J, Groenwald M, Maden C on behalf of an International Study Group</AU>
<TI>The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>1999</YR>
<VL>160</VL>
<PG>126-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell--1998" NAME="Campbell  1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell LM, Gooding TN, Aitchison WR, Smith N, Powell JA</AU>
<TI>Initial loading (400mcg twice daily) versus static (400 mcg nocte) dose budesonide for asthma management. PLAN Research Group</TI>
<SO>Int J Clin Pract</SO>
<YR>1998</YR>
<VL>52</VL>
<PG>361-370</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chanez-2001" NAME="Chanez 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chanez P, Karlstrom R, Godard P</AU>
<TI>High or standard initial dose of budesonide to control mild-to-moderate asthma?</TI>
<SO>Eur Respir J</SO>
<YR>2001</YR>
<VL>17</VL>
<PG>856-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershman-2000" NAME="Gershman 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gershman NH, Wong HH, Liu JT, Fahy JV</AU>
<TI>Low- and high-dose fluticasone propionate in asthma; effects during and after treatment</TI>
<SO>Eur Respir J</SO>
<YR>2000</YR>
<VL>15</VL>
<PG>11-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hampel-2000" NAME="Hampel 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hampel F, Lisberg E, Guerin JC, and the Study Group</AU>
<TI>Effectiveness of low doses (50 and 100 mcg b.i.d) of beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma. Study Group</TI>
<SO>J Asthma</SO>
<YR>2000</YR>
<VL>37</VL>
<PG>389-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofstra--2000" NAME="Hofstra  2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kuethe MC, Sterk PJ</AU>
<TI>Dose-responses over time to inhaled fluticasone propionate treatment of exercise-and methacholine-induced bronchoconstriction in children with asthma</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2000</YR>
<VL>29</VL>
<PG>415-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jatakanon-1999" NAME="Jatakanon 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jatakanon A, Kharitonov S, Lim S, Barnes PJ</AU>
<TI>Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma</TI>
<SO>Thorax</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>108-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonasson-1998" NAME="Jonasson 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen K- H, Hultquist C</AU>
<TI>Low-dose budesonide improves exercise-induced bronchospasm in school children</TI>
<SO>Pediatr Allergy Immunol</SO>
<YR>2000</YR>
<VL>11</VL>
<PG>120-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen K-H, Blomqvist P</AU>
<TI>Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids</TI>
<SO>Eur Respir J</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>1099-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen K-H, Jonasson C, Mowinckel P</AU>
<TI>Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>740-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen K-H, Mowinckel P</AU>
<TI>Asthma drug adherence in a long term clinical trial</TI>
<SO>Arch Dis Child</SO>
<YR>2000</YR>
<VL>83</VL>
<PG>330-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonasson G, Carlsen K-H, Sodal A, Jonasson C, Mowinckel P</AU>
<TI>Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma</TI>
<SO>Eur Respir J</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>150-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorentzson-1990" NAME="Lorentzson 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorentzson S, Boe J, Eriksson G, Persson G</AU>
<TI>Use of inhaled corticosteroids in patients with mild asthma</TI>
<SO>Thorax</SO>
<YR>1990</YR>
<VL>45</VL>
<PG>733-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Majima-1993" NAME="Majima 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Majima T, Katoh H, Yoshida N, Akiyama Y, Hashimoto N, Yamaguchi M, Horie T</AU>
<TI>Effects of high doses of beclomethasone dipropionate in bronchial asthma</TI>
<SO>Arerugi</SO>
<YR>1993</YR>
<VL>42</VL>
<PG>534-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miyamoto-2000" NAME="Miyamoto 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miyamoto T, Fujino S, Nakajima S, Tollemar U, Liljas B</AU>
<TI>Cost-effectiveness of budesonide turbuhaler in the treatment of mild-to moderate asthma in Japan</TI>
<SO>Allergol Int</SO>
<YR>1999</YR>
<VL>48</VL>
<PG>275-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O</AU>
<TO>A double-blind, placebo-controlled dose-reponse study with budesonide turbuhaler in Japanese asthma patients</TO>
<SO>Respirology</SO>
<YR>2000</YR>
<VL>5</VL>
<PG>247-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nayak-2002" NAME="Nayak 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nayak A, Lanier R, Weinstein S, Stampone P, Welch M</AU>
<TI>Efficacy and safety of beclomethasone dipropionate extrafine aerosol in childhood asthma: a 12 week, randomized, double-blind, placebo-controlled study</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>1956-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noonan-1998" NAME="Noonan 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noonan MJ, Chervisnky P, Wolfe J, Liddle R, Kellermen DJ, Crescenzi KL</AU>
<TI>Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study</TI>
<SO>J Asthma</SO>
<YR>1998</YR>
<VL>35</VL>
<PG>153-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Byrne-1996" NAME="O'Byrne 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Byrne P, Cuddy L, Taylor DW, Birch S, Morris J, Syrotuik J</AU>
<TI>Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice</TI>
<SO>Canadian Respiratory Journal</SO>
<YR>1996</YR>
<VL>3</VL>
<PG>169-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1995" NAME="Pedersen 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen S, Hansen OR</AU>
<TI>Budesonide treatment of moderate and severe asthma in children: a dose response study</TI>
<SO>J Allergy Clin Immunol</SO>
<YR>1995</YR>
<VL>95</VL>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1996" NAME="Pedersen 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P</AU>
<TI>Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>1519-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pirozynski-1996" NAME="Pirozynski 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pirozynski M, Kulaga Z, Karstrom R</AU>
<TI>Pulmicort (budesonide) Turbuhaler in mild to moderate asthma: comparison of initial high dose, constant low dose and placebo</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>A343</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheffer-1996" NAME="Sheffer 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A, and the Fluticasone Propionate Asthma Study Group</AU>
<TI>Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma</TI>
<SO>J Fam Pract</SO>
<YR>1996</YR>
<VL>42</VL>
<PG>369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szefler-2002" NAME="Szefler 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Vernon M, Chinchilli VM, Craig TJ et al. Asthma Clinical Research Netwirk of the National Heart Lung and Blood Institute</AU>
<TI>Significant variability in response to inhaled corticosteroids for persistent asthma</TI>
<SO>J Allergy Clin Immunol</SO>
<YR>2002</YR>
<VL>109</VL>
<PG>410-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tukiainen--2000" NAME="Tukiainen  2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tukiainen H, Taivainen A, Majander R, Poussa T, Svahn T, Puolijoki H, Terho EO</AU>
<TI>Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma</TI>
<SO>Respir Med</SO>
<YR>2000</YR>
<VL>94</VL>
<PG>678-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Molen--1998" NAME="van der Molen  1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Molen T, Meyboom-de Jong B, Mulder HH, Postma DS</AU>
<TI>Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>121-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visser-2001" NAME="Visser 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Visser J, Postma DS, Arends LR, de Vries TW, Duiverman EJ, Brand PLP</AU>
<TI>One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>2001</YR>
<VL>164</VL>
<PG>2073-2077</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volovitz-1998" MODIFIED="2008-07-25 17:55:54 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Volovitz 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-07-25 17:55:54 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volovitz B, Soferman R, Blau H, Nussinovitch M, Varsano I</AU>
<TI>Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes</TI>
<SO>Journal of Allergy and Clin immunology</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>464-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasserman-1996" NAME="Wasserman 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Kral KM, Schaberg A, Kellerman DJ</AU>
<TI>A 12 week dose-ranging study of fluticasone propionate powder in the treatment of asthma</TI>
<SO>J Asthma</SO>
<YR>1996</YR>
<VL>33</VL>
<PG>265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wennergren-1996" NAME="Wennergren 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wennergren G, Nordvall SL, Hedlin G, Moller C, Wille S, Nilsson EA</AU>
<TI>Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers</TI>
<SO>Acta Paediatr</SO>
<YR>1996</YR>
<VL>85</VL>
<PG>183-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Adachi-2001" NAME="Adachi 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adachi M, Kochno Y, Minoguchi K</AU>
<TI>Step-down and step-up therapy in moderate persistent asthma</TI>
<SO>Int Arch Allergy Immunol</SO>
<YR>2001</YR>
<VL>124</VL>
<PG>414-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Affrime-2000" NAME="Affrime 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Affrime MB, Kosoglou T, Thonoor CM, Flannery B, Herron JM</AU>
<TI>Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>118</VL>
<PG>1538-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agertoft-1997" NAME="Agertoft 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agertoft L, Pedersen S</AU>
<TI>Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study</TI>
<SO>Eur Respir J</SO>
<YR>1997</YR>
<VL>10</VL>
<PG>1507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-1999" NAME="Baker 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker JW, Mellon M, Wald M, Welch M, Cruz-Rivera M, Walton-Bowen K</AU>
<TI>A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants</TI>
<SO>Paediatrics</SO>
<YR>1999</YR>
<VL>103</VL>
<PG>414-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boe-1989" NAME="Boe 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boe J, Rosenhall L, Alton M, Carlsson LG, Carlsson U, Hermansson BA, Hetta L, Kiviloog J, Karlson BW, Lundback B et al</AU>
<TI>Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma</TI>
<SO>Allergy</SO>
<YR>1989</YR>
<VL>44</VL>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brompton-Hospital" NAME="Brompton Hospital" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brompton Hospital and Medical Research Council</AU>
<TI>Double-blind trial comparing two dosage schedules of beclomethasone dipropionate aerosol with a placebo in chronic bronchial asthma.</TI>
<SO>Br J Dis Chest</SO>
<YR>1979</YR>
<VL>73</VL>
<PG>121-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Busse-1999" NAME="Busse 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Busse WW, Brazinsky S, Jacobsen K, Stricker W, Schmitt K, Vanden BurgtJ, Donnell D, Hannon S, Colice GL</AU>
<TI>Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant</TI>
<SO>J Allergy Clin Immunol</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>1215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpentiere-1990" NAME="Carpentiere 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpentiere G, Marino S, Castello F, Baldanza C, Bonanno CT</AU>
<TI>Dose-related effect of beclomethasone dipropionate on airway responsiveness in asthma</TI>
<SO>Respiration</SO>
<YR>1990</YR>
<VL>57</VL>
<PG>100-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chervinsky-1994" NAME="Chervinsky 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, Pleskow W</AU>
<TI>Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Study Group</TI>
<SO>J Allergy Clin Immunol</SO>
<YR>1994</YR>
<VL>94</VL>
<PG>676-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Bufalo-1988" NAME="Del Bufalo 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Bufalo C, Sturani C, Miniero R, Testi R, Gunella G</AU>
<TI>Beclomethasone dipropionate: four week treatment with high dose vs standard dose in asthmatic patients</TI>
<SO>Eur Respir J</SO>
<YR>1988</YR>
<VL>1 (Suppl 2)</VL>
<PG>378s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellul_x002d_Micallef-1983" NAME="Ellul-Micallef 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellul-Micallef R, Johansson SA</AU>
<TI>Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1983</YR>
<VL>15</VL>
<PG>419-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falcoz-2000" NAME="Falcoz 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falcoz C, Horton J, Mackie AE, Harding SM, Daley-Yates PT</AU>
<TI>Pharmacokinetics of fluticasone propionate inhaled via the DiskhalerTM and DiskusTM powder devices in patients with mild-to-moderate asthma</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>2000</YR>
<VL>39 (Suppl 1)</VL>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillissen-2002" NAME="Gillissen 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillissen A, Richter A, Oster H, Criee C-P</AU>
<TI>Effectiveness of low doses (2x100mcg) of HFA beclomethasone (BDP) given once daily or twice in adults with mild to moderate asthma</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>2002</YR>
<VL>165 (Suppl 8)</VL>
<PG>A768</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-2002" NAME="Harrison 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison LI, Kurup S, Wagner C, Ekholm BP, Larson JS, Kaiser HB</AU>
<TI>Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma</TI>
<SO>Eur J Clin Pharmacol</SO>
<YR>2002</YR>
<VL>58</VL>
<PG>197-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kudo-1995" NAME="Kudo 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kudo K, Hojo M, Kabe J</AU>
<TI>Inhaled beclomethasone in long-term management of asthma: Optimal dose and optimal duration of treatment</TI>
<SO>Japanese Journal of Thoracic Diseases</SO>
<YR>1995</YR>
<VL>33</VL>
<PG>956-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-1999" NAME="Pearlman 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman DS, Kane RE, Banerji D, for the Azmacort HFA-134a Study Group</AU>
<TI>Comparative dose-ranging study of triamcinolone acetonide inhalation aerosol using propellants hydrofluoroalkane 134a or P-12 in children with chronic asthma</TI>
<SO>Current Therapeutic Research</SO>
<YR>1999</YR>
<VL>60</VL>
<PG>595-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reddel-2000" NAME="Reddel 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM, Badcock C-A, Woolcock AJ</AU>
<TI>Optimal asthma control, starting with high doses of inhaled budesonide</TI>
<SO>Eur Respir J</SO>
<YR>2000</YR>
<VL>16</VL>
<PG>226-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sue_x002d_Chu-1999" NAME="Sue-Chu 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sue-Chu M, Wallin A, Wilson S, Ward J, Sandstrom T, Djukanovic R, Holgate ST, Bjermer L</AU>
<TI>Bronchial biopsy study in asthmatics treated with low and high dose fluticasone propionate (FP) compared to low dose FP combined with salmeterol</TI>
<SO>European Respiratory Society</SO>
<YR>1999</YR>
<VL>Oct 9-13</VL>
<PG>Madrid, Spain</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turktas-1995" NAME="Turktas 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turktas I, Gokcora N, Yavuz O, Elbeck S, Cevik C, Demirsoy s</AU>
<TI>Effect of inhaled budesonide on lipid metabolism and hypothalamic-pituitary-adrenal axis function in patients with bronchial asthma</TI>
<SO>Turkish Journal of Medical Sciences</SO>
<YR>1995</YR>
<VL>25</VL>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visser-2002" NAME="Visser 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Visser MJ, Postma DS, Brand PL, Arends LR, Duiverman EJ, Kauffman HF</AU>
<TI>Influence of different dosage schedules of inhaled fluticasone propionate on peripheral blood cytokine concentrations in childhood asthma</TI>
<SO>Clin Exp Allergy</SO>
<YR>2002</YR>
<VL>32</VL>
<PG>1497-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welch-1997" NAME="Welch 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welch MJ, Levy S, Smith JA, Feiss G, Farrar JR</AU>
<TI>Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>597-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1999" NAME="White 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White MV, Cruz-Rivera M, Walton-Bowen K</AU>
<TI>The efficacy and safety of budesonide inhalation suspension: A nebulizable corticosteroid for persistent asthma in infants and young children</TI>
<SO>Family Medicine</SO>
<YR>1999</YR>
<VL>31</VL>
<PG>337-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ZuWallack-2000" NAME="ZuWallack 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ZuWallack R, Adelglass J, Clifford DP, Duke SP, Wire PD, Faris M, Harding SM</AU>
<TI>Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderat asthma</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>118</VL>
<PG>303-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-25 17:38:27 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-25 17:38:27 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Adams-2002" MODIFIED="2008-07-25 17:37:24 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Adams 2002" TYPE="COCHRANE_REVIEW">
<AU>Adams N, Bestall J, Jones PW</AU>
<TI>Inhaled fluticasone propionate for chronic asthma</TI>
<SO>Cochrane Library</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adams-2002-_x0028_b_x0029_" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Adams 2002 (b)" TYPE="COCHRANE_REVIEW">
<AU>Adams N, Bestall J, Jones PW</AU>
<TI>Budesonide for chronic asthma in children and adults</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adams-2002-_x0028_c_x0029_" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Adams 2002 (c)" TYPE="COCHRANE_REVIEW">
<AU>Adams N, Bestall J, Jones PW</AU>
<TI>Inhaled Beclomethasone versus placebo for chronic asthma</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1998" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Barnes 1998" TYPE="JOURNAL_ARTICLE">
<AU>Barnes PJ, Pedersen S, Busse WW</AU>
<TI>Efficacy and safety of inhaled corticosteroids</TI>
<SO>AM J Respir Crit Care Med</SO>
<YR>1998</YR>
<VL>157</VL>
<PG>S1-S53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2000" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Black 2000" TYPE="JOURNAL_ARTICLE">
<AU>Black PN, Lawrence BJ, Goh KH, Barry MS</AU>
<TI>Differences in the potencies of inhaled steroids are not reflected in the doses prescribed in primary care in New Zealand</TI>
<SO>Eur J Clin Pharmacol</SO>
<YR>2000</YR>
<VL>56</VL>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS_x002f_SIGN-2003" MODIFIED="2008-07-25 17:38:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS/SIGN 2003" TYPE="JOURNAL_ARTICLE">
<AU>The British Thoracic Society / Scottish Intercollegiate Guidelines Network</AU>
<TI>British Guideline on the Management of Asthma</TI>
<SO>Thorax</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>Suppl 1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holt-2001" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Holt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R</AU>
<TI>Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>253-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-07-25 17:38:05 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NAC-2002" MODIFIED="2008-07-25 17:37:24 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NAC 2002" TYPE="BOOK">
<AU>National Asthma Council</AU>
<SO>Asthma Management Handbook</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIH-2002" MODIFIED="2008-07-25 17:37:24 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NIH 2002" TYPE="BOOK">
<AU>National Institutes of Health, NHLBI Workshop Report, 2002</AU>
<SO>Global strategy for asthma management and prevention</SO>
<YR>NIH publication No 02-3659</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NZGG-2003" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NZGG 2003" TYPE="JOURNAL_ARTICLE">
<AU>New Zealand Guideline Group</AU>
<TI>Best practice evidence-based guidelines: the diagnosis and treatment of adult asthma</TI>
<SO>Enigma Publishing Pyt Ltd</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Powell-2003" MODIFIED="2008-07-25 17:37:24 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Powell 2003" TYPE="JOURNAL_ARTICLE">
<AU>Powell H, Gibson PG</AU>
<TI>Inhaled corticosteroid doses in asthma: an evidence-based approach</TI>
<SO>Med J Aus</SO>
<YR>2003</YR>
<VL>178</VL>
<PG>223-225</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suissa-2001" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Suissa 2001" TYPE="JOURNAL_ARTICLE">
<AU>Suissa S, Ernst P</AU>
<TI>Inhaled corticosteroids: impact on asthma morbidity and mortality</TI>
<SO>J Allergy Clin Immunol</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>937-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Todd-2002" MODIFIED="2008-07-25 17:37:23 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Todd 2002" TYPE="JOURNAL_ARTICLE">
<AU>Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner JT</AU>
<TI>Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate</TI>
<SO>Eur Respir J</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>1207-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-25 17:55:37 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-25 17:55:37 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bisgaard-1993">
<CHAR_METHODS>
<P>Study Design: Crossover RCT<BR/>Randomisation: Random stated method not described. Concealment of Allocation: Not stated<BR/>Double Blinding: No - single blind. <BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Described Statistical analysis: Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Outpatients<BR/>No eligible: Not stated. <BR/>No randomised: 18<BR/> No completed: 14 <BR/>Sex: Males 9 (64%); Females 5 (36%)<BR/>Age: mean 27 months. <BR/>Diagnostic criteria for asthma: Dr diagnosis <BR/>Inclusion criteria: &lt; 3 yrs age, recurrent wheeze, previous ICS but not in past month.<BR/>Exclusion criteria: No OCS in past 3 months, exacerbations requiring &gt; 4 puffs beta 2 agonist for &gt; 4 days during study period, temp &gt;38 degrees during study period.<BR/>Baseline severity of asthma: Not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BUD 800mcg /day<BR/>2: BUD 200mcg/day<BR/>3. Placebo<BR/>Delivery device: pMDI plus spacer <BR/>Duration of treatment: 4wks for each treatment - 12 weeks total. </P>
<P>Run in phase: not stated <BR/>Wash out phase: no washout between treatments <BR/>Other: rescue meds prn, no other meds allowed, no glucocorticoid ointments.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>exacerbations, growth rate, symptoms, rescue meds</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No washout period between treatments</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bisgaard-1999">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Random stated, method not described.<BR/>Concealment of Allocation: Not stated<BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: Described <BR/>Adverse events: Described <BR/>Statistical analysis: Described - Intention to treat<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Outpatients at 33 centres across 9 countries<BR/>No eligible: 314 enrolled <BR/>No randomised: 237 <BR/>No completed: 212 <BR/>Sex:34% female.<BR/>Age: Mean 28 months; Range: 12-47 months<BR/>Diagnostic criteria for asthma: documented history of recurrent wheeze or asthma symptoms<BR/>Inclusion criteria: Asthma symptoms or rescue Beta 2 use for 7 of the last 14 days run in. &gt; 2weeks without ICS (plus 4 week runin without ICS)<BR/>Exclusion criteria: ICS, systemic CS, methylxanthines or antibiotics for chest infection in the 2 weeks prior to run in. Ineffective use of the Babyhaler spacer device. <BR/>Baseline severity of asthma: Moderate to severe asthma symptoms. Placebo group had fewer and milder symptoms than both treatment groups. 34% used asthma medications in the month prior to randomisation. 42% had a history of eczema.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: FP 200mcg/day (100mcg bd)<BR/>2: FP 100mcg/day (50mcg bd)<BR/> 3: Placebo 2 puffs bd<BR/>Delivery device: pMDI plus Babyhaler spacer device <BR/>Duration of treatment: 12 weeks<BR/>Run in phase: 4 weeks with placebo 2 puffs bd and salbutamol prn <BR/>Other: salbutamol prn, continued regular medications including sodium cromoglycate, ketotifen &amp; antihistamines providing the dose remained constant. ICS or OCS used for treatment of an exacerbation. Withdrawan if &gt; one exacerbation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptoms, exacerbations, adverse events, control of asthma, treatment with corticosteroids, hoarseness/dysphonia, oral candidiasis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:49:58 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Campbell--1998">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: computer generated randomisation code in block sizes of 4.<BR/>Concealment of Allocation: not stated<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: described<BR/>Statistical analysis: described - per protocol analysis<BR/>Jadad Score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: 146 General Practices<BR/>No eligible: 855<BR/>No randomised: 682 (343/338) -one subject withdrew before commencement of treatment.<BR/>No completed: 454 (223/231) 18 weeks. 295 (146/149) 24 weeks<BR/>Sex: Males 297 (43.6%); Females 384 (56.4%)<BR/>Age: mean (sd) Intervention1: 33.5(13.8), Intervention 2: 33.3 (15.6)<BR/>Diagnostic criteria for asthma: 'documented diagnosis of asthma.'<BR/>Inclusion criteria: &gt; 12 years, asthma symptoms 2 out of the past 7 days, bronchodilator prn for last 2 weeks, requiring ICS according to Dr.<BR/>Exclusion criteria: PEF &lt;60% predicted, pregnancy, breast feeding, significant concomitant disease, medication in last 3 months of beta 2 blockers, sodium cromoglycate or sodium nedocromil.<BR/>Baseline severity of asthma: PEF mean (sd) - Intervention1: 418(92), Intervention 2: 408 (89)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-25 17:49:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>1: Budesonide 800mcg /day (400mcg bd) for 6 weeks; Budesonide 400mg nocte for another 12 weeks; if met asthma controlled criteria budesonide 200mcg nocte for a further 6 weeks.<BR/>2: Budesonide 400mcg nocte/ placebo mane for 6 weeks; budesonide 400mcg nocte for further 12 weeks; if asthma controlled then budesonide 200mcg nocte for 6 weeks.<BR/>Delivery device: DPI<BR/>Duration of treatment: Initial treatment 6 weeks, 12 weeks phase 2 - static dose for lntervention2 and step down for Intervention1; then for those subjects who achieved asthma control a further reduction to 200mcg for 6 weeks. Total duration 24 weeks.<BR/>Run in phase: 4-10 days<BR/>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, rescue medication, nocturnal asthma, asthma symptoms (diary and clinic), adverse events, compliance, asthma control at 18 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>High dropout rate - 50% non compliance. <BR/> For morning PEF and day rescue medications it was assumed that the variance was SE as the measure was very small in comparison to the reported clinic PEF SD and night rescue meds SD mentioned in the text.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chanez-2001">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Computer generated random list, randomised by centre in block size of four. Concealment of Allocation: Described<BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: Described Adverse events: Described Statistical analysis: Described - intention to treat analysis<BR/>Jadad Score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Multicentred - outpatients<BR/>No eligible: 214 enrolled <BR/>No randomised: 169 (83/86)<BR/>No completed: 137 (66/71) <BR/>Sex: Males 84 (50%); Females 85 (50%) <BR/>Age: mean 38 yrs<BR/>Range: eligible 18-70 yrs<BR/>Diagnostic criteria for asthma: PEF diurnal variation &gt; 20%, FEV1 &gt;12% reversibility<BR/>Inclusion criteria: uncontrolled asthma defined as daily nocturnal symptoms, wheezing and beta agonist use in last 7 days, not currently on ICS (includes beclomethasone up to 500mcg/day), use of long acting theophylline in past 2 weeks.<BR/>Exclusion criteria: FEV1 &lt;55 % predicted, use of nasal steroids or oral and parenteral steroids in past month. Use of leukotriene antagonists in past, exacerbation or airway infection during past month.<BR/>Baseline severity of asthma: FEV1: mean 74% predicted.<BR/>All subjects uncontrolled asthma at enrollment, allergy 83%, previous ICS use 50%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: Budesonide 1600mcg/day (800mcg bid) reducing by half every 4 weeks if controlled to min dose of BUD 200mcg/day (100mcg bid).<BR/>2: BUD 400mcg/day (200mcg bid)<BR/>Delivery device: DPI<BR/>Duration of treatment: 16 weeks </P>
<P>Run in phase: 2 weeks - beta agonist as needed or long acting theophylline </P>
<P>Other: No nebulised or parenteral beta agonist allowed during study. Withdrawn if not controlled i.e. an exacerbation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, FEV1, rescue medication, symptoms, exacerbations, serum eosinophils, reversibility %</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gershman-2000">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: stated, method not described<BR/>Concealment of Allocation: numbered identical containers administered sequentially<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: described<BR/>Adverse events: not described<BR/>Statistical analysis: described<BR/>Jadad Score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: recruited by advertising in local newspapers and database of subjects from previous studies- site not stated<BR/>No eligible: not stated<BR/>No randomised: 24 (12/12)<BR/>No completed: 22 (12/10)<BR/>Sex: Males = 21 (87.5 %)<BR/>Age: mean 38.7; range 22-55<BR/>Diagnostic criteria for asthma: Objective lung function.<BR/>Inclusion criteria: FEV1 &lt;=80% predicted, PC20 (methacholine), FEF25-75 &lt;75% predicted<BR/>Exclusion criteria: history of ICS or OCS use, URTI in 6 weeks prior to study, tobacco use in past year or total smoking history &gt; 10 pack years<BR/>Baseline severity of asthma: Intervention 1= FEV1 69% predicted (mean).<BR/>Intervention 2 = FEV1 66% predicted (mean).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: FP 1000mcg/day (2x250mcg twice daily)<BR/>2: FP 100mcg / day (1x50mcg &amp; 1x placebo twice daily)<BR/>Delivery device: pMDI plus spacer<BR/>Duration of treatment: 6 weeks<BR/>Run in phase: 2 weeks<BR/> Other: Salbutamol prn allowed throughout study, inhaler technique assessed at start.<BR/>3 weeks placebo run out.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function, airway hyperresponsiveness, rescue medication use, asthma symptoms, airway inflammation parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hampel-2000">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Random stated, method not described.<BR/>Concealment of Allocation: Not stated<BR/>Double Blinding: Study was 'blinded'-double blinded not stated <BR/>Withdrawals / dropouts: described <BR/>Adverse events: Described <BR/>Statistical analysis: Descibed - Intention to treat analysis<BR/>Jadad Score:2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Multi-centred study<BR/>No eligible: 270 eligible for randomisation <BR/>No randomised: 270 (92/91/87)<BR/>No completed: 253 (87/87/79)<BR/>Sex: Females: 153 (57%)<BR/>Age: Mean(SD) Intervention 1: 35.8(12.1); Intervention 2: 52 (57.1); Intervention 3: 45 (51.7)<BR/>Diagnostic criteria for asthma: Mild to mod asthma according to GINA guidelines, objective lung function<BR/>Inclusion criteria: Steroid naive(no ICS in past 3 months), mild-to-mod asthmatics, Beta 2 use only, &gt;= 15% reversibility after Beta 2, non smoker, proper MDI inhaler technique.</P>
<P>Exclusion criteria: Cardiac disease, pulmonary disease other than asthma, known hypersensitivity to BDP, history of alcohol or substance abuse, no other medications allowed except Beta 2 during study.<BR/>Baseline severity of asthma: FEV1 mean(SD) percent predicted. Intervention 1: 75.5 (7.4); Intervention 2: 75.3 (8.6); Intervention 3: 77.1 (5.8)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: Beclomethasone (BDP) 200mcg/day (100mcg bd)<BR/>2: BDP 100mcg/day (50mcg bd)</P>
<P>Delivery device: pMDI <BR/>Duration of treatment: 6 weeks <BR/>Run in phase: 14 days. eligible if 65-85% predicted normal FEV1 during this time <BR/>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, PEF, FEF25-75, nocturnal asthma, symptoms, rescue meds, adverse events, withdrawals due to adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hofstra--2000">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Computer.<BR/>Concealment of Allocation: Coded identical containers<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Described<BR/>Statistical analysis: Described<BR/>Jadad Score: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Multicentre - hospital<BR/>No eligible: 39<BR/>No randomised: 37 (14/11/12)<BR/>No completed: 36 (14/11/11)<BR/>Sex:Male 23 (62%); Female 14(38%)<BR/>Age: mean 10.3 years; Range 6-14 yrs<BR/>Diagnostic criteria for asthma: 'clinically diagnosed asthma' <BR/>Inclusion criteria: intranasal and dermatological ICS allowed, and opthalmological cromones, provided at constant dose throughout study.<BR/>Exclusion criteria: No ICS in past 4 months, no viral infection previous 2 weeks, no hospital admission or OCS in 4 weeks prior to screening.<BR/>Baseline severity of asthma: FEV1 &gt; 70% predicted, &gt; 20% fall in FEV1 after exercise test, clinically stable<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: Initially FP 500mcg/day (250mcg bd) for 24 weeks <BR/>2: FP 200mcg/day (100mcg bd) for 24 weeks<BR/>3: Placebo for 6 weeks then randomised to FP 500mcg/day or 200mcg/day groups for 18 weeks<BR/>Delivery device: pMDI with volumatic spacer.<BR/>Duration of treatment: 24 weeks<BR/>Run in phase: 2 weeks, salbutamol prn<BR/>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Exercise challenge, AHR, lung function, rescue medication, symptoms, airway inflammation, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jatakanon-1999">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: random stated, method not described.<BR/>Concealment of Allocation: Not stated.<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Not described<BR/>Statistical analysis: Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Not stated<BR/>No eligible: Not stated<BR/>No randomised: 22 (8/8/6)<BR/>No completed: 21 (7/8/6)<BR/>Sex: All males (100%)<BR/>Age: mean(SE) Intervention 1: 29 (2.4); Intervention 2:31 (1.2); Intervention 3: 31 (2.8) Range:<BR/>Diagnostic criteria for asthma: Dr diagnosis, objective lung function - PC20(methacholine) <BR/>Inclusion criteria: stable asthma with no history ICS use, Beta2 agonist therapy only, positive allergy, no exacerbation in past 3 months<BR/>Exclusion criteria: URTI in past 6 weeks, nasal steroids past 2 months <BR/>Baseline severity of asthma: FEV1 &gt;=80% predicted, Mean (se) Intervention 1: 91.5(4.2); Intervention 2: 92.3 (3.1);Intervention 3:97.2 (4.0). PEF Intervention 1:501 (19); Intervention 2: 512 (20); Intervention 3:552 (32)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: Budesonide 400mcg/day<BR/>2: Budesonide 100mcg/day<BR/>3: Placebo<BR/>Delivery device: DPI - Turbohaler<BR/>Duration of treatment: 4 weeks<BR/>Run in phase: 1 week<BR/>Other: Also concurrently ran a 1600mcg /day vs placebo crossover trial</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, FEV1, AHR, rescue medication, symptoms, sputum eosinophils, exhaled NO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jonasson-1998">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Randomised in balanced blocks of four Concealment of Allocation: Not stated <BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: Described Adverse events: Described Statistical analysis: Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: outpatient clinics<BR/>No eligible: 166 enrolled <BR/>No randomised: 163 (42/40/41/40)<BR/> No completed: 160 (42/40/38/40) <BR/>Sex: Males 107 (66%); Females 56 (34%) <BR/>Age: mean 9.9 yrs, range: 7-16<BR/>Diagnostic criteria for asthma: defined by the definition in the International Consensus Report<BR/>Inclusion criteria: 3 previous obstructive episodes or one episode with atopy, 1 episode in the past year. No previous ICS <BR/>Exclusion criteria: No ICS in past 2 months, No cromglycate/nedocromil in past 4 weeks, no respiratory tract infection in past 4 weeks<BR/>Baseline severity of asthma: <BR/>FEV1 mean 103% predicted. Atopy 67.5%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BUD 200mcg daily<BR/>2: BUD 100mcg bid (200/day)<BR/>3: BUD 100mcg daily<BR/>4:Placebo<BR/>Delivery device: DPI<BR/>Duration of treatment: 12 weeks initial and then continued for a further 24 months</P>
<P>Run in phase: 2 weeks <BR/>Other: Terbutaline as needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, FEV1, airway hyperresponsiveness, symptoms, exercise induced fall in FEV1, serum ECP/eosinophils, adherence, compliance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:52:21 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Lorentzson-1990">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: random stated, method not described<BR/>Concealment of Allocation: Not stated <BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: described Adverse events: Described Statistical analysis: Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-25 17:52:21 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Study site: multicentre<BR/>No eligible:<BR/>No randomised: 104<BR/>No completed: 103 (38/32/33)<BR/>Sex: Males 58 (56%); Females 45 (44%)<BR/>Age: mean 32<BR/>Diagnostic criteria for asthma: Not stated<BR/>Inclusion criteria: &gt;= 35 puffs beta agonist during runin, mean PEF variation 10-30% over last 4 days of runin, mean PEF 75% predicted.<BR/>Exclusion criteria: ICS or OCS use, use of spacer for beta agonist, concomitent disease, respiratory infection or acute asthma exacerbation in past month<BR/>Baseline severity of asthma: mean duration of asthma 11 yrs. Mean(SEM) morning PEF (l/min): Intervention 1:429(16); intervention 2: 398 (16); Intervention 3: 397(16)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BUD 400mcg/day (200mcg bd)<BR/>2: BUD 200mcg/day (100mcg bd)<BR/>3:Placebo<BR/>Delivery device: pMDI <BR/>Duration of treatment: 6 weeks </P>
<P>Run in phase: 1 week, Beta agonist only <BR/>Wash out phase: 1 week prior to run in for subjects who were on oral beta agonists <BR/>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, rescue medications, symptoms, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Majima-1993">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: random stated, method not described<BR/>Concealment of Allocation: "envelope" method<BR/>Double Blinding: No<BR/>Withdrawals / dropouts: not described Adverse events: Not described.<BR/> Statistical analysis: Described<BR/>Jadad Score: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Respiratory outpatients clinc, university hopsital<BR/>No eligible: Not stated <BR/>No randomised: 17<BR/> No completed: Not stated<BR/>Sex: Males 11 (65%); Females 6 (35%)<BR/>Age: mean Intervention 1: 45.3; Intervention 2: 43.3; Intervention 3: 48.6 <BR/>Diagnostic criteria for asthma: Objective lung function according to Japanese Allergy Association<BR/>Inclusion criteria: Progressive airway hypersensitivity and reversibility of bronchoconstriction identified by astrograph:Not on anti- allergy or steroid medication for more than 2 months prior to study<BR/>Exclusion criteria: <BR/>Baseline severity of asthma: mild to moderate asthmatics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BDP 800mcg/day<BR/>2: BDP 400mcg/day<BR/>3: Salbutamol 800mcg/day</P>
<P>Delivery device: Not stated<BR/>Duration of treatment: 8 weeks </P>
<P>Run in phase: not stated <BR/>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, PEF, airway sensitivity and reactivity, flow volume curve</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Miyamoto-2000">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Computer generated sequence in blocks of four.<BR/>Concealment of Allocation: sequentially administered coded containers.<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Described<BR/>Statistical analysis: Described<BR/>Jadad Score: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: multicentre trial in 62 medical centres<BR/>No eligible: Not stated<BR/>No randomised: 267 (67/67/63/70)<BR/>No completed: 224 (61/55/56/52)<BR/>Sex: Male 126/238 (53%), Female 112/238 (47%)<BR/>Age: mean (sd) Intervention 1: 50.4(15); Intervention 2: 47.8(15.9); Intervention 3: 50.9 (15.5); Intervention 4: 50.6 (14.2)<BR/>Diagnostic criteria for asthma: Not stated<BR/>Inclusion criteria: PEF 50-80% predicted, stable perennial symptoms of asthma &gt; 3 days/week during run in<BR/>Exclusion criteria: Glucocorticoid use within 1 month of study, respiratory tract infection in previous 4 weeks, other dominant respiratory disease, cardiovascular disease, hepatic or renal disease.<BR/>Baseline severity of asthma: mild asthma 147/238 (62%); Mod asthma 88/238 (37%); Severe asthma 3/238 (1%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1:BUD 800mcg/day (400mcg bd)<BR/>2: BUD 400mcg/day (200mcg bd)<BR/>3: BUD 200mcg/day (100mcg bd)<BR/>4: Placebo<BR/>Delivery device: DPI<BR/>Duration of treatment: 6 weeks<BR/>Run in phase: 2 weeks<BR/>Other: oropharyngeal rinsing after each dose to minimise oral candidiasis</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, FEV1, symptoms, safety, Doctor efficacy assessment, adverse events, hospitalisations, ER visits, lost production, symptoms, costs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nayak-2002">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation:Computer produced randomization schedule. <BR/>Concealment of Allocation: Not stated <BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: Described.<BR/> Adverse events: Described.<BR/>Statistical analysis: Intention to treat analysis<BR/>Jadad Score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: 50 outpatient centres.<BR/>No eligible: 684 screened <BR/>No randomised: 353 (117/120/116)<BR/> No completed: 310 (108/105/97) <BR/>Sex: Males 224 (63%)<BR/>Age: mean (sd) Intervention 1:8.9 (1.9); Intervention 2: 9.4 (2.0); Intervention 3: 9.3 (2.1) <BR/>Diagnostic criteria for asthma: Objective lung function <BR/>Inclusion criteria: Stable moderate symptomatic asthma &gt; 6 months duration<BR/>and on Beta agonists, FEV1 50-80 % predicted,, &gt;= 12 % reversibility, use of beta agonist on 50% of days in 2 week runin.<BR/>Exclusion criteria: significant nonreversible pulmonary disease other than asthma, evidence of any clinically significant immnuologic, neoplastic, endocrine, hematologic, cardiac, hepatic, renal, GI, neurologic, or psychiatric abnormalities or illness. Upper or lower respiratory tract infection last 2-4 weeks, use of OCS, ICS or injectable corticosteroids within 8 wks, 6 wks or 6 months respectively. <BR/>Baseline severity of asthma: FEV1 (L): mean(SD) Intervention 1: 1.5 (0.4); Intervention 2: 1.6 (0.4; Intervention 3: 1.6(0.5)<BR/>PEF l/min: mean(SD): Intervention 1: 217(65.4); Intervention 2: 232.5(62.9); Intervention 3: 235.4 (70.0).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BDP -HFA 160mcg/day (80mcg bd)<BR/>2: BDP-HFA 80mcg/day (40mcg bd)<BR/>Delivery device: pMDI <BR/>Duration of treatment: 12 weeks</P>
<P>Run in phase: 2 weeks <BR/>Other:No other asthma maintenance therapies were permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>exacerbations, adverse events, clinical improvement, PEF, symptoms, rescue medications, plasma cortisol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:52:58 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Noonan-1998">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Random stated, method not described Concealment of Allocation: Not stated <BR/>Double Blinding: yes <BR/>Withdrawals / dropouts: Described Adverse events: Described Statistical analysis: Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-25 17:52:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Study site: multicentre<BR/>No eligible: Not stated<BR/>No randomised: 138 (33/34/35/36)<BR/>No completed: 119 (30/30/31/28)<BR/>Sex: Males: 84 (61%); Females: 54 (39%).<BR/>Age: mean 23;29;30;26<BR/>Range: 12-59<BR/>Diagnostic criteria for asthma: ATS<BR/>Inclusion criteria: &gt;= 12 yrs old, 6 month history asthma, documented history of allergy, FEV1 between 60 and 85% predicted, &gt;= 15% reversability, positive PD20(methacholine) .<BR/>Exclusion criteria: recent hospitalisation for asthma, corticosteroid use, oral theophylline, inhaled cromolyn, nedocromil,, smokers, significant concurrent disease,, pregnancy or lactation.<BR/>Baseline severity of asthma: FEV1: 74;73;76;74 percent predicted<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: FP (10% lecithin) 200mcg/day<BR/>2: FP (1% Lecithin) 200mcg/day<BR/>3: FP (1% Lecithin) 100mcg/day<BR/>4: Placebo (1% Lecithin) 2 puffs day<BR/>Delivery device: pMDI <BR/>Duration of treatment: 8 weeks <BR/>Run in phase: 2 weeks</P>
<P>Other: Albuterol and oral terfanadine as needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, PEF, AHR, rescue medications, nocturnal asthma, symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-O_x0027_Byrne-1996">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Computer generated code- stratified by allergy status and randomised in blocks of 3 at each centre<BR/>Concealment of Allocation: coded identical containers <BR/>Double Blinding: Yes </P>
<P>Withdrawals / dropouts: Described.<BR/> Adverse events: Described.<BR/> Statistical analysis: Intention to treat<BR/>Jadad Score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: multicentre trial in 7 cities, at primary care physicians<BR/>No eligible: Not stated<BR/>No randomised: 57 (20/17/20)<BR/>No completed: 39 (12/13/14)<BR/>Sex: Male 25<BR/>Female 32<BR/>Age: mean 37/32/36 <BR/>Diagnostic criteria for asthma: Objective lung function:&gt; 10% PEF diurnal variation at least 3 of the last 7 days.<BR/>Inclusion criteria: &gt; 18 years, mild asthma and on clinical evaluation not requiring ICS. <BR/>Exclusion criteria: No ICS in past 3 months, Requiring ICS<BR/>Baseline severity of asthma: PEF mean (SD): Intervention 1: 364 (115); Intervention 2: 381 (112); Intervention 3 : 403 (116)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BUD 800mcg/day (400mcg bid)<BR/>2: BUD 400mcg /day (200mcg bid)<BR/>3: Placebo<BR/>Delivery device: nebuhaler<BR/>Duration of treatment: 16 weeks <BR/>Run in phase: <BR/>Other: Beta agonists as needed, theophylline if remained constant through out study, allowed budesonide and/or prednisone for exacerbation during study.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>costs, hospitalisations, ER visits, PEF, symptoms, exacerbations, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>For morning PEF it was assumed the variance estimate was SE.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pedersen-1995">
<CHAR_METHODS>
<P>Study Design: <BR/>Crossover RCT<BR/>Randomisation:Random stated, method not described.<BR/>Concealment of Allocation: Identical drug canisters administered in randomized order<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described <BR/>Adverse events: Not described <BR/>Statistical analysis: Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: multicentred<BR/>No eligible: Not stated<BR/>No randomised: 19 <BR/>No completed: 18 <BR/>Sex: Males:17(89%); Females 2(11%).<BR/>Age: mean 11yrs<BR/>Diagnostic criteria for asthma: Objective lung function<BR/>Inclusion criteria: beta 2 use only, Symptoms&gt; 3 days/week, &gt;=20% bronchial reversibility post terbutaline or &gt;=<BR/>20% fall in FEV1 post exercise test.<BR/>Exclusion criteria: Bronchopulmonary disease other than asthma, oral prednisolone within 1 month before study <BR/>Baseline severity of asthma: PC20 range: 22.5%-76.5%; bronchial reversibility range: 26.5% - 82.4%. mean duration of asthma: 7.5 yrs <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BUD 100mcg/day (50mcg bd)<BR/>2: BUD 200mcg/day (100mcg bd)<BR/>3: BUD 400mcg/day (200mcg bd) </P>
<P>Delivery device: metered-dose inhaler with spacer <BR/>Duration of treatment: 4 weeks for each treatment period, no washout. Total treatment 12 weeks. <BR/>Run in phase: 2 weeks <BR/>Wash out phase: none<BR/>Other: &gt; 80% compliance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF &amp; FEV1 post exercise testing, AHR (exercise), rescue medication, symptoms, urinary cortisol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>no washout period between dose changes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:53:45 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pedersen-1996">
<CHAR_METHODS MODIFIED="2008-07-25 17:53:41 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Study Design: Parallel RCT<BR/>Randomisation:<BR/>Random stated, method not described.<BR/>Concealment of Allocation: Not stated<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Not fully described<BR/>Adverse events: Not described<BR/>Statistical analysis: Described<BR/>Jadad Score: 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-25 17:53:45 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Study site: Not stated<BR/>No eligible: Not stated<BR/>No randomised: ? 85(29;29;27)<BR/>No completed: 53 (23;20;10)<BR/>Sex: Male 48 (55%); Female 37 (45%)<BR/>Age: mean(SD) Intervention 1: 46.1(11.2); Intervenmtion 2: 46.8 (12.5)<BR/>Diagnostic criteria for asthma: ATS criteria<BR/>Inclusion criteria:<BR/>Beta 2 use only, in need of regular maintenance treatment due to attacks of dyspnoea, cough, wheezing and airflow variability<BR/>Exclusion criteria: Not stated<BR/>Baseline severity of asthma: FEV1 % predicted mean(SD): Intervention 1: 70.7%(14.2); Intervention 2: 68.8 % (19.8).Allergic: Intervention 1: 40%; Intervention 2 : 31%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: BUD 1600mcg/day<BR/>2: BUD 400mcg/day<BR/>3: Theophylline600mg/day<BR/>Delivery device: Not stated.<BR/>Duration of treatment: 9 months<BR/>Run in phase: Not stated <BR/>Other: subjects followed up for 3 months post intervention<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, rescue meds, PC20, Vital Capacity, Blood eosinophils, serum EPX, ECP, MPO, lactoferrin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:53:52 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Pirozynski-1996">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: random stated, method not described<BR/>Concealment of Allocation: Not stated<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described <BR/>Adverse events: Not described <BR/>Statistical analysis: Not described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Not stated<BR/>No eligible: Not stated<BR/>No randomised: 262 <BR/>No completed: 23 withdrew due to exacerbation or adverse event, ? number completed.<BR/>Sex: Females: 143 (55%); Males: 119 (45%)<BR/>Age: Mean 36yrs<BR/>Diagnostic criteria for asthma: Not stated<BR/>Inclusion criteria: Not stated</P>
<P>Exclusion criteria: Not stated<BR/>Baseline severity of asthma: mild-to-moderate asthma. Mean FEV1 % predicted: 82.3%. Mean PEF: 380 l/min <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-25 17:53:52 +0100" MODIFIED_BY="Toby J Lasserson">
<P>1: BUD 800mcg/day (400mcg bd) for 4 weeks then reduced to 200mcg/day (100mcg bd) for a further 8 weeks<BR/>2: BUD 200mcg/day (100mcg bd) for 12 weeks</P>
<P>Delivery device: DPI<BR/>Duration of treatment: 12 weeks<BR/>Run in phase: 2 weeks<BR/>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Withdrawal due to exacerbations or adverse events, PEF, FEV1, rescue medications, symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sheffer-1996">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Random stated, method not described<BR/>Concealment of Allocation: Not stated<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Described<BR/>Statistical analysis:Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Multicentred<BR/>No eligible: Not stated.<BR/>No randomised: 307 (79/79/76/73)<BR/>No completed: 294(52/48/47/29)<BR/>Sex: Male 185 (60%); Female 122(40%).<BR/>Age: Mean (range) Intervention 1:28(12-72); Intervention 2: 30 (12-63); Intervention 3:30 (12-69); Intervention 4 :30 (13-54)<BR/>Diagnostic criteria for asthma:Objective lung function<BR/>Inclusion criteria:<BR/> &gt; 12 yrs, history of asthma requiring daily pharmacotherapy for at least 3 months, FEV1 45-75% predicted, &gt;= FEV1 reversibility.<BR/>Exclusion criteria: Pregnancy or lactating women, patients who had taken long term OCS, Steroids in any form in past month, cromolyn sodium in month prior to study, history of life threatening asthma.<BR/>Baseline severity of asthma: FEV1 mean (SEM): Intervention 1: 2.45 (0.06); Intervention 2: 2.38 (0.07); Intervention 3: 2.43 (0.06); Intervention 4: 2.36 (0.06)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: FP 200mcg bid (100mcg bid)<BR/>2: FP 100mcg/day (50mcg bid)<BR/>3:FP 50mcg/day (25mcg bid) <BR/>4: placebo 2 puffs bid<BR/>Delivery device: pMDI<BR/>Duration of treatment: 12 weeks<BR/>Run in phase: 1 week placebo<BR/>Other: albuterol as needed, no other medications allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, FEV1, rescue medication, asthma symptoms including night symptoms, adverse events, withdrawal due to worsening asthma</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Szefler-2002">
<CHAR_METHODS>
<P>Study Design: Parallel design of two ICS - both increasing doses.<BR/>Randomisation: Random stated, method not described. Concealment of Allocation: Not stated. <BR/>Double Blinding: No - open label <BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Not stated Statistical analysis: Described<BR/>Jadad Score: 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Multicentred<BR/>No eligible: Not stated <BR/>No randomised: 30 (FP: 15; BDP :15)<BR/> No completed: 26 <BR/>Sex: Males 23 (77%) <BR/>Age: mean (sd) FP: 29.6 (7.2); BDP: 30.3 (7.6)<BR/>Diagnostic criteria for asthma: Objective lung function.<BR/>Inclusion criteria: FEV1 55-85% predicted, beta agonist response &gt;=12%, FEV1 improvement of 200ml post beta agonist, PC20(methacholine) &lt;=8mg/ml, AHR(exercise)&gt;=12%, plasma cortisol &gt;5mcg/dL, smoking history &lt; 10 pack years .<BR/>Exclusion criteria: Corticosteroids in past 6 months<BR/>Baseline severity of asthma: FEV1 % predicted FP: 75.07(11.2); BDP: 73.3 (11.1)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: FP in increasing doses for 6 weeks each - 88mcg/day; 352mcg/day;704mcg/day<BR/>2: BDP increasing doses for 6 weeks each: 168mcg/day;672mcg/day;1344mcg/day<BR/>Delivery device: pMDI plus spacer <BR/>Duration of treatment: 24 weeks total (3wks runin, 3x6wks treatment, 3wks washout)<BR/>Run in phase: 3 weeks with placebo<BR/>Other: 3 weeks with FP 2mg/day at completion of treatments. no washout in between increasing ICS doses <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, AHR (methacholine and exercise), recue medications, symptoms, plasma cortisol, sputum eosinophils, sputum ECP, sputum neutrophils, eNO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:54:21 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Tukiainen--2000">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Computer randomisation in balanced blocks of four.<BR/>Concealment of Allocation: computer randomisation after run in<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Nil<BR/>Statistical analysis: APT (all patients treated) approach used for analysis.<BR/>Jadad Score:4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Not stated<BR/>No eligible: 105<BR/>No randomised: 101 (51/50)<BR/>No completed: 97 (49/48).<BR/>Sex:Males 36 (36%), Females 65 (64%)<BR/>Age: mean (range): Intervention 1: 40.5 (19-62); Intervention 2: 37.3 (18-68)<BR/>Diagnostic criteria for asthma: ATS<BR/>Inclusion criteria: positive histamine challenge (PC20 FEV1 &lt;= 8mgl), newly diagnosed asthma (in past 3 months), symptoms &lt; 6 months<BR/>Exclusion criteria: No ICS or previous regular pharmacological treatment for asthma<BR/>Baseline severity of asthma: <BR/>FEV1 mean (SEM) Intervention 1 : 3.05 (.1); Intervention 2: 3.29 (.1)<BR/>PEF mean (SEM) intervention 1: 432 (12); intervention 2: 456 (10)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1:Budesonide 800mcg/day (400mcg bid)<BR/>2: Budesonide 200mcg/day (100mcg bid)<BR/>Delivery device: DPI<BR/>Duration of treatment: 12 weeks<BR/>Run in phase: 1 week</P>
<P>Other: Terbutaline via DPI prn throughout run in and study period. No other regular asthma meds allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-25 17:54:21 +0100" MODIFIED_BY="Toby J Lasserson">
<P>PEF, FEV1, AHR, rescue medications, asthma symptoms (day &amp; night), airway inflammation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-der-Molen--1998">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: random stated, method not described<BR/>Concealment of Allocation: Not stated<BR/>Double Blinding: Yes<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: Described<BR/>Statistical analysis: Described<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: 25 General Practices<BR/>No eligible: unknown, 91 selected.<BR/>No randomised: 84 (44/40)<BR/>No completed: 73 (38/35) <BR/>Sex: Males = 37 (44%); Females = 47 (56%)<BR/>Age: Intervention 1: mean (sd) 31.3 (10.8); Intervention 2: mean (sd) 32.0 (8.1)<BR/>Diagnostic criteria for asthma: definition of the Dutch College for General Practitioners - objective lung function.<BR/>Inclusion criteria: PEF &amp; FEV1 &gt; 50% predicted, &gt; 3 doses bronchodilator per week in month prior to trial.<BR/>Exclusion criteria: Smoking history &gt; 20 pack years, steroid treatment, exacerbation in previous 2 months<BR/>Baseline severity of asthma: FEV1 L mean (sd): Intervention 1: 3.09(0.7); Intervention 2: 3.16 (0.79) <BR/>PEF l/min mean (sd): Intervention1: 427 (89); Intervention 2: 437(99)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: Budesonide 800mcg /day (400x2) for 4 weeks then BUD 200mcg daily for 8 weeks<BR/>2: BUD 200mcg/day (100x2) for 4 weeks then BUD 200mcg daily for 8 weeks.<BR/>Delivery device: DPI<BR/>Duration of treatment: 4 weeks initial treatment followed by 8 weeks static treatment - 12 weeks total treatment.<BR/>Run in phase: 1 week on bronchodilator therapy only</P>
<P>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function, night waking, asthma symptoms, time to reach asthma control, adverse events,compliance.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Visser-2001">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Computer randomisation.<BR/>Concealment of Allocation: Coded identical containers.<BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: Described Adverse events: Described. Statistical analysis: Described<BR/>Jadad Score: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Multicentred<BR/>No eligible: 55<BR/>No randomised: 55 (27/28)<BR/> No completed: 51 (26/25) <BR/>Sex: Males 29 (53%); Females 26 (47%) <BR/>Age: mean (sem) Intervention 1: 8.1 (0.3), Intervention 2: 7.8 (0.2) <BR/>Diagnostic criteria for asthma: Not stated <BR/>Inclusion criteria: Chronic persistent asthma, age 6-10 yrs, PD20 (methacholine ) &lt;80mcg during washout<BR/>Exclusion criteria: major illness, systemic corticosteroids during past 6 weeks, respiratory tratc infection in past 4 weeks.<BR/>Baseline severity of asthma: <BR/>FEV1 %predicted mean (sem): Intervention 1: 92.1 (2.8); Intervention 2: 89.4(2.7).<BR/>Pd20 (methacholine) geometric mean (range): Intervention 1: 36 (25-53); Intervention 2: 30 (22-43)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: FP 1000mcg/day for 2 months then step down every 2months to 500mcg /day for 2 months, 200mcg/day for 2months, then 100mcg/day for 6months.<BR/>2: FP 200mcg/day constant<BR/>Delivery device: Not stated<BR/>Duration of treatment: 12 months total</P>
<P>Run in phase: 6 weeks on FP 200mcg/day<BR/>Wash out phase: 2-8 weeks inhaled salbutamol only prior to randomisation <BR/>Other:</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEF, FEV1, airway hyperresponsiveness, symptoms, exacerbations, exhaled NO, adherence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:55:24 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Volovitz-1998">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Randomised in blocks of eight<BR/>Concealment of Allocation: patients given numbered identical looking drug packets containing four repsules each. <BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: Described Adverse events: described Statistical analysis: Described<BR/>Jadad Score: 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Outpatient asthma clinics<BR/>No eligible: 42<BR/>No randomised: 42 (21/21)<BR/> No completed: 41 (42 used for analysis) <BR/>Sex: Males 28(67%) Females 14 (33%) <BR/>Age: mean (sd) Intervention 1: 21.5 (9.4) months; Intervention 2: 17.05 (8.9) months <BR/>Diagnostic criteria for asthma: Symptoms over past 3 months <BR/>Inclusion criteria: 3 wheezing episodes and asthma symptomatology &gt; 40% of days in the past 3 months. Total symptom score of 21 during 3 week runin .<BR/>Exclusion criteria: ICS, sodium cromoglycate, or ketotife in past 4 weeks. OCS use &gt; 5 days, acute viral infection, pneumonia, chronic pulmonary disease or Tb. Family history of prematurity.<BR/>Baseline severity of asthma: <BR/>Percentage of time symptoms last 3 months: Intervention 1: 65%; Intervention 2:70%<BR/>Exacerbations in past 3 months: Intervention 1: 6.8(8.2); Intervention 2: 5.5(4.6)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-25 17:55:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>1:Budesonide 2mg (1mg bd) decreasing 25% every 2nd day for one week then maintained on BUD 0.5mg(0.25 bd) for 9 weeks<BR/>2: Budesonide 0.5mg (0.25 bd)<BR/>Delivery device: nebuliser<BR/>Duration of treatment: 1 week initial treatment for intervention 1, 10 weeks total</P>
<P>Run in phase: 3 weeks using previous anti asthma medication<BR/>Other: Terbutaline prn, budesonide suspension (0.5mg qid) with 25% decrease every 4 days for exacerbations allowed during study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptoms, plasma cortisol, Time to clinical response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:55:11 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wasserman-1996">
<CHAR_METHODS>
<P>Study Design: Parallel RCT <BR/>Randomisation: Random stated, method not described.<BR/>Concealment of Allocation: Not stated<BR/>Double Blinding: Yes <BR/>Withdrawals / dropouts: Described <BR/>Adverse events: Described <BR/>Statistical analysis: Described - intention to treat analysis for safety variables, efficacy analysis on efficacy population.<BR/>Jadad Score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: 20 sites<BR/>No eligible: <BR/>No randomised: 331 (85/82/80/84)<BR/>No completed: 256 (72/65/61/58)<BR/>Sex: Males % (71/60/63/71)<BR/>Age: Mean 29/27/29/29<BR/>Diagnostic criteria for asthma: ATS<BR/>Inclusion criteria: &gt; 12 years, FEV1 50-80% predicted, &gt;= 15% reversibility oral or inhaled bronchodilators in 2 weeks prior to screening, negative pregnancy test.</P>
<P>Exclusion criteria: Smokers, oral, intranasal, opthalmological, topical or inhaled corticosteroid within 1 month of screening or 2months for OCS<BR/>Baseline severity of asthma: Mean FEV1: 2.66/2.57/2.68/2.6.<BR/>Mean morning PEF (L/min): 436/418/434/432<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-25 17:55:11 +0100" MODIFIED_BY="Toby J Lasserson">
<P>1: FP 500mcg/day (250mcg bd)<BR/>2: FP 200mcg/day (100mcg bd)<BR/>3: FP 100mcg/day (50mcg bd)<BR/>4: Placebo<BR/>Delivery device: DPI<BR/>Duration of treatment: 12 weeks<BR/>Run in phase: 2 weeks. albuterol prn, no other asthma medications allowed. Had to meet criteria for stable asthma - &lt;= 12 puffs Beta2/day, &lt;= 4 mornings with &gt; 20% PEF variability, &lt;= 2 nights with nocturnal asthma, FEV1 50-80% predicted, reproducible lung function and adequate compliance.<BR/>Other: regularly scheduled terfenadine for allergic rhinitis allowed if dose remained constant throughout study, cromolyn sodium &amp; oxymetazoline allowed prn.<BR/>Participants withdrawn due to lack of efficacy if: exacerbation requiring emergency treatment, hospitalisation, asthma meds needed, 20% decrease in morning FEV1 or PEF on 3 of 7 days, &gt; 12 puffs beta2/day on 2 of 7 days or &gt; 2 nights nocturnal asthma.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Withrawals due to adverse events, FEV1, PEF, FEF25-75, symptoms, rescue medications, nocturnal asthma, physician global assessment, plasma cortisol, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>For FEV1 and morning PEF it was assumed the variance estimate was SE.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-25 17:55:37 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wennergren-1996">
<CHAR_METHODS>
<P>Study Design: Parallel RCT<BR/>Randomisation: Random stated, method not described<BR/>Concealment of Allocation: controlled by pharmacy<BR/>Double Blinding: Yes - Doctor and patient<BR/>Withdrawals / dropouts: Described<BR/>Adverse events: described<BR/>Statistical analysis: Described<BR/>Jadad Score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Study site: Conducted throughout 12 paediatric units<BR/>No eligible: Not stated<BR/>No randomised: 102 (50/52)<BR/>No completed: 88 (44/44)<BR/>Sex: males: 83 (81%); Females: 19 (19%)<BR/>Age:mean: Intervention 1: 20 months; Intervention 2: 23 months<BR/>Diagnostic criteria for asthma: Not stated<BR/>Inclusion criteria: &gt; 6months &lt;= 4 years, uncontrolled asthma without steroids, symptoms min 6 days/month in past 2 months, symptoms with exercise/laughter/crying 50 % of days in past month<BR/>Exclusion criteria: No ICS, concomitant lung disease, previous inclusion in study<BR/>Baseline severity of asthma: <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-25 17:55:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>1:Budesonide 2mg/day ( 1mg bid) for 3 weeks then halved every 3 weeks if subject fitted criteria for dose reduction until on placebo.<BR/>2: Budesonide 0.5mg/day (0.25mgbid) throughout study. If fulfilled criteria for dose reduction 3 times then placed on placebo<BR/>Delivery device: Nebulizer<BR/>Duration of treatment: 18 weeks<BR/>Run in phase: 2-4 weeks<BR/>Other:Allowed sodium cromoglycate during study, short courses of beclomethasone or prednisolone allowed for exacerbations</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-25 17:55:37 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Heath care utilisation, rescue medication, asthma symptoms, adverse events, overall well-being score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adachi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear if ICS free - no response from authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Affrime-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not ICS free for &gt; 28 days prior to study commencement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Agertoft-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment period 2 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baker-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>30% of subjects on ICS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boe-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects not ICS free in month prior to study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brompton-Hospital">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects on OCS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Busse-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not ICS free - steroid washout period 1-28 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carpentiere-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment period 3 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chervinsky-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects on ICS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Del-Bufalo-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear if ICS free - no response from authors</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ellul_x002d_Micallef-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment period 4 days, also given single prednisolone dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falcoz-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>ICS use not stated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gillissen-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not compare different doses of ICS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harrison-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>&lt; 4 weeks treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kudo-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pearlman-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients continued asthma medication throughout study - ? ICS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reddel-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects not ICS free in month prior to study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sue_x002d_Chu-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects not ICS free in month prior to study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Turktas-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not measure asthma outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Visser-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects not ICS free in month prior to study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Welch-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects on ICS at commencement of study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-White-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Some subjects on ICS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ZuWallack-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not ICS free for &gt; 28 days prior to study commencement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-25 17:55:39 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-07-25 17:55:39 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:51:12 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bisgaard-1993">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:51:03 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bisgaard-1999">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:50:41 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Campbell--1998">
<DESCRIPTION>
<P>Computer generated randomisation code in block sizes of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:50:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chanez-2001">
<DESCRIPTION>
<P>Computer generated random list, randomised by centre in block size of four.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:51:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Gershman-2000">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:51:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hampel-2000">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:51:46 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Hofstra--2000">
<DESCRIPTION>
<P>Computer generated random numbers </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:52:05 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jatakanon-1999">
<DESCRIPTION>
<P>Described as randomised; other information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:52:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Jonasson-1998">
<DESCRIPTION>
<P>Randomised in balanced blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:52:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Lorentzson-1990">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:52:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Majima-1993">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:52:44 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Miyamoto-2000">
<DESCRIPTION>
<P>Computer generated sequence in blocks of four.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:52:51 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Nayak-2002">
<DESCRIPTION>
<P>Computer produced randomization schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:53:10 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Noonan-1998">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:53:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-O_x0027_Byrne-1996">
<DESCRIPTION>
<P>Computer generated code- stratified by allergy status and randomised in blocks of 3 at each centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:53:39 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1995">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:53:48 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:53:54 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Pirozynski-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:53:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sheffer-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:54:04 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Szefler-2002">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:54:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Tukiainen--2000">
<DESCRIPTION>
<P>Computer randomisation in balanced blocks of four.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:54:45 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Visser-2001">
<DESCRIPTION>
<P>Computer randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:54:58 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Volovitz-1998">
<DESCRIPTION>
<P>Randomised in blocks of eight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:55:32 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Wasserman-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:55:39 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Wennergren-1996">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-25 17:54:35 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Molen--1998">
<DESCRIPTION>
<P>Described as randomised; other information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-25 17:50:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-25 17:40:18 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-07-25 17:40:18 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE>Primary Comparisons</TITLE>
<TABLE COLS="7" ROWS="31">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Age</P>
</TH>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>StepDown vs Constant</P>
</TH>
<TH>
<P>High vs Mod</P>
</TH>
<TH>
<P>High vs Low</P>
</TH>
<TH>
<P>Mod vs Low</P>
</TH>
</TR>
<TR>
<TD>
<P>Bisgaard 1993</P>
</TD>
<TD>
<P>Infants</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>800mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bisgaard 1999</P>
</TD>
<TD>
<P>Infants</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200mcg vs 100 mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Campbell 1998</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P>800-400mcg vs 400mcg</P>
</TD>
<TD>
<P>800mcg vs 400mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Chanez 2001</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P>1600-200mcg vs 400mcg</P>
</TD>
<TD>
<P>1600mcg vs 400mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gershman 2000</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1000mcg vs 100mcg</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hampel 2000</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BDP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hofstra 2000</P>
</TD>
<TD>
<P>Children</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>500mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jatakanon 1999</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>400mcg vs 100mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Jonasson 1998</P>
</TD>
<TD>
<P>Children</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200mcg vs 100mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Lorentzson 1990</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>400mcg vs 200mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Majima 1993</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BDP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>800mcg vs 400mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Miyamoto 2000</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>800mcg vs 400mcg</P>
</TD>
<TD>
<P>800mcg vs 200mcg</P>
</TD>
<TD>
<P>400mcg vs 200mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Nayak 2002</P>
</TD>
<TD>
<P>Children</P>
</TD>
<TD>
<P>BDP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>160mcg vs 80mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Noonan 1998</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200mcg vs 100mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>O'Byrne 1996</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>800mcg vs 400mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pedersen 1995</P>
</TD>
<TD>
<P>Children</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>400mcg vs 200mcg</P>
</TD>
<TD>
<P>400mcg vs 100mcg</P>
</TD>
<TD>
<P>200mcg vs 100mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Pedersen 1996</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1600mcg vs 400mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pirozynski 1996</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P>800-200mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>800mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sheffer 1996</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>200mcg vs 50mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Szefler 2002</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BDP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1344mcg vs 672mcg</P>
</TD>
<TD>
<P>1344mcg vs 168mcg</P>
</TD>
<TD>
<P>672mcg vs 168mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Szefler 2002</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>704mcg vs 352mcg</P>
</TD>
<TD>
<P>704mcg vs 88mcg</P>
</TD>
<TD>
<P>352 vs 88mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Tukiainen 2000</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>800mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>van der Molen 1998</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P>800-200mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>800mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Visser 2001</P>
</TD>
<TD>
<P>Children</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P>1000-100mcg vs 200mcg</P>
</TD>
<TD>
<P>1000mcg vs 200mcg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Volovitz 1998</P>
</TD>
<TD>
<P>Infants</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P>2-0.5mg vs 0.5mg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wasserman 1996</P>
</TD>
<TD>
<P>Adults</P>
</TD>
<TD>
<P>FP</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>500mcg vs 200mcg</P>
</TD>
<TD>
<P>500mcg vs 100mcg</P>
</TD>
<TD>
<P>200mcg vs 100mcg</P>
</TD>
</TR>
<TR>
<TD>
<P>Wennergren 1996</P>
</TD>
<TD>
<P>Infants</P>
</TD>
<TD>
<P>BUD</P>
</TD>
<TD>
<P>2mg-0.5mg vs 0.5mg</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Step down vs Constant ICS Dose (All)</NAME>
<CONT_OUTCOME CHI2="0.011498839823517779" CI_END="24.303900679069244" CI_START="-26.12603337328808" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9110663471094177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.9146044202237349" P_Q="0.9146044202237349" P_Z="0.943543120578758" Q="0.011498839823517779" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="0.0708173532809709">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="42.7555762665847" CI_START="-48.7555762665847" DF="0.0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.8977481028966664" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="30.368878236980596" Z="0.1285065653935223">
<NAME>Adults</NAME>
<CONT_DATA CI_END="42.7555762665847" CI_START="-48.7555762665847" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="420.0" MEAN_2="423.0" ORDER="4517" SD_1="98.6" SD_2="100.6" SE="23.345110740553828" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="30.368878236980596"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="30.217373222175407" CI_START="-30.217373222175407" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="69.63112176301941" Z="0.0">
<NAME>Children</NAME>
<CONT_DATA CI_END="30.217373222175407" CI_START="-30.217373222175407" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="269.0" MEAN_2="269.0" ORDER="4518" SD_1="62.7" SD_2="46.5" SE="15.417310450868582" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="69.63112176301941"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.7803864680435201" P_Q="1.0" P_Z="0.8632634359975946" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="315" TOTAL_2="328" UNITS="" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" DF="1.0" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.7803864680435201" P_Z="0.8632634359975946" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="328" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>Adults</NAME>
<CONT_DATA CI_END="11.082585483794093" CI_START="-11.082585483794093" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="45.0" ORDER="4519" SD_1="60.9" SD_2="62.2" SE="5.654484251349572" STUDY_ID="STD-Campbell--1998" TOTAL_1="232" TOTAL_2="242" WEIGHT="72.38295873935151"/>
<CONT_DATA CI_END="20.94199292850359" CI_START="-14.941992928503591" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="58.0" ORDER="4520" SD_1="59.0" SD_2="60.0" SE="9.154246236169511" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="27.617041260648495"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.5545263699591919" P_Q="1.0" P_Z="0.17387926215134233" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="331" UNITS="" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>Diary Card Symptom Score (Day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" DF="1.0" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.5545263699591919" P_Z="0.17387926215134233" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="331" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.02596715542399894" CI_START="-0.18596715542399886" EFFECT_SIZE="-0.07999999999999996" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="-0.49" ORDER="4521" SD_1="0.61" SD_2="0.57" SE="0.054065868689350566" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="245" WEIGHT="79.16408152237781"/>
<CONT_DATA CI_END="0.1965518267409323" CI_START="-0.21655182674093232" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.44" ORDER="4522" SD_1="0.67" SD_2="0.7" SE="0.10538552155559325" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="20.835918477622194"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.30186300523143084" P_Q="1.0" P_Z="0.2404150545922351" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="329" UNITS="" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>Diary Card Symptom Score (Night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" DF="1.0" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" ID="CMP-001.04.01" NO="1" P_CHI2="0.30186300523143084" P_Z="0.2404150545922351" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="329" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.1378782764578968" CI_START="-0.07787827645789676" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.45" ORDER="4523" SD_1="0.61" SD_2="0.59" SE="0.05504094835865703" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="243" WEIGHT="77.57434489354594"/>
<CONT_DATA CI_END="0.3506413716996898" CI_START="-0.05064137169968971" EFFECT_SIZE="0.15000000000000002" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.55" ORDER="4524" SD_1="0.63" SD_2="0.7" SE="0.10236992785700312" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="22.42565510645405"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.24422826085037086" P_Q="1.0" P_Z="0.1820317738928679" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" DF="1.0" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" ID="CMP-001.05.01" NO="1" P_CHI2="0.24422826085037086" P_Z="0.1820317738928679" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.03519162882360782" CI_START="-0.5751916288236079" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.13" ORDER="4525" SD_1="1.68" SD_2="1.71" SE="0.1557128759665588" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="75.98335466647684"/>
<CONT_DATA CI_END="0.6428447932693216" CI_START="-0.4428447932693219" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="4526" SD_1="1.8" SD_2="1.8" SE="0.2769667185474898" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="24.016645333523154"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.835628835215149" P_Q="1.0" P_Z="0.42197702725394737" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" DF="1.0" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.835628835215149" P_Z="0.42197702725394737" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.054527890309513175" CI_START="-0.13452789030951318" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="-0.23" ORDER="4527" SD_1="0.52" SD_2="0.53" SE="0.04822940169061121" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="93.74121528751569"/>
<CONT_DATA CI_END="0.3658307846601671" CI_START="-0.3658307846601671" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.7" ORDER="4528" SD_1="1.0" SD_2="1.4" SE="0.18665178929092252" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.258784712484326"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" METHOD="MH" NO="7" P_CHI2="0.3183119887450464" P_Q="0.0" P_Z="0.2594456111978882" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>Withdrawal due to adverse event</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" DF="1.0" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" NO="1" P_CHI2="0.3183119887450464" P_Z="0.2594456111978882" STUDIES="2" TAU2="0.0" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>Adults</NAME>
<DICH_DATA CI_END="2.8814196517478945" CI_START="0.5695414692728974" EFFECT_SIZE="1.2810495626822158" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4596065138049211" LOG_CI_START="-0.24447464872147914" LOG_EFFECT_SIZE="0.10756593254172103" ORDER="4529" O_E="0.0" SE="0.41358076012597156" STUDY_ID="STD-Campbell--1998" TOTAL_1="343" TOTAL_2="338" VAR="0.17104904514637642" WEIGHT="91.1154319522535"/>
<DICH_DATA CI_END="36.31589614749957" CI_START="0.4730030432105941" EFFECT_SIZE="4.144578313253012" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5600967654769557" LOG_CI_START="-0.32513606508604326" LOG_EFFECT_SIZE="0.6174803501954562" ORDER="4530" O_E="0.0" SE="1.1073950967257222" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" VAR="1.2263239002521715" WEIGHT="8.88456804774652"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" METHOD="MH" NO="8" P_CHI2="0.4981586221009352" P_Q="0.0" P_Z="0.9532000313190644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>Proportion Achieving Asthma Control</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" DF="1.0" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" NO="1" P_CHI2="0.4981586221009352" P_Z="0.9532000313190644" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.2033547105734104" CI_START="0.8755815859878481" EFFECT_SIZE="1.0264673526176147" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="101" LOG_CI_END="0.08039366236738556" LOG_CI_START="-0.05770338048459777" LOG_EFFECT_SIZE="0.011345140941393887" ORDER="4531" O_E="0.0" SE="0.08111888656264195" STUDY_ID="STD-Campbell--1998" TOTAL_1="153" TOTAL_2="154" VAR="0.006580273757162773" WEIGHT="82.63673813440649"/>
<DICH_DATA CI_END="1.2746520393518797" CI_START="0.6341104320018376" EFFECT_SIZE="0.8990384615384616" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.10539164515123073" LOG_CI_START="-0.19783510200375598" LOG_EFFECT_SIZE="-0.04622172842626257" ORDER="4532" O_E="0.0" SE="0.17811689227544536" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="26" TOTAL_2="33" VAR="0.03172562731386261" WEIGHT="17.36326186559352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Infants</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>High vs Moderate ICS Dose (All)</NAME>
<CONT_OUTCOME CHI2="2.7013430364302597" CI_END="9.985564020342643" CI_START="0.6464205052493579" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.315992262796001" ESTIMABLE="YES" I2="0.0" I2_Q="58.2381012500729" ID="CMP-002.01" NO="1" P_CHI2="0.4399991748897032" P_Q="0.12176074974583995" P_Z="0.02566214381797517" Q="2.3945271406074315" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="2.2312867042539875">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.08743731063389451" CI_END="18.24038092034877" CI_START="2.4470365021689826" DF="1.0" EFFECT_SIZE="10.343708711258877" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.767460734343661" P_Z="0.01024875329694216" STUDIES="2" TAU2="0.0" TOTAL_1="29" TOTAL_2="26" WEIGHT="34.967604834393455" Z="2.567321525300738">
<NAME>Adults</NAME>
<CONT_DATA CI_END="21.953515815815052" CI_START="0.8464841841849573" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" MEAN_1="81.4" MEAN_2="70.0" ORDER="4533" SD_1="8.6" SD_2="10.0" SE="5.3845457870960045" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="19.577614678263497"/>
<CONT_DATA CI_END="20.903039713633156" CI_START="-2.903039713633154" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="82.5" MEAN_2="73.5" ORDER="4534" SD_1="20.6" SD_2="19.2" SE="6.073091040204214" STUDY_ID="STD-Pedersen-1996" TOTAL_1="23" TOTAL_2="20" WEIGHT="15.389990156129956"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.21937858518893383" CI_END="8.403061580812475" CI_START="-3.1778347654826518" DF="1.0" EFFECT_SIZE="2.6126134076649117" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.6395138303455432" P_Z="0.37652172837722153" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="65.03239516560654" Z="0.8843232909493819">
<NAME>Children</NAME>
<CONT_DATA CI_END="9.891911348796498" CI_START="-7.891911348796498" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="98.3" MEAN_2="97.3" ORDER="4535" SD_1="14.7" SD_2="6.6" SE="4.536772827937023" STUDY_ID="STD-Hofstra--2000" TOTAL_1="13" TOTAL_2="11" WEIGHT="27.578069316813878"/>
<CONT_DATA CI_END="11.430026764541502" CI_START="-3.830026764541479" EFFECT_SIZE="3.8000000000000114" ESTIMABLE="YES" MEAN_1="106.4" MEAN_2="102.6" ORDER="4536" SD_1="14.3" SD_2="13.5" SE="3.892942331964346" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="37.45432584879267"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1459525699473343" CI_END="31.99730208753371" CI_START="-16.171224318684146" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.9130388844247825" ESTIMABLE="YES" I2="12.736353473516097" I2_Q="12.736353473516097" ID="CMP-002.02" NO="2" P_CHI2="0.2843980682563255" P_Q="0.2843980682563255" P_Z="0.5196022087669634" Q="1.1459525699473343" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="0.6439587165670719">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="78.70416958322528" CI_START="-228.70416958322528" DF="0.0" EFFECT_SIZE="-75.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="0.33888783771392517" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.4552483712649638" Z="0.9563650695950074">
<NAME>Adults</NAME>
<CONT_DATA CI_END="78.70416958322528" CI_START="-228.70416958322528" EFFECT_SIZE="-75.0" ESTIMABLE="YES" MEAN_1="375.0" MEAN_2="450.0" ORDER="4537" SD_1="120.0" SD_2="150.0" SE="78.4219357067906" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.4552483712649638"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.38548575498966" CI_START="-14.385485754989656" DF="0.0" EFFECT_SIZE="10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="0.421545981993972" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="97.54475162873504" Z="0.8037420309082892">
<NAME>Children</NAME>
<CONT_DATA CI_END="34.38548575498966" CI_START="-14.385485754989656" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="244.0" MEAN_2="234.0" ORDER="4538" SD_1="51.0" SD_2="37.0" SE="12.441802985840177" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="97.54475162873504"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.181336540258029" CI_END="13.004971082457143" CI_START="-1.56446065905169" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.720255211702726" ESTIMABLE="YES" I2="4.336808063931614" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.3820205779981115" P_Q="1.0" P_Z="0.12379369075052236" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="563" TOTAL_2="554" UNITS="" WEIGHT="99.99999999999999" Z="1.5390434433174134">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.181336540258029" CI_END="13.004971082457143" CI_START="-1.56446065905169" DF="4.0" EFFECT_SIZE="5.720255211702726" ESTIMABLE="YES" I2="4.336808063931614" ID="CMP-002.03.01" NO="1" P_CHI2="0.3820205779981115" P_Z="0.12379369075052236" STUDIES="5" TAU2="0.0" TOTAL_1="563" TOTAL_2="554" WEIGHT="99.99999999999999" Z="1.5390434433174134">
<NAME>Adults</NAME>
<CONT_DATA CI_END="19.409209826058163" CI_START="-1.409209826058163" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="26.0" ORDER="4539" SD_1="70.8" SD_2="62.0" SE="5.310918929207211" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="314" WEIGHT="48.97672135866124"/>
<CONT_DATA CI_END="18.43950212106763" CI_START="-14.43950212106763" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="4540" SD_1="55.0" SD_2="54.0" SE="8.387655207310095" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="19.635768974566297"/>
<CONT_DATA CI_END="39.1568927245098" CI_START="-3.156892724509806" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="53.0" ORDER="4541" SD_1="69.0" SD_2="46.0" SE="10.794531374756207" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="55" WEIGHT="11.85554346052663"/>
<CONT_DATA CI_END="35.95884107860774" CI_START="-31.95884107860774" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="66.0" ORDER="4542" SD_1="53.7" SD_2="51.5" SE="17.326257699871398" STUDY_ID="STD-O_x0027_Byrne-1996" TOTAL_1="20" TOTAL_2="17" WEIGHT="4.601712837987033"/>
<CONT_DATA CI_END="10.102937532401661" CI_START="-27.60293753240166" EFFECT_SIZE="-8.75" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="51.25" ORDER="4543" SD_1="62.7" SD_2="61.6" SE="9.619022431591207" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" WEIGHT="14.930253368258791"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.3193479923711562" P_Q="1.0" P_Z="0.6268056443156612" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="397" TOTAL_2="397" UNITS="" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>Diary Card Symptom Score (day) change baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" DF="1.0" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="0.3193479923711562" P_Z="0.6268056443156612" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="397" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.0949956579110747" CI_START="-0.0949956579110747" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.42" ORDER="4544" SD_1="0.64" SD_2="0.57" SE="0.048468063015641265" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="311" WEIGHT="80.74828420233813"/>
<CONT_DATA CI_END="0.30455199359843693" CI_START="-0.08455199359843696" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.45" ORDER="4545" SD_1="0.65" SD_2="0.64" SE="0.09926304520544164" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="19.251715797661884"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.63874798732214" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="398" TOTAL_2="402" UNITS="" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>Diary Card Symptom Score (night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" DF="1.0" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="1.0" P_Z="0.63874798732214" STUDIES="2" TAU2="0.0" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.11212736432696213" CI_START="-0.0721273643269622" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.36" ORDER="4546" SD_1="0.61" SD_2="0.57" SE="0.04700462103061641" STUDY_ID="STD-Campbell--1998" TOTAL_1="315" TOTAL_2="316" WEIGHT="82.14859018915008"/>
<CONT_DATA CI_END="0.2176298057826377" CI_START="-0.17762980578263776" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.42" ORDER="4547" SD_1="0.62" SD_2="0.69" SE="0.10083338639970754" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="17.851409810849916"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.28244531465389533" P_Q="1.0" P_Z="0.4581819409042932" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" DF="1.0" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" ID="CMP-002.06.01" NO="1" P_CHI2="0.28244531465389533" P_Z="0.4581819409042932" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.12857546261999508" CI_START="-0.5685754626199953" EFFECT_SIZE="-0.22000000000000008" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.88" ORDER="4548" SD_1="1.95" SD_2="2.44" SE="0.17784789178245822" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="64.31488393177654"/>
<CONT_DATA CI_END="0.5679602891997918" CI_START="-0.36796028919979185" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.9" ORDER="4549" SD_1="1.6" SD_2="1.5" SE="0.23875963685608656" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="35.685116068223465"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="0.676104830152686" P_Q="1.0" P_Z="0.4135226426615982" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" DF="1.0" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="0.676104830152686" P_Z="0.4135226426615982" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.05666452505601076" CI_START="-0.11666452505601076" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.21" ORDER="4550" SD_1="0.55" SD_2="0.55" SE="0.04421740692156053" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="93.03540991685338"/>
<CONT_DATA CI_END="0.21675079895488042" CI_START="-0.4167507989548804" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.5" ORDER="4551" SD_1="1.0" SD_2="1.1" SE="0.16161052011841556" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.964590083146619"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.49814332460811017" CI_END="2.430232132656587" CI_START="0.1425511244648875" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5885850178359098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.3856477588315893" LOG_CI_START="-0.846029352560276" LOG_EFFECT_SIZE="-0.23019079686434335" METHOD="MH" NO="8" P_CHI2="0.48031711852951564" P_Q="0.0" P_Z="0.46380011309239444" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="149" WEIGHT="100.0" Z="0.7326038086667791">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.49814332460811017" CI_END="2.430232132656587" CI_START="0.1425511244648875" DF="1.0" EFFECT_SIZE="0.5885850178359098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.3856477588315893" LOG_CI_START="-0.846029352560276" LOG_EFFECT_SIZE="-0.23019079686434335" NO="1" P_CHI2="0.48031711852951564" P_Z="0.46380011309239444" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="149" WEIGHT="100.0" Z="0.7326038086667791">
<NAME>Adults</NAME>
<DICH_DATA CI_END="3.123898577516711" CI_START="0.035568091714244104" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4946969253525552" LOG_CI_START="-1.4489394347918803" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="4552" O_E="0.0" SE="1.141701619103992" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="67" VAR="1.3034825870646765" WEIGHT="59.571938168846614"/>
<DICH_DATA CI_END="6.688632338481282" CI_START="0.1391401698209774" EFFECT_SIZE="0.9647058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8253373242592293" LOG_CI_START="-0.8565474709203815" LOG_EFFECT_SIZE="-0.015605073330576038" ORDER="4553" O_E="0.0" SE="0.9879474541525108" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" VAR="0.9760401721664276" WEIGHT="40.42806183115339"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>High vs Low ICS Dose (All)</NAME>
<CONT_OUTCOME CHI2="0.47957962686212796" CI_END="0.15824712397451318" CI_START="-0.5519871257736606" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.19687000089957368" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.4886128305196745" P_Q="1.0" P_Z="0.27722877741232155" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="60" UNITS="" WEIGHT="99.99999999999999" Z="1.0865657676642473">
<NAME>FEV1</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.47957962686212796" CI_END="0.15824712397451318" CI_START="-0.5519871257736606" DF="1.0" EFFECT_SIZE="-0.19687000089957368" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.4886128305196745" P_Z="0.27722877741232155" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="99.99999999999999" Z="1.0865657676642473">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.38218729482511854" CI_START="-1.3241029633789665" EFFECT_SIZE="-0.470957834276924" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="3.09" ORDER="4554" SD_1="0.69" SD_2="0.7" SE="0.4352861255775833" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="17.32596371581677"/>
<CONT_DATA CI_END="0.25112982880466106" CI_START="-0.5299888820138743" EFFECT_SIZE="-0.13942952660460659" ESTIMABLE="YES" MEAN_1="88.3" MEAN_2="89.7" ORDER="4555" SD_1="9.3" SD_2="10.6" SE="0.199268638857627" STUDY_ID="STD-Tukiainen--2000" TOTAL_1="51" TOTAL_2="50" WEIGHT="82.67403628418322"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6006627985107081" CI_END="19.949593455634396" CI_START="-56.04269451338604" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.046550528875823" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.43832541588337126" P_Q="1.0" P_Z="0.35190559627399653" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="100.00000000000001" Z="0.9308994380113496">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6006627985107081" CI_END="19.949593455634396" CI_START="-56.04269451338604" DF="1.0" EFFECT_SIZE="-18.046550528875823" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="0.43832541588337126" P_Z="0.35190559627399653" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.00000000000001" Z="0.9308994380113496">
<NAME>Adults</NAME>
<CONT_DATA CI_END="30.660977310090047" CI_START="-116.66097731009005" EFFECT_SIZE="-43.0" ESTIMABLE="YES" MEAN_1="457.0" MEAN_2="500.0" ORDER="4556" SD_1="114.3" SD_2="56.9" SE="37.58282187382954" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="26.60750155551713"/>
<CONT_DATA CI_END="35.352049019096704" CI_START="-53.352049019096704" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="425.0" MEAN_2="434.0" ORDER="4557" SD_1="98.6" SD_2="94.7" SE="22.629012251725033" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="73.39249844448288"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.15071704735946023" P_Q="1.0" P_Z="0.08146767927689498" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="146" TOTAL_2="136" UNITS="" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>FavoursHigh Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" DF="1.0" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" ID="CMP-003.04.01" NO="1" P_CHI2="0.15071704735946023" P_Z="0.08146767927689498" STUDIES="2" TAU2="0.0" TOTAL_1="146" TOTAL_2="136" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>Adults</NAME>
<CONT_DATA CI_END="49.383191322099684" CI_START="2.616808677900316" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="45.0" ORDER="4558" SD_1="69.0" SD_2="60.0" SE="11.930418878379047" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="56" WEIGHT="33.351797424210346"/>
<CONT_DATA CI_END="21.54128271599394" CI_START="-11.54128271599394" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="37.5" ORDER="4559" SD_1="62.7" SD_2="44.7" SE="8.439585036495297" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" WEIGHT="66.64820257578967"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6737537845299415" CI_END="0.5585664838908377" CI_START="-0.6461874794450229" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0438104977770926" ESTIMABLE="YES" I2="62.59939842681495" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.10201521524358914" P_Q="1.0" P_Z="0.8866480021204945" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="99.99999999999999" Z="0.1425469438591681">
<NAME>Rescue Medications (puffs per day)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6737537845299415" CI_END="0.5585664838908377" CI_START="-0.6461874794450229" DF="1.0" EFFECT_SIZE="-0.0438104977770926" ESTIMABLE="YES" I2="62.59939842681495" ID="CMP-003.06.01" NO="1" P_CHI2="0.10201521524358914" P_Z="0.8866480021204945" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="99.99999999999999" Z="0.1425469438591681">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.3895248256254782" CI_START="-3.9895248256254785" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.6" ORDER="4560" SD_1="1.73" SD_2="3.16" SE="1.1171250303047253" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="7.568973567215399"/>
<CONT_DATA CI_END="0.7265554040177095" CI_START="-0.5265554040177095" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.8" ORDER="4561" SD_1="1.54" SD_2="1.18" SE="0.31967699863869875" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="92.43102643278459"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" METHOD="MH" NO="9" P_CHI2="0.20416258909086904" P_Q="0.0" P_Z="0.42845627127583574" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="0.7918360754774336">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" DF="1.0" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" ID="CMP-003.09.01" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" NO="1" P_CHI2="0.20416258909086904" P_Z="0.42845627127583574" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="0.7918360754774336">
<NAME>Adults</NAME>
<DICH_DATA CI_END="2.0468258985652774" CI_START="0.026997938727846522" EFFECT_SIZE="0.23507462686567165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31108090347930123" LOG_CI_START="-1.5686693926297155" LOG_EFFECT_SIZE="-0.628794244575207" ORDER="4562" O_E="0.0" SE="1.1041746288484697" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="1.2192016109926558" WEIGHT="80.00723719920391"/>
<DICH_DATA CI_END="20.35820012661124" CI_START="0.174045474212828" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3087393792819173" LOG_CI_START="-0.7593372653986533" LOG_EFFECT_SIZE="0.27470105694163205" ORDER="4563" O_E="0.0" SE="1.214798458229861" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" VAR="1.4757352941176471" WEIGHT="19.992762800796093"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Moderate vs Low ICS Dose (All)</NAME>
<CONT_OUTCOME CHI2="3.8829016852751153" CI_END="0.2840817161698702" CI_START="-0.05573095452110609" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.11417538082438207" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.4220854290959357" P_Q="0.6223046783380115" P_Z="0.18781299736300933" Q="0.24264165400343218" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="268" TOTAL_2="268" UNITS="" WEIGHT="100.0" Z="1.3170764579313636">
<NAME>FEV1 change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.640260031271683" CI_END="0.38046115567818906" CI_START="-0.07564733531473994" DF="3.0" EFFECT_SIZE="0.15240691018172456" ESTIMABLE="YES" I2="17.588304840080767" ID="CMP-004.01.01" NO="1" P_CHI2="0.3030214714970112" P_Z="0.1902537041727641" STUDIES="4" TAU2="0.0" TOTAL_1="151" TOTAL_2="148" WEIGHT="55.506369520258524" Z="1.3098289588993508">
<NAME>Adults</NAME>
<CONT_DATA CI_END="2.2544040863311006" CI_START="0.015887887004713663" EFFECT_SIZE="1.135145986667907" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.0" ORDER="4564" SD_1="0.53" SD_2="0.28" SE="0.5710605442200767" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="2.3044041775507043"/>
<CONT_DATA CI_END="0.7088785734083383" CI_START="-0.23848234131754717" EFFECT_SIZE="0.23519811604539556" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.14" ORDER="4565" SD_1="0.42" SD_2="0.33" SE="0.24167814362879814" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="35" TOTAL_2="34" WEIGHT="12.866138165611913"/>
<CONT_DATA CI_END="0.6740450407355303" CI_START="-0.33996335355591273" EFFECT_SIZE="0.1670408435898088" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.3" ORDER="4566" SD_1="0.55" SD_2="0.38" SE="0.25868036410102735" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="11.230420982933778"/>
<CONT_DATA CI_END="0.3472907387291552" CI_START="-0.2825818896783239" EFFECT_SIZE="0.032354424525415634" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="0.4" ORDER="4567" SD_1="0.62" SD_2="0.61" SE="0.16068474558099896" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="29.105406194162125"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.32119965731034755" CI_START="-0.18823753322396347" DF="0.0" EFFECT_SIZE="0.06648106204319203" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" NO="2" P_CHI2="1.0" P_Z="0.6089682149834563" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="44.49363047974147" Z="0.5115468194301506">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.32119965731034755" CI_START="-0.18823753322396347" EFFECT_SIZE="0.06648106204319203" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.2" ORDER="4568" SD_1="12.98" SD_2="10.95" SE="0.1299608550342472" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="44.49363047974147"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5037226311746015" CI_END="20.933815511487794" CI_START="1.3387608045442096" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.136288158016002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.9731375802234453" P_Q="1.0" P_Z="0.025895269370531142" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="202" UNITS="" WEIGHT="100.00000000000001" Z="2.2277787980287576">
<NAME>Morning PEF (L/min) change baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5037226311746015" CI_END="20.933815511487794" CI_START="1.3387608045442096" DF="4.0" EFFECT_SIZE="11.136288158016002" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" NO="1" P_CHI2="0.9731375802234453" P_Z="0.025895269370531142" STUDIES="5" TAU2="0.0" TOTAL_1="209" TOTAL_2="202" WEIGHT="100.00000000000001" Z="2.2277787980287576">
<NAME>Adults</NAME>
<CONT_DATA CI_END="45.09887700374776" CI_START="-13.098877003747763" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="20.0" ORDER="4569" SD_1="37.0" SD_2="14.1" SE="14.846638628707462" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="11.33653965800383"/>
<CONT_DATA CI_END="34.60004411485052" CI_START="-12.600044114850519" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="36.0" ORDER="4570" SD_1="55.48" SD_2="45.25" SE="12.041060091412216" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="17.2348433234299"/>
<CONT_DATA CI_END="27.868123256247863" CI_START="-11.868123256247863" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="45.0" ORDER="4571" SD_1="46.0" SD_2="60.0" SE="10.136983849175333" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="24.3175197993566"/>
<CONT_DATA CI_END="32.84374715781936" CI_START="-22.843747157819358" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="29.0" ORDER="4572" SD_1="49.3" SD_2="60.2" SE="14.206254491127021" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="12.381623860886464"/>
<CONT_DATA CI_END="30.62521941892898" CI_START="-2.6252194189289817" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="31.0" ORDER="4573" SD_1="53.3" SD_2="52.3" SE="8.482410671862642" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="34.72947335832321"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4779818931326487" CI_END="14.752780494942527" CI_START="-6.162564258825797" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.295108118058365" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.477595685290381" P_Q="1.0" P_Z="0.42082901508280557" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="0.804983835572042">
<NAME>Evening PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4779818931326487" CI_END="14.752780494942527" CI_START="-6.162564258825797" DF="2.0" EFFECT_SIZE="4.295108118058365" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" NO="1" P_CHI2="0.477595685290381" P_Z="0.42082901508280557" STUDIES="3" TAU2="0.0" TOTAL_1="123" TOTAL_2="118" WEIGHT="100.0" Z="0.804983835572042">
<NAME>Adults</NAME>
<CONT_DATA CI_END="17.071234070417596" CI_START="-19.071234070417596" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.0" ORDER="4574" SD_1="36.99" SD_2="39.6" SE="9.220186805962346" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="33.48840331538059"/>
<CONT_DATA CI_END="18.814036787541017" CI_START="-18.814036787541017" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="41.0" ORDER="4575" SD_1="42.0" SD_2="58.0" SE="9.599174748078912" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="30.8962724445258"/>
<CONT_DATA CI_END="30.523327618696882" CI_START="-4.523327618696882" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="16.0" ORDER="4576" SD_1="43.8" SD_2="21.9" SE="8.9406375611586" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="35.61532424009362"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="0.2996611106850058" P_Q="1.0" P_Z="0.12015294096517" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="64" UNITS="" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>PEF Diurnal Variation change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" DF="1.0" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" ID="CMP-004.04.01" NO="1" P_CHI2="0.2996611106850058" P_Z="0.12015294096517" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="64" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.25578014000653204" CI_START="-1.8833514573756898" EFFECT_SIZE="-0.8137856586845789" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.4" ORDER="4577" SD_1="3.97" SD_2="3.68" SE="0.5457068635585701" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="10.852737797516065"/>
<CONT_DATA CI_END="0.1588467426680976" CI_START="-0.5875215012691248" EFFECT_SIZE="-0.21433737930051364" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-4.0" ORDER="4578" SD_1="27.0" SD_2="37.0" SE="0.19040356093899682" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="89.14726220248393"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.975259928265272" CI_END="0.13224825732538276" CI_START="-0.21047048014087072" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.039111111407743995" ESTIMABLE="YES" I2="83.26432637232037" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="0.014507992318637974" P_Q="1.0" P_Z="0.6546276125075663" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="0.44734274128831386">
<NAME>Symptom Score change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.975259928265272" CI_END="0.13224825732538276" CI_START="-0.21047048014087072" DF="1.0" EFFECT_SIZE="-0.039111111407743995" ESTIMABLE="YES" I2="83.26432637232037" ID="CMP-004.05.01" NO="1" P_CHI2="0.014507992318637974" P_Z="0.6546276125075663" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="38" WEIGHT="100.0" Z="0.44734274128831386">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-0.1430767548112396" CI_START="-1.2569232451887604" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.4" ORDER="4579" SD_1="0.53" SD_2="0.57" SE="0.2841497341694541" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="9.467275535307396"/>
<CONT_DATA CI_END="0.21009641115078911" CI_START="-0.15009641115078912" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.23" ORDER="4580" SD_1="0.33" SD_2="0.38" SE="0.0918876125129679" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="90.5327244646926"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.001652262246133" CI_END="-0.05962694869083565" CI_START="-0.5279432585579156" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2937851036243756" ESTIMABLE="YES" I2="0.08254491937968925" I2_Q="0.0" ID="CMP-004.06" NO="6" P_CHI2="0.36757576228425937" P_Q="1.0" P_Z="0.013930254474781564" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="138" UNITS="" WEIGHT="99.99999999999997" Z="2.4590568817113074">
<NAME>Symptom (Night Waking) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.001652262246133" CI_END="-0.05962694869083565" CI_START="-0.5279432585579156" DF="2.0" EFFECT_SIZE="-0.2937851036243756" ESTIMABLE="YES" I2="0.08254491937968925" ID="CMP-004.06.01" NO="1" P_CHI2="0.36757576228425937" P_Z="0.013930254474781564" STUDIES="3" TAU2="0.0" TOTAL_1="147" TOTAL_2="138" WEIGHT="99.99999999999997" Z="2.4590568817113074">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.4702516451262082" CI_START="-0.4702516451262082" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" ORDER="4581" SD_1="0.62" SD_2="0.57" SE="0.23992871748434827" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="24.794646886093386"/>
<CONT_DATA CI_END="0.10123416745845132" CI_START="-0.9222319568228723" EFFECT_SIZE="-0.4104988946822105" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.01" ORDER="4582" SD_1="0.16" SD_2="0.22" SE="0.2610930946574258" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.937827673025744"/>
<CONT_DATA CI_END="-0.06512079875216148" CI_START="-0.7008457743231314" EFFECT_SIZE="-0.38298328653764646" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="-0.1" ORDER="4583" SD_1="0.27" SD_2="0.35" SE="0.16217771871970288" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="54.26752544088085"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03982061266901364" CI_END="0.2757419795110977" CI_START="-0.9762891845804921" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3502736025346972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" NO="7" P_CHI2="0.9979116736366878" P_Q="0.9836691160726027" P_Z="0.27279188348267214" Q="4.189863978633912E-4" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="234" UNITS="" WEIGHT="99.99999999999999" Z="1.0966558427500661">
<NAME>Rescue Medications (no. of puffs) change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.03940162627115025" CI_END="0.2887619622378015" CI_START="-0.9921330062265987" DF="2.0" EFFECT_SIZE="-0.3516855219943986" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" NO="1" P_CHI2="0.980491985927362" P_Z="0.28180895110427184" STUDIES="3" TAU2="0.0" TOTAL_1="116" TOTAL_2="114" WEIGHT="95.5439602353685" Z="1.0762646024280136">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.43031635091716447" CI_START="-1.2303163509171644" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.5" ORDER="4584" SD_1="0.79" SD_2="0.85" SE="0.4236385757425105" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="56.843800422214244"/>
<CONT_DATA CI_END="3.7765170490521847" CI_START="-4.696517049052185" EFFECT_SIZE="-0.45999999999999985" ESTIMABLE="YES" MEAN_1="-1.39" MEAN_2="-0.93" ORDER="4585" SD_1="11.7" SD_2="1.81" SE="2.1615280089171485" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="2.1834958439488927"/>
<CONT_DATA CI_END="0.7659519106797645" CI_START="-1.3059519106797646" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.85" MEAN_2="-1.58" ORDER="4586" SD_1="2.8" SD_2="3.7" SE="0.528556605555623" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="36.516663969205375"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.645586625714369" CI_START="-3.2855866257143687" DF="0.0" EFFECT_SIZE="-0.31999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.02" NO="2" P_CHI2="1.0" P_Z="0.8325058398955612" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="4.456039764631482" Z="0.21148883988567901">
<NAME>Children</NAME>
<CONT_DATA CI_END="2.645586625714369" CI_START="-3.2855866257143687" EFFECT_SIZE="-0.31999999999999995" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-0.56" ORDER="4587" SD_1="2.16" SD_2="16.43" SE="1.5130822041152479" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="4.456039764631482"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.39840228821690266" CI_END="2.4643517225494174" CI_START="0.40946152387386703" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0045183978784429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.39170269223476323" LOG_CI_START="-0.3877869016064639" LOG_EFFECT_SIZE="0.0019578953141497087" METHOD="MH" NO="8" P_CHI2="0.8193851354593066" P_Q="0.0" P_Z="0.9921442025631493" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="260" TOTAL_2="263" WEIGHT="99.99999999999999" Z="0.009845941065929866">
<NAME>Withdrawal due to Adverse Event</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.027248350434825" CI_START="0.1642880478216715" DF="0.0" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="0.48104805121725613" LOG_CI_START="-0.7843940309283456" LOG_EFFECT_SIZE="-0.1516729898555447" NO="1" P_CHI2="1.0" P_Z="0.6384739162380269" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="63" WEIGHT="45.77201908248417" Z="0.4698335889704865">
<NAME>Adults</NAME>
<DICH_DATA CI_END="3.0272483504348244" CI_START="0.16428804782167156" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.481048051217256" LOG_CI_START="-0.7843940309283454" LOG_EFFECT_SIZE="-0.1516729898555447" ORDER="4588" O_E="0.0" SE="0.743326943091658" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="0.552534944325989" WEIGHT="45.77201908248417"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.206354283559662" CI_START="0.06490907795006694" DF="0.0" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.08.02" LOG_CI_END="1.2096853286913705" LOG_CI_START="-1.1876945600884439" LOG_EFFECT_SIZE="0.010995384301463145" NO="2" P_CHI2="1.0" P_Z="0.9856560650087007" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="10.960898202729775" Z="0.01797842496961412">
<NAME>Children</NAME>
<DICH_DATA CI_END="16.206354283559662" CI_START="0.06490907795006694" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096853286913705" LOG_CI_START="-1.1876945600884439" LOG_EFFECT_SIZE="0.010995384301463145" ORDER="4589" O_E="0.0" SE="1.4082328138911044" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="1.9831196581196582" WEIGHT="10.960898202729775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.717069281884235" CI_START="0.3670291521278235" DF="0.0" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-004.08.03" LOG_CI_END="0.6736722549862263" LOG_CI_START="-0.435299439547809" LOG_EFFECT_SIZE="0.11918640771920867" NO="3" P_CHI2="1.0" P_Z="0.6735410625558998" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="43.26708271478604" Z="0.4212931091528167">
<NAME>Infants</NAME>
<DICH_DATA CI_END="4.7170692818842355" CI_START="0.3670291521278234" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6736722549862264" LOG_CI_START="-0.4352994395478091" LOG_EFFECT_SIZE="0.11918640771920867" ORDER="4590" O_E="0.0" SE="0.6514154628677139" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4243421052631579" WEIGHT="43.26708271478604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5183178956499688" CI_END="1.1708833067993532" CI_START="0.9305743803910735" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0438361977509016" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="148" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.06851361433927847" LOG_CI_START="-0.03124890818352177" LOG_EFFECT_SIZE="0.018632353077878375" METHOD="MH" NO="9" P_CHI2="0.7717003656253315" P_Q="0.0" P_Z="0.4640993465234754" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="261" TOTAL_2="262" WEIGHT="100.00000000000001" Z="0.732113424087276">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.897996678081558" CI_START="0.19140590658602794" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="1.320104655806998" LOG_CI_START="-0.7180446644790355" LOG_EFFECT_SIZE="0.3010299956639812" NO="1" P_CHI2="1.0" P_Z="0.5626131970048236" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="62" WEIGHT="0.6881302556199538" Z="0.5789644005914643">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4591" O_E="0.0" SE="0.0" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="4592" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.6881302556199538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1950311955197361" CI_START="0.8594272876174881" DF="0.0" EFFECT_SIZE="1.0134310134310134" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="84" I2="0.0" ID="CMP-004.09.02" LOG_CI_END="0.07737924240988746" LOG_CI_START="-0.0657908611785766" LOG_EFFECT_SIZE="0.005794190615655409" NO="2" P_CHI2="1.0" P_Z="0.8739508360429238" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="57.07125866863212" Z="0.15864212767335892">
<NAME>Children</NAME>
<DICH_DATA CI_END="1.195031195519736" CI_START="0.8594272876174881" EFFECT_SIZE="1.0134310134310134" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="84" LOG_CI_END="0.07737924240988739" LOG_CI_START="-0.0657908611785766" LOG_EFFECT_SIZE="0.005794190615655409" ORDER="4593" O_E="0.0" SE="0.08409882755130633" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.007072612795504361" WEIGHT="57.07125866863212"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2421247758921332" CI_START="0.9205903412664099" DF="0.0" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="63" I2="0.0" ID="CMP-004.09.03" LOG_CI_END="0.09416522447145745" LOG_CI_START="-0.03593358598854208" LOG_EFFECT_SIZE="0.029115819241457678" NO="3" P_CHI2="1.0" P_Z="0.3803394665569523" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="42.240611075747935" Z="0.8772710048902561">
<NAME>Infants</NAME>
<DICH_DATA CI_END="1.2421247758921332" CI_START="0.9205903412664099" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="63" LOG_CI_END="0.09416522447145745" LOG_CI_START="-0.03593358598854208" LOG_EFFECT_SIZE="0.029115819241457678" ORDER="4594" O_E="0.0" SE="0.07642068526370178" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.005840121136173767" WEIGHT="42.240611075747935"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.907967776753731" CI_END="2.3857048546202426" CI_START="0.34106425463937723" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.902041378225299" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="74.4112526733606" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="0.3776167142973157" LOG_CI_START="-0.46716379459536894" LOG_EFFECT_SIZE="-0.04477354014902663" METHOD="MH" NO="10" P_CHI2="0.04805773694647619" P_Q="0.0" P_Z="0.8354187201061429" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.2077569859358535">
<NAME>Oral Candidiasis</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="158.21294703008436" CI_START="0.47429055370374523" DF="0.0" EFFECT_SIZE="8.6625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="2.199242020208752" LOG_CI_START="-0.3239555249690255" LOG_EFFECT_SIZE="0.9376432476198632" NO="1" P_CHI2="1.0" P_Z="0.14520444943436198" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="76" WEIGHT="6.1359345500314655" Z="1.4566810269725603">
<NAME>Adults</NAME>
<DICH_DATA CI_END="158.21294703008422" CI_START="0.4742905537037454" EFFECT_SIZE="8.6625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1992420202087515" LOG_CI_START="-0.32395552496902535" LOG_EFFECT_SIZE="0.9376432476198632" ORDER="4595" O_E="0.0" SE="1.4821387280667113" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" VAR="2.196735209235209" WEIGHT="6.1359345500314655"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4328858780172062" CI_START="0.10874360401321813" DF="0.0" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-004.10.03" LOG_CI_END="0.15621160245523724" LOG_CI_START="-0.9635962775774951" LOG_EFFECT_SIZE="-0.40369233756112893" NO="3" P_CHI2="1.0" P_Z="0.15761467503410106" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="93.86406544996852" Z="1.4131396225421655">
<NAME>Infants</NAME>
<DICH_DATA CI_END="1.4328858780172062" CI_START="0.10874360401321813" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.15621160245523724" LOG_CI_START="-0.9635962775774951" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="4596" O_E="0.0" SE="0.6577806918696316" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4326754385964912" WEIGHT="93.86406544996852"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5703993490512858" CI_END="1.426180986805702" CI_START="0.472745362488104" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8211092787084454" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="0.15417464233450784" LOG_CI_START="-0.3253727227805531" LOG_EFFECT_SIZE="-0.08559904022302264" METHOD="MH" NO="11" P_CHI2="0.45010038935989527" P_Q="0.0" P_Z="0.4841110596104947" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0" Z="0.6997057982294007">
<NAME>Exacerbations</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.040938856995785" CI_START="0.2617940396194572" DF="0.0" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-004.11.02" LOG_CI_END="0.9562135321613053" LOG_CI_START="-0.5820402454470163" LOG_EFFECT_SIZE="0.18708664335714445" NO="2" P_CHI2="1.0" P_Z="0.6335384529374273" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="8.801319329919279" Z="0.4767523906732895">
<NAME>Children</NAME>
<DICH_DATA CI_END="9.040938856995785" CI_START="0.2617940396194572" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9562135321613053" LOG_CI_START="-0.5820402454470163" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="4597" O_E="0.0" SE="0.9035778834461319" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.8164529914529914" WEIGHT="8.801319329919279"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.347580365927445" CI_START="0.4195097349554893" DF="0.0" EFFECT_SIZE="0.7518796992481203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="0.0" ID="CMP-004.11.03" LOG_CI_END="0.1295546747404524" LOG_CI_START="-0.37725795667462403" LOG_EFFECT_SIZE="-0.12385164096708583" NO="3" P_CHI2="1.0" P_Z="0.33809957453792894" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="91.19868067008072" Z="0.9579270155280218">
<NAME>Infants</NAME>
<DICH_DATA CI_END="1.347580365927445" CI_START="0.4195097349554893" EFFECT_SIZE="0.7518796992481203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.1295546747404524" LOG_CI_START="-0.37725795667462403" LOG_EFFECT_SIZE="-0.12385164096708583" ORDER="4598" O_E="0.0" SE="0.2977042484562022" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.08862781954887218" WEIGHT="91.19868067008072"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17122975367256682" CI_END="1.2712187758150482" CI_START="0.29980616043983177" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6173485403369258" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="0.104220298746719" LOG_CI_START="-0.5231594474799434" LOG_EFFECT_SIZE="-0.2094695743666122" METHOD="MH" NO="12" P_CHI2="0.6790214714162608" P_Q="0.0" P_Z="0.19060695065167968" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="1.308785704622247">
<NAME>Plasma Cortisol below reference range</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.593272699972858E-32" CI_END="1.8840158732341867" CI_START="0.12630127082724826" DF="0.0" EFFECT_SIZE="0.48780487804878053" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" ID="CMP-004.12.01" LOG_CI_END="0.2750845574955937" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.31175386105575426" NO="1" P_CHI2="0.0" P_Z="0.29777470273847273" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="80" WEIGHT="33.89138851103903" Z="1.0412173443227255">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.8840158732341865" CI_START="0.12630127082724826" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27508455749559363" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.3117538610557543" ORDER="4599" O_E="0.0" SE="0.6894235839081664" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" VAR="0.47530487804878047" WEIGHT="33.89138851103903"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4485744510283997E-31" CI_END="1.6119451793392632" CI_START="0.29004005759582824" DF="0.0" EFFECT_SIZE="0.6837606837606837" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="100.0" ID="CMP-004.12.02" LOG_CI_END="0.20735026779457044" LOG_CI_START="-0.5375420173030068" LOG_EFFECT_SIZE="-0.1650958747542181" NO="2" P_CHI2="0.0" P_Z="0.38495542610345057" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="66.10861148896096" Z="0.8688020402091169">
<NAME>Children</NAME>
<DICH_DATA CI_END="1.6119451793392634" CI_START="0.2900400575958283" EFFECT_SIZE="0.6837606837606838" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2073502677945705" LOG_CI_START="-0.5375420173030067" LOG_EFFECT_SIZE="-0.16509587475421805" ORDER="4600" O_E="0.0" SE="0.4375534155425957" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.19145299145299144" WEIGHT="66.10861148896096"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Fold Difference in ICS Dose (All)</NAME>
<CONT_OUTCOME CHI2="7.298428171491328" CI_END="0.3469075067536008" CI_START="-0.17725771531019271" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08482489572170407" ESTIMABLE="YES" I2="45.19367861117611" I2_Q="63.7767557326098" ID="CMP-005.01" NO="1" P_CHI2="0.12093339396003233" P_Q="0.09660856039691712" P_Z="0.5258483626052557" Q="2.7606583016647273" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="118" TOTAL_2="111" UNITS="" WEIGHT="200.0" Z="0.6343562434467344">
<NAME>FEV1</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Base Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fold Change</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.537769869826601" CI_END="0.3054776947290886" CI_START="-0.23043672817020902" DF="3.0" EFFECT_SIZE="0.03752048327943977" ESTIMABLE="YES" I2="33.888229547554445" ID="CMP-005.01.01" NO="1" P_CHI2="0.208945994424796" P_Z="0.7837447328389964" STUDIES="4" TAU2="0.0" TOTAL_1="112" TOTAL_2="105" WEIGHT="100.0" Z="0.27444230932391894">
<NAME>&gt; = 4 Fold Change</NAME>
<CONT_DATA CI_END="0.38218729482511854" CI_START="-1.3241029633789665" EFFECT_SIZE="-0.470957834276924" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="3.09" ORDER="4601" SD_1="0.69" SD_2="0.7" SE="0.4352861255775833" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="9.864726932766398"/>
<CONT_DATA CI_END="1.0497522845465137" CI_START="-0.16469837979559876" EFFECT_SIZE="0.44252695237545747" ESTIMABLE="YES" MEAN_1="82.5" MEAN_2="73.5" ORDER="4602" SD_1="20.6" SD_2="19.2" SE="0.30981453585921587" STUDY_ID="STD-Pedersen-1996" TOTAL_1="23" TOTAL_2="20" WEIGHT="19.472922566467144"/>
<CONT_DATA CI_END="0.25112982880466106" CI_START="-0.5299888820138743" EFFECT_SIZE="-0.13942952660460659" ESTIMABLE="YES" MEAN_1="88.3" MEAN_2="89.7" ORDER="4603" SD_1="9.3" SD_2="10.6" SE="0.199268638857627" STUDY_ID="STD-Tukiainen--2000" TOTAL_1="51" TOTAL_2="50" WEIGHT="47.07136675050126"/>
<CONT_DATA CI_END="0.8205928815243554" CI_START="-0.28278028900507957" EFFECT_SIZE="0.2689062962596379" ESTIMABLE="YES" MEAN_1="106.4" MEAN_2="102.6" ORDER="4604" SD_1="14.3" SD_2="13.5" SE="0.2814779198068693" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="23.590983750265195"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.3868423117151716" CI_START="-0.1301983775874438" DF="0.0" EFFECT_SIZE="1.1283219670638638" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" NO="2" P_CHI2="1.0" P_Z="0.07888393258715808" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="1.7571987833246225">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="2.3868423117151716" CI_START="-0.1301983775874438" EFFECT_SIZE="1.1283219670638638" ESTIMABLE="YES" MEAN_1="81.4" MEAN_2="70.0" ORDER="4605" SD_1="8.6" SD_2="10.0" SE="0.6421140156545505" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.739371949183415" CI_END="0.2797638632817516" CI_START="0.023757012521276433" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.15176043790151403" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="0.6917338229411432" P_Q="0.8073889717267632" P_Z="0.02014014008415401" Q="0.05943639467894357" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="475" TOTAL_2="469" UNITS="" WEIGHT="200.0" Z="2.3237268196646035">
<NAME>FEV1 change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Base Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fold Change</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.078602477501003" CI_END="0.4343332664660963" CI_START="-0.07591099053708611" DF="2.0" EFFECT_SIZE="0.1792111379645051" ESTIMABLE="YES" I2="50.963595716113566" ID="CMP-005.02.01" NO="1" P_CHI2="0.13011985921984637" P_Z="0.16857987369086894" STUDIES="3" TAU2="0.0" TOTAL_1="122" TOTAL_2="118" WEIGHT="100.0" Z="1.3767813011824965">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="2.2544040863311006" CI_START="0.015887887004713663" EFFECT_SIZE="1.135145986667907" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.0" ORDER="4606" SD_1="0.53" SD_2="0.28" SE="0.5710605442200767" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="5.195600709110136"/>
<CONT_DATA CI_END="0.8115227043344951" CI_START="-0.13301458231189234" EFFECT_SIZE="0.3392540610113014" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.14" ORDER="4607" SD_1="0.47" SD_2="0.33" SE="0.24095781710704303" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="36" TOTAL_2="34" WEIGHT="29.18220048804987"/>
<CONT_DATA CI_END="0.3472907387291552" CI_START="-0.2825818896783239" EFFECT_SIZE="0.032354424525415634" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="0.4" ORDER="4608" SD_1="0.62" SD_2="0.61" SE="0.16068474558099896" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="65.62219880283999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.601333077003468" CI_END="0.2905023172886521" CI_START="-0.005451829975065159" DF="4.0" EFFECT_SIZE="0.14252524365679348" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" NO="2" P_CHI2="0.9629154704904836" P_Z="0.05905895436813621" STUDIES="5" TAU2="0.0" TOTAL_1="353" TOTAL_2="351" WEIGHT="99.99999999999999" Z="1.8877542148864996">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="0.4469757111072744" CI_START="-0.13348057199638239" EFFECT_SIZE="0.15674756955544603" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="6.7" ORDER="4609" SD_1="12.7" SD_2="11.4" SE="0.14807830339797615" STUDY_ID="STD-Hampel-2000" TOTAL_1="92" TOTAL_2="91" WEIGHT="25.996197473920002"/>
<CONT_DATA CI_END="0.7088785734083383" CI_START="-0.23848234131754717" EFFECT_SIZE="0.23519811604539556" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.14" ORDER="4610" SD_1="0.42" SD_2="0.33" SE="0.24167814362879814" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="35" TOTAL_2="34" WEIGHT="9.759283503273927"/>
<CONT_DATA CI_END="0.32119965731034755" CI_START="-0.18823753322396347" EFFECT_SIZE="0.06648106204319203" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.2" ORDER="4611" SD_1="12.98" SD_2="10.95" SE="0.1299608550342472" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="33.74951740393152"/>
<CONT_DATA CI_END="0.6740450407355303" CI_START="-0.33996335355591273" EFFECT_SIZE="0.1670408435898088" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.3" ORDER="4612" SD_1="0.55" SD_2="0.38" SE="0.25868036410102735" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="8.51855162930736"/>
<CONT_DATA CI_END="0.5074838205188713" CI_START="-0.12383052881289355" EFFECT_SIZE="0.1918266458529889" ESTIMABLE="YES" MEAN_1="0.51" MEAN_2="0.4" ORDER="4613" SD_1="0.53" SD_2="0.61" SE="0.16105253828934915" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="21.976449989567172"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.0257995889317733" CI_END="20.81446967476814" CI_START="-19.86951870785429" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4724754834569238" ESTIMABLE="YES" I2="0.8526535936532904" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="0.38766468048035696" P_Q="0.3315830791990193" P_Z="0.9636901945372544" Q="0.9427059446863031" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="76" UNITS="" WEIGHT="200.0" Z="0.04552331115841451">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Base Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fold Change</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.08309364424547" CI_END="22.340475846010893" CI_START="-18.704556984662037" DF="2.0" EFFECT_SIZE="1.817959430674427" ESTIMABLE="YES" I2="3.988953855963975" ID="CMP-005.03.01" NO="1" P_CHI2="0.3529085343194539" P_Z="0.8621635114619038" STUDIES="3" TAU2="0.0" TOTAL_1="76" TOTAL_2="70" WEIGHT="100.0" Z="0.17362076547367697">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="30.660977310090047" CI_START="-116.66097731009005" EFFECT_SIZE="-43.0" ESTIMABLE="YES" MEAN_1="457.0" MEAN_2="500.0" ORDER="4614" SD_1="114.3" SD_2="56.9" SE="37.58282187382954" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="7.762225766462573"/>
<CONT_DATA CI_END="35.352049019096704" CI_START="-53.352049019096704" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="425.0" MEAN_2="434.0" ORDER="4615" SD_1="98.6" SD_2="94.7" SE="22.629012251725033" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="21.410846911054787"/>
<CONT_DATA CI_END="34.38548575498966" CI_START="-14.385485754989656" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="244.0" MEAN_2="234.0" ORDER="4616" SD_1="51.0" SD_2="37.0" SE="12.441802985840177" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="70.82692732248265"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="78.70416958322528" CI_START="-228.70416958322528" DF="0.0" EFFECT_SIZE="-75.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" NO="2" P_CHI2="1.0" P_Z="0.33888783771392517" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.9563650695950074">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="78.70416958322528" CI_START="-228.70416958322528" EFFECT_SIZE="-75.0" ESTIMABLE="YES" MEAN_1="375.0" MEAN_2="450.0" ORDER="4617" SD_1="120.0" SD_2="150.0" SE="78.4219357067906" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.660322928459275" CI_END="12.871528458148138" CI_START="3.0311895845987253" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.951359021373431" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" NO="4" P_CHI2="0.8792207376053537" P_Q="0.5197094457529463" P_Z="0.0015378358950590015" Q="0.4144699111228345" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1025" TOTAL_2="1002" UNITS="" WEIGHT="200.0" Z="3.1674472821113913">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Base</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fold Change</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.4425813576852713" CI_END="18.667347995659117" CI_START="1.7538930193648241" DF="4.0" EFFECT_SIZE="10.21062050751197" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" NO="1" P_CHI2="0.48666279931789325" P_Z="0.017959452598025318" STUDIES="5" TAU2="0.0" TOTAL_1="315" TOTAL_2="306" WEIGHT="100.0" Z="2.3664530378422115">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="18.43950212106763" CI_START="-14.43950212106763" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="4618" SD_1="55.0" SD_2="54.0" SE="8.387655207310095" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="26.462285509180894"/>
<CONT_DATA CI_END="45.09887700374776" CI_START="-13.098877003747763" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="20.0" ORDER="4619" SD_1="37.0" SD_2="14.1" SE="14.846638628707462" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="8.44602211660912"/>
<CONT_DATA CI_END="49.383191322099684" CI_START="2.616808677900316" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="45.0" ORDER="4620" SD_1="69.0" SD_2="60.0" SE="11.930418878379047" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="56" WEIGHT="13.079679605417335"/>
<CONT_DATA CI_END="30.62521941892898" CI_START="-2.6252194189289817" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="31.0" ORDER="4621" SD_1="53.3" SD_2="52.3" SE="8.482410671862642" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="25.874376920252818"/>
<CONT_DATA CI_END="21.54128271599394" CI_START="-11.54128271599394" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="37.5" ORDER="4622" SD_1="62.7" SD_2="44.7" SE="8.439585036495297" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" WEIGHT="26.13763584853984"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.8032716596511684" CI_END="12.844700170661495" CI_START="0.7458442598527846" DF="7.0" EFFECT_SIZE="6.79527221525714" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" NO="2" P_CHI2="0.9025853012505465" P_Z="0.0276927786533407" STUDIES="8" TAU2="0.0" TOTAL_1="710" TOTAL_2="696" WEIGHT="100.0" Z="2.2016112771706644">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="19.409209826058163" CI_START="-1.409209826058163" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="26.0" ORDER="4623" SD_1="70.8" SD_2="62.0" SE="5.310918929207211" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="314" WEIGHT="33.77482378611206"/>
<CONT_DATA CI_END="19.480753424106165" CI_START="-10.880753424106171" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" MEAN_1="33.8" MEAN_2="29.5" ORDER="4624" SD_1="54.07" SD_2="50.67" SE="7.745424683233985" STUDY_ID="STD-Hampel-2000" TOTAL_1="92" TOTAL_2="91" WEIGHT="15.879688005966742"/>
<CONT_DATA CI_END="34.60004411485052" CI_START="-12.600044114850519" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="36.0" ORDER="4625" SD_1="55.48" SD_2="45.25" SE="12.041060091412216" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="6.57056912053531"/>
<CONT_DATA CI_END="27.868123256247863" CI_START="-11.868123256247863" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="45.0" ORDER="4626" SD_1="46.0" SD_2="60.0" SE="10.136983849175333" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="9.270751215036908"/>
<CONT_DATA CI_END="32.84374715781936" CI_START="-22.843747157819358" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="29.0" ORDER="4627" SD_1="49.3" SD_2="60.2" SE="14.206254491127021" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="4.720339713899615"/>
<CONT_DATA CI_END="35.95884107860774" CI_START="-31.95884107860774" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="66.0" ORDER="4628" SD_1="53.7" SD_2="51.5" SE="17.326257699871398" STUDY_ID="STD-O_x0027_Byrne-1996" TOTAL_1="20" TOTAL_2="17" WEIGHT="3.173385965939433"/>
<CONT_DATA CI_END="12.625219418928982" CI_START="-20.62521941892898" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="31.0" ORDER="4629" SD_1="53.3" SD_2="52.3" SE="8.482410671862642" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="13.240178685606974"/>
<CONT_DATA CI_END="30.29414491855707" CI_START="-2.7941449185570697" EFFECT_SIZE="13.75" ESTIMABLE="YES" MEAN_1="51.25" MEAN_2="37.5" ORDER="4630" SD_1="61.6" SD_2="44.7" SE="8.441045370759449" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" WEIGHT="13.370263506902964"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9772188914078024" CI_END="11.59186375928496" CI_START="-3.6416516778397257" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.975106040722617" ESTIMABLE="YES" I2="0.0" I2_Q="14.44923684020151" ID="CMP-005.05" NO="5" P_CHI2="0.5616450373818258" P_Q="0.27962811814534705" P_Z="0.30636239469135473" Q="1.1688966445946494" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="276" TOTAL_2="265" UNITS="" WEIGHT="200.0" Z="1.0228846659460893">
<NAME>Evening PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Base</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fold Change</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.649677832307427E-32" CI_END="36.38857088056914" CI_START="-6.388570880569139" DF="0.0" EFFECT_SIZE="15.000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-005.05.01" NO="1" P_CHI2="0.0" P_Z="0.16927390456949326" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="56" WEIGHT="100.0" Z="1.374540633512327">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="36.38857088056914" CI_START="-6.388570880569141" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="56.0" MEAN_2="41.0" ORDER="4631" SD_1="60.0" SD_2="58.0" SE="10.91273668765317" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.808322246813153" CI_END="10.525028377447832" CI_START="-5.777217845841307" DF="3.0" EFFECT_SIZE="2.3739052658032627" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="0.6131257483188802" P_Z="0.5681262638827227" STUDIES="4" TAU2="0.0" TOTAL_1="215" TOTAL_2="209" WEIGHT="100.0" Z="0.5708132192283423">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="12.411039205138945" CI_START="-13.61103920513894" EFFECT_SIZE="-0.5999999999999979" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="22.7" ORDER="4632" SD_1="48.06" SD_2="41.54" SE="6.638407291036141" STUDY_ID="STD-Hampel-2000" TOTAL_1="92" TOTAL_2="91" WEIGHT="39.247403855446294"/>
<CONT_DATA CI_END="17.071234070417596" CI_START="-19.071234070417596" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.0" ORDER="4633" SD_1="36.99" SD_2="39.6" SE="9.220186805962346" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="20.345074421452498"/>
<CONT_DATA CI_END="18.814036787541017" CI_START="-18.814036787541017" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="41.0" ORDER="4634" SD_1="42.0" SD_2="58.0" SE="9.599174748078912" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="18.770287621943787"/>
<CONT_DATA CI_END="30.523327618696882" CI_START="-4.523327618696882" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="16.0" ORDER="4635" SD_1="43.8" SD_2="21.9" SE="8.9406375611586" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="21.637234101157414"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0817414899396196" CI_END="-0.01641297859724178" CI_START="-0.522951460055431" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2696822193263364" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" NO="6" P_CHI2="0.5822411605989675" P_Q="0.6922739283825092" P_Z="0.036890086261040074" Q="0.15663493402083817" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="123" TOTAL_2="120" UNITS="" WEIGHT="200.0" Z="2.0869784093356394">
<NAME>PEF Diurnal Variation change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9251065559187814" CI_END="0.02790485361554429" CI_START="-0.6617863518834504" DF="1.0" EFFECT_SIZE="-0.31694074913395304" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.01" NO="1" P_CHI2="0.3361378662149962" P_Z="0.07164552681372097" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="64" WEIGHT="100.0" Z="1.8013639976350195">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="0.25578014000653204" CI_START="-1.8833514573756898" EFFECT_SIZE="-0.8137856586845789" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.4" ORDER="4636" SD_1="3.97" SD_2="3.68" SE="0.5457068635585701" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="10.395236415229194"/>
<CONT_DATA CI_END="0.10499924670823219" CI_START="-0.6236007065081894" EFFECT_SIZE="-0.2593007298999786" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-4.0" ORDER="4637" SD_1="32.0" SD_2="37.0" SE="0.1858707504228458" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="56" WEIGHT="89.60476358477081"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1588467426680976" CI_START="-0.5875215012691248" DF="0.0" EFFECT_SIZE="-0.21433737930051364" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.02" NO="2" P_CHI2="1.0" P_Z="0.2602923403820918" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="56" WEIGHT="100.0" Z="1.125700476627036">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="0.1588467426680976" CI_START="-0.5875215012691248" EFFECT_SIZE="-0.21433737930051364" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-4.0" ORDER="4638" SD_1="27.0" SD_2="37.0" SE="0.19040356093899682" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0118479863352356" CI_END="0.10099348895166023" CI_START="-0.06226425541370091" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.019364616768979662" ESTIMABLE="YES" I2="0.0" I2_Q="1.170925523916622" ID="CMP-005.07" NO="7" P_CHI2="0.6029482659305361" P_Q="0.31446080094798645" P_Z="0.6419619365710726" Q="1.0118479863352356" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="435" TOTAL_2="429" UNITS="" WEIGHT="200.0" Z="0.46495744001805933">
<NAME>Diary Card Symptom Score (Day) change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.954633315660354E-32" CI_END="0.30455199359843693" CI_START="-0.08455199359843694" DF="0.0" EFFECT_SIZE="0.11" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-005.07.01" NO="1" P_CHI2="0.0" P_Z="0.267789852353972" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="86" WEIGHT="100.0" Z="1.1081666875354914">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="0.30455199359843693" CI_START="-0.08455199359843696" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.45" ORDER="4639" SD_1="0.65" SD_2="0.64" SE="0.09926304520544164" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.08992723721555886" CI_START="-0.08992723721555886" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.07.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="2" TAU2="0.0" TOTAL_1="352" TOTAL_2="343" WEIGHT="100.0" Z="0.0">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="0.0949956579110747" CI_START="-0.0949956579110747" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.42" ORDER="4640" SD_1="0.64" SD_2="0.57" SE="0.048468063015641265" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="311" WEIGHT="89.61382036082031"/>
<CONT_DATA CI_END="0.27903799076618413" CI_START="-0.27903799076618413" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-0.3" ORDER="4641" SD_1="0.62" SD_2="0.57" SE="0.14236893788212446" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="10.38617963917969"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.669109559308273" CI_END="0.05227402607747963" CI_START="-0.17083374287043124" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.05927985839647581" ESTIMABLE="YES" I2="34.803382826480544" I2_Q="18.248101023473353" ID="CMP-005.08" NO="8" P_CHI2="0.17543929033995498" P_Q="0.268731059843775" P_Z="0.29763102378040796" Q="1.2232131761087643" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="624" TOTAL_2="616" UNITS="" WEIGHT="200.0" Z="1.0415270433084114">
<NAME>Symptoms (Night Waking) change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.417802913819484" CI_END="0.05330092115172361" CI_START="-0.3842711681297887" DF="1.0" EFFECT_SIZE="-0.16548512348903252" ESTIMABLE="YES" I2="70.74143754876509" ID="CMP-005.08.01" NO="1" P_CHI2="0.06449689590341134" P_Z="0.13821390161608815" STUDIES="2" TAU2="0.0" TOTAL_1="162" TOTAL_2="162" WEIGHT="100.0" Z="1.4824751850523064">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="0.33192288061134356" CI_START="-0.27127348225257164" EFFECT_SIZE="0.03032469917938597" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.42" ORDER="4642" SD_1="0.62" SD_2="0.69" SE="0.15387945075058806" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="52.62375046329787"/>
<CONT_DATA CI_END="-0.06512079875216148" CI_START="-0.7008457743231314" EFFECT_SIZE="-0.38298328653764646" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="-0.1" ORDER="4643" SD_1="0.27" SD_2="0.35" SE="0.16217771871970288" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="47.37624953670213"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.028093469380025" CI_END="0.10770698244986858" CI_START="-0.15164600036702086" DF="3.0" EFFECT_SIZE="-0.021969508958576148" ESTIMABLE="YES" I2="0.9277609711888154" ID="CMP-005.08.02" NO="2" P_CHI2="0.38731418041870247" P_Z="0.7398493658158796" STUDIES="4" TAU2="0.0" TOTAL_1="462" TOTAL_2="454" WEIGHT="100.00000000000001" Z="0.3320528327776397">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="0.189901558352274" CI_START="-0.12222104792948307" EFFECT_SIZE="0.03384025521139546" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.36" ORDER="4644" SD_1="0.61" SD_2="0.57" SE="0.07962457696767399" STUDY_ID="STD-Campbell--1998" TOTAL_1="315" TOTAL_2="316" WEIGHT="69.04496995340321"/>
<CONT_DATA CI_END="0.4702516451262082" CI_START="-0.4702516451262082" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" ORDER="4645" SD_1="0.62" SD_2="0.57" SE="0.23992871748434827" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="7.604345767749069"/>
<CONT_DATA CI_END="0.10123416745845132" CI_START="-0.9222319568228723" EFFECT_SIZE="-0.4104988946822105" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.01" ORDER="4646" SD_1="0.16" SD_2="0.22" SE="0.2610930946574258" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.421486137015075"/>
<CONT_DATA CI_END="0.2030879266642424" CI_START="-0.42724944013763605" EFFECT_SIZE="-0.1120807567366968" ESTIMABLE="YES" MEAN_1="-0.14" MEAN_2="-0.1" ORDER="4647" SD_1="0.36" SD_2="0.35" SE="0.160803303472385" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="16.929198141832657"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3516539732103934" CI_END="0.17880630982632123" CI_START="-0.37723371209007833" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09921370113187854" ESTIMABLE="YES" I2="0.0" I2_Q="7.058465568021615" ID="CMP-005.09" NO="9" P_CHI2="0.5087355733289602" P_Q="0.2996068360733065" P_Z="0.4842839234983868" Q="1.0759452231035365" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="435" TOTAL_2="423" UNITS="" WEIGHT="200.0" Z="0.6994290818175639">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5679602891997919" CI_START="-0.3679602891997919" DF="0.0" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.01" NO="1" P_CHI2="1.0" P_Z="0.6753394569878546" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="86" WEIGHT="100.0" Z="0.41883126192001796">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="0.5679602891997918" CI_START="-0.36796028919979185" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.9" ORDER="4648" SD_1="1.6" SD_2="1.5" SE="0.23875963685608656" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2757087501068568" CI_END="0.13774311283807017" CI_START="-0.553519133272109" DF="1.0" EFFECT_SIZE="-0.20788801021701941" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.02" NO="2" P_CHI2="0.5995278055811888" P_Z="0.23845129023506229" STUDIES="2" TAU2="0.0" TOTAL_1="352" TOTAL_2="337" WEIGHT="100.00000000000001" Z="1.1788666750884862">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="0.12857546261999508" CI_START="-0.5685754626199953" EFFECT_SIZE="-0.22000000000000008" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.88" ORDER="4649" SD_1="1.95" SD_2="2.44" SE="0.17784789178245822" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="98.31777919680825"/>
<CONT_DATA CI_END="3.1648412529215655" CI_START="-2.1648412529215655" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-4.2" MEAN_2="-4.7" ORDER="4650" SD_1="4.93" SD_2="6.22" SE="1.359637867808538" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="1.6822208031917645"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7923472469982068" CI_END="0.050370419715524285" CI_START="-0.11658065578154914" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03310511803301242" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.10" NO="10" P_CHI2="0.6728900714039912" P_Q="0.6678538422197866" P_Z="0.4369867228740225" Q="0.18412281981231227" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="435" TOTAL_2="423" UNITS="" WEIGHT="199.99999999999997" Z="0.7772916569176488">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21675079895488042" CI_START="-0.4167507989548804" DF="0.0" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.01" NO="1" P_CHI2="1.0" P_Z="0.536066837847653" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="86" WEIGHT="99.99999999999999" Z="0.6187715993162314">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="0.21675079895488042" CI_START="-0.4167507989548804" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.5" ORDER="4651" SD_1="1.0" SD_2="1.1" SE="0.16161052011841556" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6082244271858945" CI_END="0.0584221954641093" CI_START="-0.11464699650265929" DF="1.0" EFFECT_SIZE="-0.028112400519274997" ESTIMABLE="YES" I2="0.0" ID="CMP-005.10.02" NO="2" P_CHI2="0.43545730819081274" P_Z="0.5242998349766093" STUDIES="2" TAU2="0.0" TOTAL_1="352" TOTAL_2="337" WEIGHT="99.99999999999999" Z="0.6367313779025889">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="0.05666452505601076" CI_START="-0.11666452505601076" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.21" ORDER="4652" SD_1="0.55" SD_2="0.55" SE="0.04421740692156053" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="99.70038103480555"/>
<CONT_DATA CI_END="2.1809026246874277" CI_START="-0.980902624687428" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-2.3" ORDER="4653" SD_1="2.47" SD_2="3.96" SE="0.8065977932030313" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="0.2996189651944442"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4450029342680173" CI_END="0.10871525100116121" CI_START="-0.1678060878312163" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.029545418415027547" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.11" NO="11" P_CHI2="0.919327887463837" P_Q="0.5359082750737169" P_Z="0.6753391114975931" Q="0.38317681905109313" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="404" TOTAL_2="401" UNITS="" WEIGHT="200.0" Z="0.4188317346222839">
<NAME>Rescue Medications (no. of puffs) change baseline</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.46488745980617524" CI_END="0.1872227739931451" CI_START="-0.415429759678706" DF="1.0" EFFECT_SIZE="-0.11410349284278046" ESTIMABLE="YES" I2="0.0" ID="CMP-005.11.01" NO="1" P_CHI2="0.4953486599849164" P_Z="0.4579774705271792" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="84" WEIGHT="99.99999999999999" Z="0.7421813532235029">
<NAME>&gt;= 4 Fold Change</NAME>
<CONT_DATA CI_END="0.5746211917584301" CI_START="-1.4896601300618522" EFFECT_SIZE="-0.45751946915171104" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.5" ORDER="4654" SD_1="0.79" SD_2="0.85" SE="0.5266120546354601" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="8.52307298825365"/>
<CONT_DATA CI_END="0.23294445365208039" CI_START="-0.3971580471888745" EFFECT_SIZE="-0.08210679676839705" ESTIMABLE="YES" MEAN_1="-1.85" MEAN_2="-1.58" ORDER="4655" SD_1="2.8" SD_2="3.7" SE="0.1607433875854666" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="91.47692701174634"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.596938655410749" CI_END="0.14861257411001955" CI_START="-0.16260354329068438" DF="3.0" EFFECT_SIZE="-0.006995484590332412" ESTIMABLE="YES" I2="0.0" ID="CMP-005.11.02" NO="2" P_CHI2="0.8971328456422631" P_Z="0.9297878601880174" STUDIES="4" TAU2="0.0" TOTAL_1="318" TOTAL_2="317" WEIGHT="100.0" Z="0.08811174669211043">
<NAME>2 Fold Change</NAME>
<CONT_DATA CI_END="0.3760001494723776" CI_START="-0.2038216165897917" EFFECT_SIZE="0.08608926644129294" ESTIMABLE="YES" MEAN_1="-1.04" MEAN_2="-1.19" ORDER="4656" SD_1="1.75" SD_2="1.72" SE="0.14791643383136868" STUDY_ID="STD-Hampel-2000" TOTAL_1="92" TOTAL_2="91" WEIGHT="28.809460919292768"/>
<CONT_DATA CI_END="0.22760345669721951" CI_START="-0.2817144042538023" EFFECT_SIZE="-0.027055473778291393" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-0.56" ORDER="4657" SD_1="2.16" SD_2="16.43" SE="0.12993041325464552" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="37.33759561671355"/>
<CONT_DATA CI_END="0.45192576476409946" CI_START="-0.560394405398192" EFFECT_SIZE="-0.05423432031704627" ESTIMABLE="YES" MEAN_1="-1.39" MEAN_2="-0.93" ORDER="4658" SD_1="11.7" SD_2="1.81" SE="0.2582496867665283" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="9.45123105320016"/>
<CONT_DATA CI_END="0.24710456038027778" CI_START="-0.3829119460889316" EFFECT_SIZE="-0.0679036928543269" ESTIMABLE="YES" MEAN_1="-1.81" MEAN_2="-1.58" ORDER="4659" SD_1="3.02" SD_2="3.7" SE="0.16072144984262446" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="24.401712410793515"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.6939395719747705" CI_END="1.8374361720776018" CI_START="0.46326392391640026" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9226147034502539" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-005.12" LOG_CI_END="0.26421226171762197" LOG_CI_START="-0.3341715186055412" LOG_EFFECT_SIZE="-0.03497962844395962" METHOD="MH" NO="12" P_CHI2="0.8461626340651814" P_Q="0.0" P_Z="0.8187549558392765" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="586" TOTAL_2="577" WEIGHT="200.0" Z="0.2291466252836193">
<NAME>Withdrawal due to adverse event</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" DF="1.0" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" ID="CMP-005.12.01" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" NO="1" P_CHI2="0.20416258909086904" P_Z="0.42845627127583574" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="0.7918360754774336">
<NAME>&gt;= 4 Fold Change</NAME>
<DICH_DATA CI_END="2.0468258985652774" CI_START="0.026997938727846522" EFFECT_SIZE="0.23507462686567165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31108090347930123" LOG_CI_START="-1.5686693926297155" LOG_EFFECT_SIZE="-0.628794244575207" ORDER="4660" O_E="0.0" SE="1.1041746288484697" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="1.2192016109926558" WEIGHT="80.00723719920391"/>
<DICH_DATA CI_END="20.35820012661124" CI_START="0.174045474212828" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3087393792819173" LOG_CI_START="-0.7593372653986533" LOG_EFFECT_SIZE="0.27470105694163205" ORDER="4661" O_E="0.0" SE="1.214798458229861" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" VAR="1.4757352941176471" WEIGHT="19.992762800796093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6630972648533949" CI_END="2.4232743892483146" CI_START="0.4903217259793018" DF="4.0" EFFECT_SIZE="1.0900385686101535" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-005.12.02" LOG_CI_END="0.38440259242457486" LOG_CI_START="-0.3095188628952037" LOG_EFFECT_SIZE="0.03744186476468561" NO="2" P_CHI2="0.9558005862694291" P_Z="0.832491482185759" STUDIES="5" TAU2="0.0" TOTAL_1="434" TOTAL_2="434" WEIGHT="100.0" Z="0.21150724160556567">
<NAME>2 Fold Change</NAME>
<DICH_DATA CI_END="4.7170692818842355" CI_START="0.3670291521278234" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6736722549862264" LOG_CI_START="-0.4352994395478091" LOG_EFFECT_SIZE="0.11918640771920867" ORDER="4662" O_E="0.0" SE="0.6514154628677139" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4243421052631579" WEIGHT="35.3487611396312"/>
<DICH_DATA CI_END="15.575357563614977" CI_START="0.06281583026374868" EFFECT_SIZE="0.9891304347826086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1924380255477356" LOG_CI_START="-1.2019308955966588" LOG_EFFECT_SIZE="-0.004746435024461691" ORDER="4663" O_E="0.0" SE="1.4064641565975287" STUDY_ID="STD-Hampel-2000" TOTAL_1="92" TOTAL_2="91" VAR="1.9781414237935977" WEIGHT="9.11930938804981"/>
<DICH_DATA CI_END="3.0272483504348244" CI_START="0.16428804782167156" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.481048051217256" LOG_CI_START="-0.7843940309283454" LOG_EFFECT_SIZE="-0.1516729898555447" ORDER="4664" O_E="0.0" SE="0.743326943091658" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="0.552534944325989" WEIGHT="37.395268363504584"/>
<DICH_DATA CI_END="16.206354283559662" CI_START="0.06490907795006694" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096853286913705" LOG_CI_START="-1.1876945600884439" LOG_EFFECT_SIZE="0.010995384301463145" ORDER="4665" O_E="0.0" SE="1.4082328138911044" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="1.9831196581196582" WEIGHT="8.954940988237684"/>
<DICH_DATA CI_END="21.095685716573634" CI_START="0.18047564966233032" EFFECT_SIZE="1.951219512195122" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.324193646716429" LOG_CI_START="-0.743581386172013" LOG_EFFECT_SIZE="0.2903061302722081" ORDER="4666" O_E="0.0" SE="1.214621289970162" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" VAR="1.4753048780487805" WEIGHT="9.18172012057672"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.56894795340122" CI_END="2.122356006827043" CI_START="0.5266622776519698" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0572439872346733" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="28.17314807984494" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="0.32681823481149747" LOG_CI_START="-0.27846778700474545" LOG_EFFECT_SIZE="0.024175223903376022" METHOD="MH" NO="13" P_CHI2="0.23373531629250377" P_Q="0.0" P_Z="0.8755896020089196" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="401" TOTAL_2="392" WEIGHT="200.0" Z="0.15656257194451972">
<NAME>Oral Candidiasis</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Fold Change</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Base</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4584314782487346" CI_END="7.832374367325216" CI_START="0.6773174270766057" DF="1.0" EFFECT_SIZE="2.3032593545620244" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="31.43318593199957" ID="CMP-005.13.01" LOG_CI_END="0.8938934374490518" LOG_CI_START="-0.16920775004573108" LOG_EFFECT_SIZE="0.36234284370166037" NO="1" P_CHI2="0.22718015271680914" P_Z="0.18153246816440843" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="156" WEIGHT="100.0" Z="1.3360514164877002">
<NAME>&gt;= 4 Fold Change</NAME>
<DICH_DATA CI_END="158.21294703008422" CI_START="0.4742905537037454" EFFECT_SIZE="8.6625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1992420202087515" LOG_CI_START="-0.32395552496902535" LOG_EFFECT_SIZE="0.9376432476198632" ORDER="4667" O_E="0.0" SE="1.4821387280667113" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" VAR="2.196735209235209" WEIGHT="14.152460598263108"/>
<DICH_DATA CI_END="5.433263697558104" CI_START="0.28984032781034996" EFFECT_SIZE="1.2549019607843137" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.735060783556677" LOG_CI_START="-0.5378411877847755" LOG_EFFECT_SIZE="0.0986097978859508" ORDER="4668" O_E="0.0" SE="0.7477089189323479" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" VAR="0.5590686274509804" WEIGHT="85.8475394017369"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2751118204780907" CI_END="1.637642322886447" CI_START="0.26735099205351504" DF="2.0" EFFECT_SIZE="0.661683685496714" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="12.092232918040875" ID="CMP-005.13.02" LOG_CI_END="0.2142190536154458" LOG_CI_START="-0.5729182000335565" LOG_EFFECT_SIZE="-0.17934957320905542" NO="2" P_CHI2="0.3206020013923264" P_Z="0.3717729346368184" STUDIES="3" TAU2="0.0" TOTAL_1="237" TOTAL_2="236" WEIGHT="100.0" Z="0.8931573305743359">
<NAME>2 Fold Change</NAME>
<DICH_DATA CI_END="1.4328858780172062" CI_START="0.10874360401321813" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.15621160245523724" LOG_CI_START="-0.9635962775774951" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="4669" O_E="0.0" SE="0.6577806918696316" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4326754385964912" WEIGHT="68.72897979820605"/>
<DICH_DATA CI_END="98.633834505556" CI_START="0.2348094481584349" EFFECT_SIZE="4.8125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.994025917157204" LOG_CI_START="-0.6292844321240898" LOG_EFFECT_SIZE="0.682370742516557" ORDER="4670" O_E="0.0" SE="1.5409454847634898" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" VAR="2.3745129870129866" WEIGHT="4.49284313129406"/>
<DICH_DATA CI_END="3.789849969334319" CI_START="0.11162146891118543" EFFECT_SIZE="0.6504065040650406" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5786220176778571" LOG_CI_START="-0.9522522665727658" LOG_EFFECT_SIZE="-0.18681512444745435" ORDER="4671" O_E="0.0" SE="0.8992431325187387" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" VAR="0.8086382113821138" WEIGHT="26.778177070499876"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1714082208794902" CI_END="1.1553669775639863" CI_START="0.3326431673047737" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6199394573796928" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="0.06271995047673715" LOG_CI_START="-0.478021392802057" LOG_EFFECT_SIZE="-0.20765072116265992" METHOD="MH" NO="14" P_CHI2="0.9178658138247517" P_Q="0.0" P_Z="0.13224795101216533" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="284" TOTAL_2="280" WEIGHT="200.0" Z="1.5052961638731175">
<NAME>Plasma Cortisol below reference range</NAME>
<GROUP_LABEL_1>Fold Change Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Base Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Base</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fold Change</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.141851886333664" CI_START="0.18381043773712552" DF="0.0" EFFECT_SIZE="0.6274509803921569" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-005.14.01" LOG_CI_END="0.3307894351363424" LOG_CI_START="-0.7356298306924032" LOG_EFFECT_SIZE="-0.2024201977780304" NO="1" P_CHI2="1.0" P_Z="0.4568443377921172" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="80" WEIGHT="100.0" Z="0.7440531320110744">
<NAME>&gt;= 4 Fold Change</NAME>
<DICH_DATA CI_END="2.141851886333664" CI_START="0.18381043773712552" EFFECT_SIZE="0.6274509803921569" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3307894351363424" LOG_CI_START="-0.7356298306924032" LOG_EFFECT_SIZE="-0.2024201977780304" ORDER="4672" O_E="0.0" SE="0.6264199556083073" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" VAR="0.39240196078431366" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.17122975367256682" CI_END="1.2712187758150482" CI_START="0.29980616043983177" DF="1.0" EFFECT_SIZE="0.6173485403369258" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" ID="CMP-005.14.02" LOG_CI_END="0.104220298746719" LOG_CI_START="-0.5231594474799434" LOG_EFFECT_SIZE="-0.2094695743666122" NO="2" P_CHI2="0.6790214714162608" P_Z="0.19060695065167968" STUDIES="2" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="1.308785704622247">
<NAME>2 Fold Change</NAME>
<DICH_DATA CI_END="1.6119451793392634" CI_START="0.2900400575958283" EFFECT_SIZE="0.6837606837606838" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2073502677945705" LOG_CI_START="-0.5375420173030067" LOG_EFFECT_SIZE="-0.16509587475421805" ORDER="4673" O_E="0.0" SE="0.4375534155425957" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.19145299145299144" WEIGHT="66.10861148896096"/>
<DICH_DATA CI_END="1.8840158732341865" CI_START="0.12630127082724826" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27508455749559363" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.3117538610557543" ORDER="4674" O_E="0.0" SE="0.6894235839081664" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" VAR="0.47530487804878047" WEIGHT="33.89138851103903"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Step down vs Constant ICS Dose (ICS Type)</NAME>
<CONT_OUTCOME CHI2="0.011498839823517779" CI_END="24.303900679069244" CI_START="-26.12603337328808" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9110663471094177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.9146044202237349" P_Q="0.9146044202237349" P_Z="0.943543120578758" Q="0.011498839823517779" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="0.0708173532809709">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="42.7555762665847" CI_START="-48.7555762665847" DF="0.0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="1.0" P_Z="0.8977481028966664" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="0.1285065653935223">
<NAME>BUD</NAME>
<CONT_DATA CI_END="42.7555762665847" CI_START="-48.7555762665847" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="420.0" MEAN_2="423.0" ORDER="4675" SD_1="98.6" SD_2="100.6" SE="23.345110740553828" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="30.217373222175407" CI_START="-30.217373222175407" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>FP</NAME>
<CONT_DATA CI_END="30.217373222175407" CI_START="-30.217373222175407" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="269.0" MEAN_2="269.0" ORDER="4676" SD_1="62.7" SD_2="46.5" SE="15.417310450868582" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.7803864680435201" P_Q="1.0" P_Z="0.8632634359975946" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="315" TOTAL_2="328" UNITS="" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" DF="1.0" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" NO="1" P_CHI2="0.7803864680435201" P_Z="0.8632634359975946" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="328" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>BUD</NAME>
<CONT_DATA CI_END="11.082585483794093" CI_START="-11.082585483794093" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="45.0" ORDER="4677" SD_1="60.9" SD_2="62.2" SE="5.654484251349572" STUDY_ID="STD-Campbell--1998" TOTAL_1="232" TOTAL_2="242" WEIGHT="72.38295873935151"/>
<CONT_DATA CI_END="20.94199292850359" CI_START="-14.941992928503591" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="58.0" ORDER="4678" SD_1="59.0" SD_2="60.0" SE="9.154246236169511" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="27.617041260648495"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="0.5545263699591919" P_Q="1.0" P_Z="0.17387926215134233" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="331" UNITS="" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>Diary Card Symptom Score (Day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" DF="1.0" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" NO="1" P_CHI2="0.5545263699591919" P_Z="0.17387926215134233" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="331" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.02596715542399894" CI_START="-0.18596715542399886" EFFECT_SIZE="-0.07999999999999996" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="-0.49" ORDER="4679" SD_1="0.61" SD_2="0.57" SE="0.054065868689350566" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="245" WEIGHT="79.16408152237781"/>
<CONT_DATA CI_END="0.1965518267409323" CI_START="-0.21655182674093232" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.44" ORDER="4680" SD_1="0.67" SD_2="0.7" SE="0.10538552155559325" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="20.835918477622194"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="0.30186300523143084" P_Q="1.0" P_Z="0.2404150545922351" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="329" UNITS="" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>Diary Card Symptom Score (Night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" DF="1.0" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" ID="CMP-006.04.01" NO="1" P_CHI2="0.30186300523143084" P_Z="0.2404150545922351" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="329" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.1378782764578968" CI_START="-0.07787827645789676" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.45" ORDER="4681" SD_1="0.61" SD_2="0.59" SE="0.05504094835865703" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="243" WEIGHT="77.57434489354594"/>
<CONT_DATA CI_END="0.3506413716996898" CI_START="-0.05064137169968971" EFFECT_SIZE="0.15000000000000002" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.55" ORDER="4682" SD_1="0.63" SD_2="0.7" SE="0.10236992785700312" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="22.42565510645405"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.24422826085037086" P_Q="1.0" P_Z="0.1820317738928679" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" DF="1.0" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" ID="CMP-006.05.01" NO="1" P_CHI2="0.24422826085037086" P_Z="0.1820317738928679" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.03519162882360782" CI_START="-0.5751916288236079" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.13" ORDER="4683" SD_1="1.68" SD_2="1.71" SE="0.1557128759665588" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="75.98335466647684"/>
<CONT_DATA CI_END="0.6428447932693216" CI_START="-0.4428447932693219" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="4684" SD_1="1.8" SD_2="1.8" SE="0.2769667185474898" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="24.016645333523154"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.835628835215149" P_Q="1.0" P_Z="0.42197702725394737" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" DF="1.0" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" NO="1" P_CHI2="0.835628835215149" P_Z="0.42197702725394737" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.054527890309513175" CI_START="-0.13452789030951318" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="-0.23" ORDER="4685" SD_1="0.52" SD_2="0.53" SE="0.04822940169061121" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="93.74121528751569"/>
<CONT_DATA CI_END="0.3658307846601671" CI_START="-0.3658307846601671" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.7" ORDER="4686" SD_1="1.0" SD_2="1.4" SE="0.18665178929092252" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.258784712484326"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" METHOD="MH" NO="7" P_CHI2="0.3183119887450464" P_Q="0.0" P_Z="0.2594456111978882" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>Withdrawal due to adverse event</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" DF="1.0" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" NO="1" P_CHI2="0.3183119887450464" P_Z="0.2594456111978882" STUDIES="2" TAU2="0.0" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>BUD</NAME>
<DICH_DATA CI_END="2.8814196517478945" CI_START="0.5695414692728974" EFFECT_SIZE="1.2810495626822158" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4596065138049211" LOG_CI_START="-0.24447464872147914" LOG_EFFECT_SIZE="0.10756593254172103" ORDER="4687" O_E="0.0" SE="0.41358076012597156" STUDY_ID="STD-Campbell--1998" TOTAL_1="343" TOTAL_2="338" VAR="0.17104904514637642" WEIGHT="91.1154319522535"/>
<DICH_DATA CI_END="36.31589614749957" CI_START="0.4730030432105941" EFFECT_SIZE="4.144578313253012" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5600967654769557" LOG_CI_START="-0.32513606508604326" LOG_EFFECT_SIZE="0.6174803501954562" ORDER="4688" O_E="0.0" SE="1.1073950967257222" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" VAR="1.2263239002521715" WEIGHT="8.88456804774652"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" METHOD="MH" NO="8" P_CHI2="0.4981586221009352" P_Q="0.0" P_Z="0.9532000313190644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>Proportion Achieving Asthma Control</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" DF="1.0" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" NO="1" P_CHI2="0.4981586221009352" P_Z="0.9532000313190644" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>BUD</NAME>
<DICH_DATA CI_END="1.2033547105734104" CI_START="0.8755815859878481" EFFECT_SIZE="1.0264673526176147" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="101" LOG_CI_END="0.08039366236738556" LOG_CI_START="-0.05770338048459777" LOG_EFFECT_SIZE="0.011345140941393887" ORDER="4689" O_E="0.0" SE="0.08111888656264195" STUDY_ID="STD-Campbell--1998" TOTAL_1="153" TOTAL_2="154" VAR="0.006580273757162773" WEIGHT="82.63673813440649"/>
<DICH_DATA CI_END="1.2746520393518797" CI_START="0.6341104320018376" EFFECT_SIZE="0.8990384615384616" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.10539164515123073" LOG_CI_START="-0.19783510200375598" LOG_EFFECT_SIZE="-0.04622172842626257" ORDER="4690" O_E="0.0" SE="0.17811689227544536" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="26" TOTAL_2="33" VAR="0.03172562731386261" WEIGHT="17.36326186559352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>High vs Moderate ICS Dose (ICS Type)</NAME>
<CONT_OUTCOME CHI2="2.7013430364302593" CI_END="9.985564020342643" CI_START="0.6464205052493579" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.315992262796001" ESTIMABLE="YES" I2="0.0" I2_Q="19.418668587306993" ID="CMP-007.01" NO="1" P_CHI2="0.4399991748897033" P_Q="0.2891002036491277" P_Z="0.02566214381797517" Q="2.4819644512413257" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="68" TOTAL_2="62" UNITS="" WEIGHT="300.0" Z="2.2312867042539875">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.903039713633156" CI_START="-2.903039713633154" DF="0.0" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="1.0" P_Z="0.13835435610022342" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="20" WEIGHT="100.0" Z="1.4819471567970048">
<NAME>BUD</NAME>
<CONT_DATA CI_END="20.903039713633156" CI_START="-2.903039713633154" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="82.5" MEAN_2="73.5" ORDER="4691" SD_1="20.6" SD_2="19.2" SE="6.073091040204214" STUDY_ID="STD-Pedersen-1996" TOTAL_1="23" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.21937858518893383" CI_END="8.403061580812475" CI_START="-3.1778347654826518" DF="1.0" EFFECT_SIZE="2.6126134076649117" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.02" NO="2" P_CHI2="0.6395138303455432" P_Z="0.37652172837722153" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="100.0" Z="0.8843232909493819">
<NAME>FP</NAME>
<CONT_DATA CI_END="9.891911348796498" CI_START="-7.891911348796498" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="98.3" MEAN_2="97.3" ORDER="4692" SD_1="14.7" SD_2="6.6" SE="4.536772827937023" STUDY_ID="STD-Hofstra--2000" TOTAL_1="13" TOTAL_2="11" WEIGHT="42.40666401196768"/>
<CONT_DATA CI_END="11.430026764541502" CI_START="-3.830026764541479" EFFECT_SIZE="3.8000000000000114" ESTIMABLE="YES" MEAN_1="106.4" MEAN_2="102.6" ORDER="4693" SD_1="14.3" SD_2="13.5" SE="3.892942331964346" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="57.59333598803233"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="21.953515815815052" CI_START="0.8464841841849573" DF="0.0" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.03" NO="3" P_CHI2="1.0" P_Z="0.03424540366490605" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="2.1171702221048916">
<NAME>BDP</NAME>
<CONT_DATA CI_END="21.953515815815052" CI_START="0.8464841841849573" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" MEAN_1="81.4" MEAN_2="70.0" ORDER="4694" SD_1="8.6" SD_2="10.0" SE="5.3845457870960045" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1459525699473343" CI_END="31.99730208753371" CI_START="-16.171224318684146" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.9130388844247825" ESTIMABLE="YES" I2="12.736353473516097" I2_Q="12.736353473516097" ID="CMP-007.02" NO="2" P_CHI2="0.2843980682563255" P_Q="0.2843980682563255" P_Z="0.5196022087669634" Q="1.1459525699473343" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="31" UNITS="" WEIGHT="200.0" Z="0.6439587165670719">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>BUD</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.38548575498966" CI_START="-14.385485754989656" DF="0.0" EFFECT_SIZE="10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.02" NO="2" P_CHI2="1.0" P_Z="0.421545981993972" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.8037420309082892">
<NAME>FP</NAME>
<CONT_DATA CI_END="34.38548575498966" CI_START="-14.385485754989656" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="244.0" MEAN_2="234.0" ORDER="4695" SD_1="51.0" SD_2="37.0" SE="12.441802985840177" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="78.70416958322528" CI_START="-228.70416958322528" DF="0.0" EFFECT_SIZE="-75.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.03" NO="3" P_CHI2="1.0" P_Z="0.33888783771392517" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.9563650695950074">
<NAME>BDP</NAME>
<CONT_DATA CI_END="78.70416958322528" CI_START="-228.70416958322528" EFFECT_SIZE="-75.0" ESTIMABLE="YES" MEAN_1="375.0" MEAN_2="450.0" ORDER="4696" SD_1="120.0" SD_2="150.0" SE="78.4219357067906" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.181336540258029" CI_END="13.004971082457143" CI_START="-1.5644606590516892" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.720255211702727" ESTIMABLE="YES" I2="4.336808063931614" I2_Q="62.4089347655765" ID="CMP-007.03" NO="3" P_CHI2="0.3820205779981115" P_Q="0.10288742704183285" P_Z="0.12379369075052225" Q="2.6602066043190065" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="563" TOTAL_2="554" UNITS="" WEIGHT="200.0" Z="1.5390434433174138">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.521129935939023" CI_END="16.158016237356893" CI_START="0.36172823030463164" DF="3.0" EFFECT_SIZE="8.259872233830762" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.01" NO="1" P_CHI2="0.6774022419887514" P_Z="0.04039091699691824" STUDIES="4" TAU2="0.0" TOTAL_1="478" TOTAL_2="472" WEIGHT="100.0" Z="2.0497286562492514">
<NAME>BUD</NAME>
<CONT_DATA CI_END="19.409209826058163" CI_START="-1.409209826058163" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="26.0" ORDER="4697" SD_1="70.8" SD_2="62.0" SE="5.310918929207211" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="314" WEIGHT="57.572431208331665"/>
<CONT_DATA CI_END="18.43950212106763" CI_START="-14.43950212106763" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="4698" SD_1="55.0" SD_2="54.0" SE="8.387655207310095" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="23.081964801855666"/>
<CONT_DATA CI_END="39.1568927245098" CI_START="-3.156892724509806" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="53.0" ORDER="4699" SD_1="69.0" SD_2="46.0" SE="10.794531374756207" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="55" WEIGHT="13.936262807797167"/>
<CONT_DATA CI_END="35.95884107860774" CI_START="-31.95884107860774" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="66.0" ORDER="4700" SD_1="53.7" SD_2="51.5" SE="17.326257699871398" STUDY_ID="STD-O_x0027_Byrne-1996" TOTAL_1="20" TOTAL_2="17" WEIGHT="5.409341182015515"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.102937532401661" CI_START="-27.60293753240166" DF="0.0" EFFECT_SIZE="-8.75" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.02" NO="2" P_CHI2="1.0" P_Z="0.3630040464503077" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="82" WEIGHT="99.99999999999999" Z="0.9096558472785004">
<NAME>FP</NAME>
<CONT_DATA CI_END="10.102937532401661" CI_START="-27.60293753240166" EFFECT_SIZE="-8.75" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="51.25" ORDER="4701" SD_1="62.7" SD_2="61.6" SE="9.619022431591207" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.04" NO="4" P_CHI2="0.3193479923711562" P_Q="1.0" P_Z="0.6268056443156612" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="397" UNITS="" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>Diary Card Symptom Score (day) change baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" DF="1.0" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" ID="CMP-007.04.01" NO="1" P_CHI2="0.3193479923711562" P_Z="0.6268056443156612" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="397" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.0949956579110747" CI_START="-0.0949956579110747" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.42" ORDER="4702" SD_1="0.64" SD_2="0.57" SE="0.048468063015641265" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="311" WEIGHT="80.74828420233813"/>
<CONT_DATA CI_END="0.30455199359843693" CI_START="-0.08455199359843696" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.45" ORDER="4703" SD_1="0.65" SD_2="0.64" SE="0.09926304520544164" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="19.251715797661884"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.63874798732214" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="398" TOTAL_2="402" UNITS="" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>Diary Card Symptom Score (night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" DF="1.0" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" ID="CMP-007.05.01" NO="1" P_CHI2="1.0" P_Z="0.63874798732214" STUDIES="2" TAU2="0.0" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.11212736432696213" CI_START="-0.0721273643269622" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.36" ORDER="4704" SD_1="0.61" SD_2="0.57" SE="0.04700462103061641" STUDY_ID="STD-Campbell--1998" TOTAL_1="315" TOTAL_2="316" WEIGHT="82.14859018915008"/>
<CONT_DATA CI_END="0.2176298057826377" CI_START="-0.17762980578263776" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.42" ORDER="4705" SD_1="0.62" SD_2="0.69" SE="0.10083338639970754" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="17.851409810849916"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" I2_Q="0.0" ID="CMP-007.06" NO="6" P_CHI2="0.28244531465389533" P_Q="1.0" P_Z="0.4581819409042932" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" DF="1.0" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" ID="CMP-007.06.01" NO="1" P_CHI2="0.28244531465389533" P_Z="0.4581819409042932" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.12857546261999508" CI_START="-0.5685754626199953" EFFECT_SIZE="-0.22000000000000008" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.88" ORDER="4706" SD_1="1.95" SD_2="2.44" SE="0.17784789178245822" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="64.31488393177654"/>
<CONT_DATA CI_END="0.5679602891997918" CI_START="-0.36796028919979185" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.9" ORDER="4707" SD_1="1.6" SD_2="1.5" SE="0.23875963685608656" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="35.685116068223465"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.07" NO="7" P_CHI2="0.676104830152686" P_Q="1.0" P_Z="0.4135226426615982" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" DF="1.0" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" ID="CMP-007.07.01" NO="1" P_CHI2="0.676104830152686" P_Z="0.4135226426615982" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.05666452505601076" CI_START="-0.11666452505601076" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.21" ORDER="4708" SD_1="0.55" SD_2="0.55" SE="0.04421740692156053" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="93.03540991685338"/>
<CONT_DATA CI_END="0.21675079895488042" CI_START="-0.4167507989548804" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.5" ORDER="4709" SD_1="1.0" SD_2="1.1" SE="0.16161052011841556" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.964590083146619"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.49814332460811017" CI_END="2.430232132656587" CI_START="0.1425511244648875" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5885850178359098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-007.08" LOG_CI_END="0.3856477588315893" LOG_CI_START="-0.846029352560276" LOG_EFFECT_SIZE="-0.23019079686434335" METHOD="MH" NO="8" P_CHI2="0.48031711852951564" P_Q="0.0" P_Z="0.46380011309239444" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="149" WEIGHT="200.0" Z="0.7326038086667791">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.123898577516711" CI_START="0.035568091714244104" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-007.08.01" LOG_CI_END="0.4946969253525552" LOG_CI_START="-1.4489394347918803" LOG_EFFECT_SIZE="-0.4771212547196625" NO="1" P_CHI2="1.0" P_Z="0.3359196933198786" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="0.9622586762470402">
<NAME>BUD</NAME>
<DICH_DATA CI_END="3.123898577516711" CI_START="0.035568091714244104" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4946969253525552" LOG_CI_START="-1.4489394347918803" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="4710" O_E="0.0" SE="1.141701619103992" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="67" VAR="1.3034825870646765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.688632338481282" CI_START="0.1391401698209774" DF="0.0" EFFECT_SIZE="0.9647058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-007.08.02" LOG_CI_END="0.8253373242592293" LOG_CI_START="-0.8565474709203815" LOG_EFFECT_SIZE="-0.015605073330576038" NO="2" P_CHI2="1.0" P_Z="0.9709870440686783" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="82" WEIGHT="100.0" Z="0.03637036471427199">
<NAME>FP</NAME>
<DICH_DATA CI_END="6.688632338481282" CI_START="0.1391401698209774" EFFECT_SIZE="0.9647058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8253373242592293" LOG_CI_START="-0.8565474709203815" LOG_EFFECT_SIZE="-0.015605073330576038" ORDER="4711" O_E="0.0" SE="0.9879474541525108" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" VAR="0.9760401721664276" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>High vs Low ICS Dose (ICS Type)</NAME>
<CONT_OUTCOME CHI2="0.47957962686212796" CI_END="0.15824712397451318" CI_START="-0.5519871257736606" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.19687000089957368" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="0.4886128305196745" P_Q="0.4886128305196745" P_Z="0.27722877741232155" Q="0.47957962686212796" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="1.0865657676642473">
<NAME>FEV1</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.25112982880466106" CI_START="-0.5299888820138743" DF="0.0" EFFECT_SIZE="-0.13942952660460659" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" NO="1" P_CHI2="1.0" P_Z="0.48411073175601294" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="50" WEIGHT="100.0" Z="0.6997063231019803">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.25112982880466106" CI_START="-0.5299888820138743" EFFECT_SIZE="-0.13942952660460659" ESTIMABLE="YES" MEAN_1="88.3" MEAN_2="89.7" ORDER="4712" SD_1="9.3" SD_2="10.6" SE="0.199268638857627" STUDY_ID="STD-Tukiainen--2000" TOTAL_1="51" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6263380359126845E-32" CI_END="0.3821872948251185" CI_START="-1.3241029633789667" DF="0.0" EFFECT_SIZE="-0.47095783427692406" ESTIMABLE="YES" I2="100.0" ID="CMP-008.01.02" NO="2" P_CHI2="0.0" P_Z="0.2792747514598898" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="1.0819500246005034">
<NAME>FP</NAME>
<CONT_DATA CI_END="0.38218729482511854" CI_START="-1.3241029633789665" EFFECT_SIZE="-0.470957834276924" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="3.09" ORDER="4713" SD_1="0.69" SD_2="0.7" SE="0.4352861255775833" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6006627985107081" CI_END="19.949593455634396" CI_START="-56.04269451338604" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.046550528875823" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" NO="2" P_CHI2="0.43832541588337126" P_Q="0.43832541588337126" P_Z="0.35190559627399653" Q="0.6006627985107081" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="200.0" Z="0.9308994380113496">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="35.352049019096704" CI_START="-53.352049019096704" DF="0.0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.01" NO="1" P_CHI2="1.0" P_Z="0.6908369444214122" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="0.39771952482432904">
<NAME>BUD</NAME>
<CONT_DATA CI_END="35.352049019096704" CI_START="-53.352049019096704" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="425.0" MEAN_2="434.0" ORDER="4714" SD_1="98.6" SD_2="94.7" SE="22.629012251725033" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="30.660977310090047" CI_START="-116.66097731009005" DF="0.0" EFFECT_SIZE="-43.0" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.02" NO="2" P_CHI2="1.0" P_Z="0.2525657088725335" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.00000000000001" Z="1.1441397387443828">
<NAME>FP</NAME>
<CONT_DATA CI_END="30.660977310090047" CI_START="-116.66097731009005" EFFECT_SIZE="-43.0" ESTIMABLE="YES" MEAN_1="457.0" MEAN_2="500.0" ORDER="4715" SD_1="114.3" SD_2="56.9" SE="37.58282187382954" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" I2_Q="0.0" ID="CMP-008.03" NO="3" P_CHI2="0.15071704735946023" P_Q="1.0" P_Z="0.08146767927689498" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="136" UNITS="" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Figh Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" DF="1.0" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" ID="CMP-008.03.01" NO="1" P_CHI2="0.15071704735946023" P_Z="0.08146767927689498" STUDIES="2" TAU2="0.0" TOTAL_1="146" TOTAL_2="136" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>BUD</NAME>
<CONT_DATA CI_END="49.383191322099684" CI_START="2.616808677900316" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="45.0" ORDER="4716" SD_1="69.0" SD_2="60.0" SE="11.930418878379047" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="56" WEIGHT="33.351797424210346"/>
<CONT_DATA CI_END="21.54128271599394" CI_START="-11.54128271599394" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="37.5" ORDER="4717" SD_1="62.7" SD_2="44.7" SE="8.439585036495297" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" WEIGHT="66.64820257578967"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-008.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FP</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6737537845299415" CI_END="0.5585664838908377" CI_START="-0.6461874794450229" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0438104977770926" ESTIMABLE="YES" I2="62.59939842681495" I2_Q="62.59939842681495" ID="CMP-008.04" NO="4" P_CHI2="0.10201521524358914" P_Q="0.10201521524358914" P_Z="0.8866480021204945" Q="2.6737537845299415" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="200.0" Z="0.1425469438591681">
<NAME>Rescue Medications (no. of puffs)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7265554040177095" CI_START="-0.5265554040177095" DF="0.0" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.01" NO="1" P_CHI2="1.0" P_Z="0.754420649396242" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="0.3128157497281207">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.7265554040177095" CI_START="-0.5265554040177095" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.8" ORDER="4718" SD_1="1.54" SD_2="1.18" SE="0.31967699863869875" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3895248256254782" CI_START="-3.9895248256254785" DF="0.0" EFFECT_SIZE="-1.8" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.02" NO="2" P_CHI2="1.0" P_Z="0.1071189455955537" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="1.6112789089588322">
<NAME>FP</NAME>
<CONT_DATA CI_END="0.3895248256254782" CI_START="-3.9895248256254785" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.6" ORDER="4719" SD_1="1.73" SD_2="3.16" SE="1.1171250303047253" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" METHOD="MH" NO="5" P_CHI2="0.20416258909086904" P_Q="0.0" P_Z="0.42845627127583574" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="143" WEIGHT="200.0" Z="0.7918360754774336">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0468258985652774" CI_START="0.026997938727846522" DF="0.0" EFFECT_SIZE="0.23507462686567165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-008.05.01" LOG_CI_END="0.31108090347930123" LOG_CI_START="-1.5686693926297155" LOG_EFFECT_SIZE="-0.628794244575207" NO="1" P_CHI2="1.0" P_Z="0.1897723140004191" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="63" WEIGHT="100.0" Z="1.3112529633372136">
<NAME>BUD</NAME>
<DICH_DATA CI_END="2.0468258985652774" CI_START="0.026997938727846522" EFFECT_SIZE="0.23507462686567165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31108090347930123" LOG_CI_START="-1.5686693926297155" LOG_EFFECT_SIZE="-0.628794244575207" ORDER="4720" O_E="0.0" SE="1.1041746288484697" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="1.2192016109926558" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.35820012661124" CI_START="0.174045474212828" DF="0.0" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-008.05.02" LOG_CI_END="1.3087393792819173" LOG_CI_START="-0.7593372653986533" LOG_EFFECT_SIZE="0.27470105694163205" NO="2" P_CHI2="1.0" P_Z="0.6025889670172215" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="80" WEIGHT="100.0" Z="0.5206810680886016">
<NAME>FP</NAME>
<DICH_DATA CI_END="20.35820012661124" CI_START="0.174045474212828" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3087393792819173" LOG_CI_START="-0.7593372653986533" LOG_EFFECT_SIZE="0.27470105694163205" ORDER="4721" O_E="0.0" SE="1.214798458229861" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" VAR="1.4757352941176471" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Moderate vs Low ICS Dose (ICS Type)</NAME>
<CONT_OUTCOME CHI2="3.8829016852751153" CI_END="0.2840817161698702" CI_START="-0.05573095452110609" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.11417538082438207" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.4220854290959357" P_Q="0.45361823967670745" P_Z="0.18781299736300933" Q="1.5809993537800833" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="268" TOTAL_2="268" UNITS="" WEIGHT="300.0" Z="1.3170764579313636">
<NAME>FEV1 change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1062867780146273" CI_END="0.8081235873607749" CI_START="-0.06432333506696708" DF="1.0" EFFECT_SIZE="0.37190012614690393" ESTIMABLE="YES" I2="52.52308420496312" ID="CMP-009.01.01" NO="1" P_CHI2="0.1466949500364031" P_Z="0.09473007776219053" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="1.6709574745601894">
<NAME>BUD</NAME>
<CONT_DATA CI_END="2.2544040863311006" CI_START="0.015887887004713663" EFFECT_SIZE="1.135145986667907" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.0" ORDER="4722" SD_1="0.53" SD_2="0.28" SE="0.5710605442200767" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="15.189992061090038"/>
<CONT_DATA CI_END="0.7088785734083383" CI_START="-0.23848234131754717" EFFECT_SIZE="0.23519811604539556" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.14" ORDER="4723" SD_1="0.42" SD_2="0.33" SE="0.24167814362879814" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="35" TOTAL_2="34" WEIGHT="84.81000793890996"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.19561555348040466" CI_END="0.33737904320583756" CI_START="-0.19767060730454145" DF="1.0" EFFECT_SIZE="0.06985421795064807" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.02" NO="2" P_CHI2="0.6582833755627859" P_Z="0.6088104953588821" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="106" WEIGHT="100.0" Z="0.5117721363648503">
<NAME>FP</NAME>
<CONT_DATA CI_END="0.6740450407355303" CI_START="-0.33996335355591273" EFFECT_SIZE="0.1670408435898088" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.3" ORDER="4724" SD_1="0.55" SD_2="0.38" SE="0.25868036410102735" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="27.842297453393506"/>
<CONT_DATA CI_END="0.3472907387291552" CI_START="-0.2825818896783239" EFFECT_SIZE="0.032354424525415634" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="0.4" ORDER="4725" SD_1="0.62" SD_2="0.61" SE="0.16068474558099896" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="72.1577025466065"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.32119965731034755" CI_START="-0.18823753322396347" DF="0.0" EFFECT_SIZE="0.06648106204319203" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.03" NO="3" P_CHI2="1.0" P_Z="0.6089682149834563" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0" Z="0.5115468194301506">
<NAME>BDP</NAME>
<CONT_DATA CI_END="0.32119965731034755" CI_START="-0.18823753322396347" EFFECT_SIZE="0.06648106204319203" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.2" ORDER="4726" SD_1="12.98" SD_2="10.95" SE="0.1299608550342472" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5037226311746015" CI_END="20.933815511487794" CI_START="1.3387608045442079" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.136288158016" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="0.9731375802234453" P_Q="0.9250367687879517" P_Z="0.025895269370531142" Q="0.008853140285945749" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="209" TOTAL_2="202" UNITS="" WEIGHT="200.0" Z="2.2277787980287576">
<NAME>Morning PEF (L/min) change baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.19899956923017526" CI_END="24.164442786469838" CI_START="-2.7796894734916755" DF="2.0" EFFECT_SIZE="10.692376656489081" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.01" NO="1" P_CHI2="0.9052902196647598" P_Z="0.11981159146675145" STUDIES="3" TAU2="0.0" TOTAL_1="100" TOTAL_2="96" WEIGHT="100.0" Z="1.5555648965542404">
<NAME>BUD</NAME>
<CONT_DATA CI_END="45.09887700374776" CI_START="-13.098877003747763" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="20.0" ORDER="4727" SD_1="37.0" SD_2="14.1" SE="14.846638628707462" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="21.43462817708775"/>
<CONT_DATA CI_END="34.60004411485052" CI_START="-12.600044114850519" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="36.0" ORDER="4728" SD_1="55.48" SD_2="45.25" SE="12.041060091412216" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="32.58688007740204"/>
<CONT_DATA CI_END="27.868123256247863" CI_START="-11.868123256247863" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="45.0" ORDER="4729" SD_1="46.0" SD_2="60.0" SE="10.136983849175333" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="45.978491745510205"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2958699216584805" CI_END="25.90894372529403" CI_START="-2.6396598973020318" DF="1.0" EFFECT_SIZE="11.634641913996" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.02" NO="2" P_CHI2="0.5864833528982394" P_Z="0.11014989783729992" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="106" WEIGHT="100.00000000000001" Z="1.5975197544445567">
<NAME>FP</NAME>
<CONT_DATA CI_END="32.84374715781936" CI_START="-22.843747157819358" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="29.0" ORDER="4730" SD_1="49.3" SD_2="60.2" SE="14.206254491127021" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="26.28175651115556"/>
<CONT_DATA CI_END="30.62521941892898" CI_START="-2.6252194189289817" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="31.0" ORDER="4731" SD_1="53.3" SD_2="52.3" SE="8.482410671862642" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="73.71824348884445"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.477981893132649" CI_END="14.752780494942527" CI_START="-6.162564258825797" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.295108118058365" ESTIMABLE="YES" I2="0.0" I2_Q="32.0807737854877" ID="CMP-009.03" NO="3" P_CHI2="0.477595685290381" P_Q="0.22497762762535978" P_Z="0.42082901508280557" Q="1.4723371506643137" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="123" TOTAL_2="118" UNITS="" WEIGHT="200.0" Z="0.804983835572042">
<NAME>Evening PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.005644742468335344" CI_END="12.512851370018767" CI_START="-13.5531114294236" DF="1.0" EFFECT_SIZE="-0.5201300297024168" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.01" NO="1" P_CHI2="0.9401100844388356" P_Z="0.9376532776379688" STUDIES="2" TAU2="0.0" TOTAL_1="93" TOTAL_2="88" WEIGHT="99.99999999999999" Z="0.07821971767076216">
<NAME>BUD</NAME>
<CONT_DATA CI_END="17.071234070417596" CI_START="-19.071234070417596" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.0" ORDER="4732" SD_1="36.99" SD_2="39.6" SE="9.220186805962346" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="52.01300297024168"/>
<CONT_DATA CI_END="18.814036787541017" CI_START="-18.814036787541017" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="41.0" ORDER="4733" SD_1="42.0" SD_2="58.0" SE="9.599174748078912" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="47.98699702975831"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.947511879507159E-32" CI_END="30.523327618696882" CI_START="-4.5233276186968805" DF="0.0" EFFECT_SIZE="13.000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-009.03.02" NO="2" P_CHI2="0.0" P_Z="0.14593660084523544" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.4540350071315673">
<NAME>FP</NAME>
<CONT_DATA CI_END="30.523327618696882" CI_START="-4.523327618696882" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="16.0" ORDER="4734" SD_1="43.8" SD_2="21.9" SE="8.9406375611586" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" I2_Q="0.0" ID="CMP-009.04" NO="4" P_CHI2="0.2996611106850058" P_Q="1.0" P_Z="0.12015294096517" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="64" UNITS="" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>PEF Diurnal Variation change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" DF="1.0" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" ID="CMP-009.04.01" NO="1" P_CHI2="0.2996611106850058" P_Z="0.12015294096517" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="64" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.25578014000653204" CI_START="-1.8833514573756898" EFFECT_SIZE="-0.8137856586845789" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.4" ORDER="4735" SD_1="3.97" SD_2="3.68" SE="0.5457068635585701" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="10.852737797516065"/>
<CONT_DATA CI_END="0.1588467426680976" CI_START="-0.5875215012691248" EFFECT_SIZE="-0.21433737930051364" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-4.0" ORDER="4736" SD_1="27.0" SD_2="37.0" SE="0.19040356093899682" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="89.14726220248393"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.975259928265272" CI_END="0.13224825732538276" CI_START="-0.21047048014087072" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.039111111407743995" ESTIMABLE="YES" I2="83.26432637232037" I2_Q="83.26432637232037" ID="CMP-009.05" NO="5" P_CHI2="0.014507992318637974" P_Q="0.014507992318637974" P_Z="0.6546276125075663" Q="5.975259928265272" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="38" UNITS="" WEIGHT="200.0" Z="0.44734274128831386">
<NAME>Symptom Score change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1430767548112396" CI_START="-1.2569232451887604" DF="0.0" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-009.05.01" NO="1" P_CHI2="1.0" P_Z="0.013759177221544818" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0" Z="2.463489899246401">
<NAME>BUD</NAME>
<CONT_DATA CI_END="-0.1430767548112396" CI_START="-1.2569232451887604" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.4" ORDER="4737" SD_1="0.53" SD_2="0.57" SE="0.2841497341694541" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21009641115078911" CI_START="-0.15009641115078912" DF="0.0" EFFECT_SIZE="0.03" ESTIMABLE="YES" I2="0.0" ID="CMP-009.05.02" NO="2" P_CHI2="1.0" P_Z="0.7440568373366976" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.32648579258456806">
<NAME>FP</NAME>
<CONT_DATA CI_END="0.21009641115078911" CI_START="-0.15009641115078912" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.23" ORDER="4738" SD_1="0.33" SD_2="0.38" SE="0.0918876125129679" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.001652262246133" CI_END="-0.05962694869083568" CI_START="-0.5279432585579156" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.29378510362437565" ESTIMABLE="YES" I2="0.08254491937968925" I2_Q="49.84044468783476" ID="CMP-009.06" NO="6" P_CHI2="0.36757576228425937" P_Q="0.15796135320575422" P_Z="0.013930254474781564" Q="1.9936380890471515" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="147" TOTAL_2="138" UNITS="" WEIGHT="200.0" Z="2.4590568817113074">
<NAME>Symptoms (night waking) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.47025164512620826" CI_START="-0.47025164512620826" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-009.06.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0" Z="0.0">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.4702516451262082" CI_START="-0.4702516451262082" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" ORDER="4739" SD_1="0.62" SD_2="0.57" SE="0.23992871748434827" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0080141731989814" CI_END="-0.12063072570710959" CI_START="-0.6606570190081009" DF="1.0" EFFECT_SIZE="-0.3906438723576052" ESTIMABLE="YES" I2="0.0" ID="CMP-009.06.02" NO="2" P_CHI2="0.9286671384970573" P_Z="0.004574041337037612" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="106" WEIGHT="100.00000000000001" Z="2.835594970467201">
<NAME>FP</NAME>
<CONT_DATA CI_END="0.10123416745845132" CI_START="-0.9222319568228723" EFFECT_SIZE="-0.4104988946822105" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.01" ORDER="4740" SD_1="0.16" SD_2="0.22" SE="0.2610930946574258" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="27.840874094844224"/>
<CONT_DATA CI_END="-0.06512079875216148" CI_START="-0.7008457743231314" EFFECT_SIZE="-0.38298328653764646" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="-0.1" ORDER="4741" SD_1="0.27" SD_2="0.35" SE="0.16217771871970288" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="72.15912590515579"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03982061266901365" CI_END="0.2757419795110977" CI_START="-0.9762891845804921" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3502736025346972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.07" NO="7" P_CHI2="0.9979116736366878" P_Q="0.9838665619102023" P_Z="0.27279188348267214" Q="0.032530003731841235" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="234" UNITS="" WEIGHT="300.0" Z="1.0966558427500661">
<NAME>Rescue Medications (no. of puffs) change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.43031635091716447" CI_START="-1.2303163509171644" DF="0.0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-009.07.01" NO="1" P_CHI2="1.0" P_Z="0.345066915792426" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0" Z="0.9442010782396782">
<NAME>BUD</NAME>
<CONT_DATA CI_END="0.43031635091716447" CI_START="-1.2303163509171644" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.5" ORDER="4742" SD_1="0.79" SD_2="0.85" SE="0.4236385757425105" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0072906089371724105" CI_END="0.7255830310796303" CI_START="-1.2870229534134539" DF="1.0" EFFECT_SIZE="-0.2807199611669117" ESTIMABLE="YES" I2="0.0" ID="CMP-009.07.02" NO="2" P_CHI2="0.9319552682589916" P_Z="0.5845471872000887" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="106" WEIGHT="100.00000000000001" Z="0.546754822223396">
<NAME>FP</NAME>
<CONT_DATA CI_END="3.7765170490521847" CI_START="-4.696517049052185" EFFECT_SIZE="-0.45999999999999985" ESTIMABLE="YES" MEAN_1="-1.39" MEAN_2="-0.93" ORDER="4743" SD_1="11.7" SD_2="1.81" SE="2.1615280089171485" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="5.6420848246903565"/>
<CONT_DATA CI_END="0.7659519106797645" CI_START="-1.3059519106797646" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.85" MEAN_2="-1.58" ORDER="4744" SD_1="2.8" SD_2="3.7" SE="0.528556605555623" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="94.35791517530966"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.645586625714369" CI_START="-3.2855866257143687" DF="0.0" EFFECT_SIZE="-0.31999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-009.07.03" NO="3" P_CHI2="1.0" P_Z="0.8325058398955612" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0" Z="0.21148883988567901">
<NAME>BDP</NAME>
<CONT_DATA CI_END="2.645586625714369" CI_START="-3.2855866257143687" EFFECT_SIZE="-0.31999999999999995" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-0.56" ORDER="4745" SD_1="2.16" SD_2="16.43" SE="1.5130822041152479" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.39840228821690266" CI_END="2.4643517225494174" CI_START="0.40946152387386703" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0045183978784429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-009.08" LOG_CI_END="0.39170269223476323" LOG_CI_START="-0.3877869016064639" LOG_EFFECT_SIZE="0.0019578953141497087" METHOD="MH" NO="8" P_CHI2="0.8193851354593066" P_Q="0.0" P_Z="0.9921442025631493" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="260" TOTAL_2="263" WEIGHT="300.0" Z="0.009845941065929866">
<NAME>Withdrawal due to Adverse Event</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.027248350434825" CI_START="0.1642880478216715" DF="0.0" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-009.08.01" LOG_CI_END="0.48104805121725613" LOG_CI_START="-0.7843940309283456" LOG_EFFECT_SIZE="-0.1516729898555447" NO="1" P_CHI2="1.0" P_Z="0.6384739162380269" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="63" WEIGHT="100.0" Z="0.4698335889704865">
<NAME>BUD</NAME>
<DICH_DATA CI_END="3.0272483504348244" CI_START="0.16428804782167156" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.481048051217256" LOG_CI_START="-0.7843940309283454" LOG_EFFECT_SIZE="-0.1516729898555447" ORDER="4746" O_E="0.0" SE="0.743326943091658" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="0.552534944325989" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.717069281884235" CI_START="0.3670291521278235" DF="0.0" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-009.08.02" LOG_CI_END="0.6736722549862263" LOG_CI_START="-0.435299439547809" LOG_EFFECT_SIZE="0.11918640771920867" NO="2" P_CHI2="1.0" P_Z="0.6735410625558998" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="0.4212931091528167">
<NAME>FP</NAME>
<DICH_DATA CI_END="4.7170692818842355" CI_START="0.3670291521278234" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6736722549862264" LOG_CI_START="-0.4352994395478091" LOG_EFFECT_SIZE="0.11918640771920867" ORDER="4747" O_E="0.0" SE="0.6514154628677139" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4243421052631579" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.206354283559662" CI_START="0.06490907795006694" DF="0.0" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-009.08.03" LOG_CI_END="1.2096853286913705" LOG_CI_START="-1.1876945600884439" LOG_EFFECT_SIZE="0.010995384301463145" NO="3" P_CHI2="1.0" P_Z="0.9856560650087007" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0" Z="0.01797842496961412">
<NAME>BDP</NAME>
<DICH_DATA CI_END="16.206354283559662" CI_START="0.06490907795006694" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096853286913705" LOG_CI_START="-1.1876945600884439" LOG_EFFECT_SIZE="0.010995384301463145" ORDER="4748" O_E="0.0" SE="1.4082328138911044" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="1.9831196581196582" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5183178956499688" CI_END="1.1708833067993532" CI_START="0.9305743803910735" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0438361977509016" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="148" I2="0.0" I2_Q="0.0" ID="CMP-009.09" LOG_CI_END="0.06851361433927847" LOG_CI_START="-0.03124890818352177" LOG_EFFECT_SIZE="0.018632353077878375" METHOD="MH" NO="9" P_CHI2="0.7717003656253315" P_Q="0.0" P_Z="0.4640993465234754" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="262" WEIGHT="200.0" Z="0.732113424087276">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>BUD</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4749" O_E="0.0" SE="0.0" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29439053727122244" CI_END="1.2660709182213397" CI_START="0.9285543554901408" DF="1.0" EFFECT_SIZE="1.0842581175503492" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="64" I2="0.0" ID="CMP-009.09.02" LOG_CI_END="0.10245803311385852" LOG_CI_START="-0.03219266855480265" LOG_EFFECT_SIZE="0.03513268227952795" NO="2" P_CHI2="0.5874206924073679" P_Z="0.3064135088367619" STUDIES="2" TAU2="0.0" TOTAL_1="106" TOTAL_2="110" WEIGHT="100.0" Z="1.0227765781363118">
<NAME>FP</NAME>
<DICH_DATA CI_END="1.2421247758921332" CI_START="0.9205903412664099" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="63" LOG_CI_END="0.09416522447145745" LOG_CI_START="-0.03593358598854208" LOG_EFFECT_SIZE="0.029115819241457678" ORDER="4750" O_E="0.0" SE="0.07642068526370178" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.005840121136173767" WEIGHT="98.39704069050555"/>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="4751" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="1.6029593094944512"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1950311955197361" CI_START="0.8594272876174881" DF="0.0" EFFECT_SIZE="1.0134310134310134" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="84" I2="0.0" ID="CMP-009.09.03" LOG_CI_END="0.07737924240988746" LOG_CI_START="-0.0657908611785766" LOG_EFFECT_SIZE="0.005794190615655409" NO="3" P_CHI2="1.0" P_Z="0.8739508360429238" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0" Z="0.15864212767335892">
<NAME>BDP</NAME>
<DICH_DATA CI_END="1.195031195519736" CI_START="0.8594272876174881" EFFECT_SIZE="1.0134310134310134" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="84" LOG_CI_END="0.07737924240988739" LOG_CI_START="-0.0657908611785766" LOG_EFFECT_SIZE="0.005794190615655409" ORDER="4752" O_E="0.0" SE="0.08409882755130633" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.007072612795504361" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.907967776753731" CI_END="2.3857048546202426" CI_START="0.34106425463937723" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.902041378225299" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="74.4112526733606" I2_Q="0.0" ID="CMP-009.10" LOG_CI_END="0.3776167142973157" LOG_CI_START="-0.46716379459536894" LOG_EFFECT_SIZE="-0.04477354014902663" METHOD="MH" NO="10" P_CHI2="0.04805773694647619" P_Q="0.0" P_Z="0.8354187201061429" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.2077569859358535">
<NAME>Oral Candidiasis</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>BUD</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.907967776753731" CI_END="2.3857048546202426" CI_START="0.34106425463937723" DF="1.0" EFFECT_SIZE="0.902041378225299" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="74.4112526733606" ID="CMP-009.10.02" LOG_CI_END="0.3776167142973157" LOG_CI_START="-0.46716379459536894" LOG_EFFECT_SIZE="-0.04477354014902663" NO="2" P_CHI2="0.04805773694647619" P_Z="0.8354187201061429" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.2077569859358535">
<NAME>FP</NAME>
<DICH_DATA CI_END="1.4328858780172062" CI_START="0.10874360401321813" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.15621160245523724" LOG_CI_START="-0.9635962775774951" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="4753" O_E="0.0" SE="0.6577806918696316" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4326754385964912" WEIGHT="93.86406544996852"/>
<DICH_DATA CI_END="158.21294703008422" CI_START="0.4742905537037454" EFFECT_SIZE="8.6625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1992420202087515" LOG_CI_START="-0.32395552496902535" LOG_EFFECT_SIZE="0.9376432476198632" ORDER="4754" O_E="0.0" SE="1.4821387280667113" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" VAR="2.196735209235209" WEIGHT="6.1359345500314655"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5703993490512858" CI_END="1.426180986805702" CI_START="0.472745362488104" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8211092787084454" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-009.11" LOG_CI_END="0.15417464233450784" LOG_CI_START="-0.3253727227805531" LOG_EFFECT_SIZE="-0.08559904022302264" METHOD="MH" NO="11" P_CHI2="0.45010038935989527" P_Q="0.0" P_Z="0.4841110596104947" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="193" TOTAL_2="200" WEIGHT="200.0" Z="0.6997057982294007">
<NAME>Exacerbations</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>BUD</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.347580365927445" CI_START="0.4195097349554893" DF="0.0" EFFECT_SIZE="0.7518796992481203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="0.0" ID="CMP-009.11.02" LOG_CI_END="0.1295546747404524" LOG_CI_START="-0.37725795667462403" LOG_EFFECT_SIZE="-0.12385164096708583" NO="2" P_CHI2="1.0" P_Z="0.33809957453792894" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="80" WEIGHT="100.0" Z="0.9579270155280218">
<NAME>FP</NAME>
<DICH_DATA CI_END="1.347580365927445" CI_START="0.4195097349554893" EFFECT_SIZE="0.7518796992481203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.1295546747404524" LOG_CI_START="-0.37725795667462403" LOG_EFFECT_SIZE="-0.12385164096708583" ORDER="4755" O_E="0.0" SE="0.2977042484562022" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.08862781954887218" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.040938856995785" CI_START="0.2617940396194572" DF="0.0" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-009.11.03" LOG_CI_END="0.9562135321613053" LOG_CI_START="-0.5820402454470163" LOG_EFFECT_SIZE="0.18708664335714445" NO="3" P_CHI2="1.0" P_Z="0.6335384529374273" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0" Z="0.4767523906732895">
<NAME>BDP</NAME>
<DICH_DATA CI_END="9.040938856995785" CI_START="0.2617940396194572" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9562135321613053" LOG_CI_START="-0.5820402454470163" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="4756" O_E="0.0" SE="0.9035778834461319" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.8164529914529914" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17122975367256682" CI_END="1.2712187758150482" CI_START="0.29980616043983177" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6173485403369258" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-009.12" LOG_CI_END="0.104220298746719" LOG_CI_START="-0.5231594474799434" LOG_EFFECT_SIZE="-0.2094695743666122" METHOD="MH" NO="12" P_CHI2="0.6790214714162608" P_Q="0.0" P_Z="0.19060695065167968" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" WEIGHT="200.0" Z="1.308785704622247">
<NAME>Plasma Cortisol below reference range</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>BUD</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.593272699972858E-32" CI_END="1.8840158732341867" CI_START="0.12630127082724826" DF="0.0" EFFECT_SIZE="0.48780487804878053" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" ID="CMP-009.12.02" LOG_CI_END="0.2750845574955937" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.31175386105575426" NO="2" P_CHI2="0.0" P_Z="0.29777470273847273" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="80" WEIGHT="99.99999999999999" Z="1.0412173443227255">
<NAME>FP</NAME>
<DICH_DATA CI_END="1.8840158732341865" CI_START="0.12630127082724826" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27508455749559363" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.3117538610557543" ORDER="4757" O_E="0.0" SE="0.6894235839081664" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" VAR="0.47530487804878047" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4485744510283997E-31" CI_END="1.6119451793392632" CI_START="0.29004005759582824" DF="0.0" EFFECT_SIZE="0.6837606837606837" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="100.0" ID="CMP-009.12.03" LOG_CI_END="0.20735026779457044" LOG_CI_START="-0.5375420173030068" LOG_EFFECT_SIZE="-0.1650958747542181" NO="3" P_CHI2="0.0" P_Z="0.38495542610345057" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0" Z="0.8688020402091169">
<NAME>BDP</NAME>
<DICH_DATA CI_END="1.6119451793392634" CI_START="0.2900400575958283" EFFECT_SIZE="0.6837606837606838" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2073502677945705" LOG_CI_START="-0.5375420173030067" LOG_EFFECT_SIZE="-0.16509587475421805" ORDER="4758" O_E="0.0" SE="0.4375534155425957" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.19145299145299144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Step down vs Constant ICS Dose (Device)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="42.7555762665847" CI_START="-48.7555762665847" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8977481028966664" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="0.1285065653935223">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="42.7555762665847" CI_START="-48.7555762665847" DF="0.0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.01" NO="1" P_CHI2="1.0" P_Z="0.8977481028966664" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="0.1285065653935223">
<NAME>DPI</NAME>
<CONT_DATA CI_END="42.7555762665847" CI_START="-48.7555762665847" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="420.0" MEAN_2="423.0" ORDER="4759" SD_1="98.6" SD_2="100.6" SE="23.345110740553828" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.02" NO="2" P_CHI2="0.7803864680435201" P_Q="1.0" P_Z="0.8632634359975946" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="315" TOTAL_2="328" UNITS="" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" DF="1.0" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" ID="CMP-010.02.01" NO="1" P_CHI2="0.7803864680435201" P_Z="0.8632634359975946" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="328" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>DPI</NAME>
<CONT_DATA CI_END="11.082585483794093" CI_START="-11.082585483794093" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="45.0" ORDER="4760" SD_1="60.9" SD_2="62.2" SE="5.654484251349572" STUDY_ID="STD-Campbell--1998" TOTAL_1="232" TOTAL_2="242" WEIGHT="72.38295873935151"/>
<CONT_DATA CI_END="20.94199292850359" CI_START="-14.941992928503591" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="58.0" ORDER="4761" SD_1="59.0" SD_2="60.0" SE="9.154246236169511" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="27.617041260648495"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.03" NO="3" P_CHI2="0.5545263699591919" P_Q="1.0" P_Z="0.17387926215134233" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="331" UNITS="" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>Diary Card Symptom Score (Day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" DF="1.0" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" ID="CMP-010.03.01" NO="1" P_CHI2="0.5545263699591919" P_Z="0.17387926215134233" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="331" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.02596715542399894" CI_START="-0.18596715542399886" EFFECT_SIZE="-0.07999999999999996" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="-0.49" ORDER="4762" SD_1="0.61" SD_2="0.57" SE="0.054065868689350566" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="245" WEIGHT="79.16408152237781"/>
<CONT_DATA CI_END="0.1965518267409323" CI_START="-0.21655182674093232" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.44" ORDER="4763" SD_1="0.67" SD_2="0.7" SE="0.10538552155559325" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="20.835918477622194"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" I2_Q="0.0" ID="CMP-010.04" NO="4" P_CHI2="0.30186300523143084" P_Q="1.0" P_Z="0.2404150545922351" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="329" UNITS="" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>Diary Card Symptom Score (Night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" DF="1.0" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" ID="CMP-010.04.01" NO="1" P_CHI2="0.30186300523143084" P_Z="0.2404150545922351" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="329" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.1378782764578968" CI_START="-0.07787827645789676" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.45" ORDER="4764" SD_1="0.61" SD_2="0.59" SE="0.05504094835865703" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="243" WEIGHT="77.57434489354594"/>
<CONT_DATA CI_END="0.3506413716996898" CI_START="-0.05064137169968971" EFFECT_SIZE="0.15000000000000002" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.55" ORDER="4765" SD_1="0.63" SD_2="0.7" SE="0.10236992785700312" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="22.42565510645405"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" I2_Q="0.0" ID="CMP-010.05" NO="5" P_CHI2="0.24422826085037086" P_Q="1.0" P_Z="0.1820317738928679" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" DF="1.0" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" ID="CMP-010.05.01" NO="1" P_CHI2="0.24422826085037086" P_Z="0.1820317738928679" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.03519162882360782" CI_START="-0.5751916288236079" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.13" ORDER="4766" SD_1="1.68" SD_2="1.71" SE="0.1557128759665588" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="75.98335466647684"/>
<CONT_DATA CI_END="0.6428447932693216" CI_START="-0.4428447932693219" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="4767" SD_1="1.8" SD_2="1.8" SE="0.2769667185474898" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="24.016645333523154"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.06" NO="6" P_CHI2="0.835628835215149" P_Q="1.0" P_Z="0.42197702725394737" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" DF="1.0" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" ID="CMP-010.06.01" NO="1" P_CHI2="0.835628835215149" P_Z="0.42197702725394737" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.054527890309513175" CI_START="-0.13452789030951318" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="-0.23" ORDER="4768" SD_1="0.52" SD_2="0.53" SE="0.04822940169061121" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="93.74121528751569"/>
<CONT_DATA CI_END="0.3658307846601671" CI_START="-0.3658307846601671" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.7" ORDER="4769" SD_1="1.0" SD_2="1.4" SE="0.18665178929092252" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.258784712484326"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.06.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-010.07" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" METHOD="MH" NO="7" P_CHI2="0.3183119887450464" P_Q="0.0" P_Z="0.2594456111978882" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>Withdrawal due to adverse event</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" DF="1.0" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-010.07.01" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" NO="1" P_CHI2="0.3183119887450464" P_Z="0.2594456111978882" STUDIES="2" TAU2="0.0" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>DPI</NAME>
<DICH_DATA CI_END="2.8814196517478945" CI_START="0.5695414692728974" EFFECT_SIZE="1.2810495626822158" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4596065138049211" LOG_CI_START="-0.24447464872147914" LOG_EFFECT_SIZE="0.10756593254172103" ORDER="4770" O_E="0.0" SE="0.41358076012597156" STUDY_ID="STD-Campbell--1998" TOTAL_1="343" TOTAL_2="338" VAR="0.17104904514637642" WEIGHT="91.1154319522535"/>
<DICH_DATA CI_END="36.31589614749957" CI_START="0.4730030432105941" EFFECT_SIZE="4.144578313253012" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5600967654769557" LOG_CI_START="-0.32513606508604326" LOG_EFFECT_SIZE="0.6174803501954562" ORDER="4771" O_E="0.0" SE="1.1073950967257222" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" VAR="1.2263239002521715" WEIGHT="8.88456804774652"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" I2_Q="0.0" ID="CMP-010.08" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" METHOD="MH" NO="8" P_CHI2="0.4981586221009352" P_Q="0.0" P_Z="0.9532000313190644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>Proportion Achieving Asthma Control</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" DF="1.0" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" ID="CMP-010.08.01" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" NO="1" P_CHI2="0.4981586221009352" P_Z="0.9532000313190644" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>DPI</NAME>
<DICH_DATA CI_END="1.2033547105734104" CI_START="0.8755815859878481" EFFECT_SIZE="1.0264673526176147" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="101" LOG_CI_END="0.08039366236738556" LOG_CI_START="-0.05770338048459777" LOG_EFFECT_SIZE="0.011345140941393887" ORDER="4772" O_E="0.0" SE="0.08111888656264195" STUDY_ID="STD-Campbell--1998" TOTAL_1="153" TOTAL_2="154" VAR="0.006580273757162773" WEIGHT="82.63673813440649"/>
<DICH_DATA CI_END="1.2746520393518797" CI_START="0.6341104320018376" EFFECT_SIZE="0.8990384615384616" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.10539164515123073" LOG_CI_START="-0.19783510200375598" LOG_EFFECT_SIZE="-0.04622172842626257" ORDER="4773" O_E="0.0" SE="0.17811689227544536" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="26" TOTAL_2="33" VAR="0.03172562731386261" WEIGHT="17.36326186559352"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>High vs Moderate ICS Dose (Device)</NAME>
<CONT_OUTCOME CHI2="1.113726386713319" CI_END="10.989058803401644" CI_START="-3.2582940093077464" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.865382397046949" ESTIMABLE="YES" I2="10.211339882943161" I2_Q="10.211339882943161" ID="CMP-011.01" NO="1" P_CHI2="0.29127338209499953" P_Q="0.29127338209499953" P_Z="0.2875565264021285" Q="1.113726386713319" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="31" UNITS="" WEIGHT="200.0" Z="1.0634972523357353">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.903039713633156" CI_START="-2.903039713633154" DF="0.0" EFFECT_SIZE="9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.01" NO="1" P_CHI2="1.0" P_Z="0.13835435610022342" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="20" WEIGHT="100.0" Z="1.4819471567970048">
<NAME>DPI</NAME>
<CONT_DATA CI_END="20.903039713633156" CI_START="-2.903039713633154" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="82.5" MEAN_2="73.5" ORDER="4774" SD_1="20.6" SD_2="19.2" SE="6.073091040204214" STUDY_ID="STD-Pedersen-1996" TOTAL_1="23" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.891911348796498" CI_START="-7.891911348796498" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.02" NO="2" P_CHI2="1.0" P_Z="0.8255432926925941" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="100.0" Z="0.22042099922704825">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="9.891911348796498" CI_START="-7.891911348796498" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="98.3" MEAN_2="97.3" ORDER="4775" SD_1="14.7" SD_2="6.6" SE="4.536772827937023" STUDY_ID="STD-Hofstra--2000" TOTAL_1="13" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.181336540258029" CI_END="13.004971082457143" CI_START="-1.56446065905169" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.720255211702726" ESTIMABLE="YES" I2="4.336808063931614" I2_Q="0.0" ID="CMP-011.02" NO="2" P_CHI2="0.3820205779981115" P_Q="0.8259993309450235" P_Z="0.12379369075052236" Q="0.048327613700049454" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="563" TOTAL_2="554" UNITS="" WEIGHT="200.0" Z="1.5390434433174134">
<NAME>Morning PEF(L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.13300892655798" CI_END="13.358051202889605" CI_START="-1.5586339966148355" DF="3.0" EFFECT_SIZE="5.899708603137385" ESTIMABLE="YES" I2="27.41365786261593" ID="CMP-011.02.01" NO="1" P_CHI2="0.24745524662517115" P_Z="0.12105190613014623" STUDIES="4" TAU2="0.0" TOTAL_1="543" TOTAL_2="537" WEIGHT="100.0" Z="1.5503734545278918">
<NAME>DPI</NAME>
<CONT_DATA CI_END="19.409209826058163" CI_START="-1.409209826058163" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="26.0" ORDER="4776" SD_1="70.8" SD_2="62.0" SE="5.310918929207211" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="314" WEIGHT="51.33920410487567"/>
<CONT_DATA CI_END="18.43950212106763" CI_START="-14.43950212106763" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="4777" SD_1="55.0" SD_2="54.0" SE="8.387655207310095" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="20.58293661103084"/>
<CONT_DATA CI_END="39.1568927245098" CI_START="-3.156892724509806" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="53.0" ORDER="4778" SD_1="69.0" SD_2="46.0" SE="10.794531374756207" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="55" WEIGHT="12.427417528359396"/>
<CONT_DATA CI_END="10.102937532401661" CI_START="-27.60293753240166" EFFECT_SIZE="-8.75" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="51.25" ORDER="4779" SD_1="62.7" SD_2="61.6" SE="9.619022431591207" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" WEIGHT="15.650441755734091"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="35.95884107860774" CI_START="-31.95884107860774" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-011.02.02" NO="2" P_CHI2="1.0" P_Z="0.9081029256212692" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="100.0" Z="0.1154317357299173">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="35.95884107860774" CI_START="-31.95884107860774" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="66.0" ORDER="4780" SD_1="53.7" SD_2="51.5" SE="17.326257699871398" STUDY_ID="STD-O_x0027_Byrne-1996" TOTAL_1="20" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.03" NO="3" P_CHI2="0.3193479923711562" P_Q="1.0" P_Z="0.6268056443156612" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="397" UNITS="" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>Diary Card Symptom Score (day) change baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" DF="1.0" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.01" NO="1" P_CHI2="0.3193479923711562" P_Z="0.6268056443156612" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="397" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.0949956579110747" CI_START="-0.0949956579110747" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.42" ORDER="4781" SD_1="0.64" SD_2="0.57" SE="0.048468063015641265" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="311" WEIGHT="80.74828420233813"/>
<CONT_DATA CI_END="0.30455199359843693" CI_START="-0.08455199359843696" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.45" ORDER="4782" SD_1="0.65" SD_2="0.64" SE="0.09926304520544164" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="19.251715797661884"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.63874798732214" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="398" TOTAL_2="402" UNITS="" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>Diary Card Symptom Score (night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" DF="1.0" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" ID="CMP-011.04.01" NO="1" P_CHI2="1.0" P_Z="0.63874798732214" STUDIES="2" TAU2="0.0" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.11212736432696213" CI_START="-0.0721273643269622" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.36" ORDER="4783" SD_1="0.61" SD_2="0.57" SE="0.04700462103061641" STUDY_ID="STD-Campbell--1998" TOTAL_1="315" TOTAL_2="316" WEIGHT="82.14859018915008"/>
<CONT_DATA CI_END="0.2176298057826377" CI_START="-0.17762980578263776" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.42" ORDER="4784" SD_1="0.62" SD_2="0.69" SE="0.10083338639970754" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="17.851409810849916"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" I2_Q="0.0" ID="CMP-011.05" NO="5" P_CHI2="0.28244531465389533" P_Q="1.0" P_Z="0.4581819409042932" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" DF="1.0" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" ID="CMP-011.05.01" NO="1" P_CHI2="0.28244531465389533" P_Z="0.4581819409042932" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.12857546261999508" CI_START="-0.5685754626199953" EFFECT_SIZE="-0.22000000000000008" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.88" ORDER="4785" SD_1="1.95" SD_2="2.44" SE="0.17784789178245822" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="64.31488393177654"/>
<CONT_DATA CI_END="0.5679602891997918" CI_START="-0.36796028919979185" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.9" ORDER="4786" SD_1="1.6" SD_2="1.5" SE="0.23875963685608656" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="35.685116068223465"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.06" NO="6" P_CHI2="0.676104830152686" P_Q="1.0" P_Z="0.4135226426615982" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" DF="1.0" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" ID="CMP-011.06.01" NO="1" P_CHI2="0.676104830152686" P_Z="0.4135226426615982" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.05666452505601076" CI_START="-0.11666452505601076" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.21" ORDER="4787" SD_1="0.55" SD_2="0.55" SE="0.04421740692156053" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="93.03540991685338"/>
<CONT_DATA CI_END="0.21675079895488042" CI_START="-0.4167507989548804" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.5" ORDER="4788" SD_1="1.0" SD_2="1.1" SE="0.16161052011841556" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.964590083146619"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.06.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.49814332460811017" CI_END="2.430232132656587" CI_START="0.1425511244648875" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5885850178359098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.07" LOG_CI_END="0.3856477588315893" LOG_CI_START="-0.846029352560276" LOG_EFFECT_SIZE="-0.23019079686434335" METHOD="MH" NO="7" P_CHI2="0.48031711852951564" P_Q="0.0" P_Z="0.46380011309239444" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="149" WEIGHT="100.0" Z="0.7326038086667791">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.49814332460811017" CI_END="2.430232132656587" CI_START="0.1425511244648875" DF="1.0" EFFECT_SIZE="0.5885850178359098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-011.07.01" LOG_CI_END="0.3856477588315893" LOG_CI_START="-0.846029352560276" LOG_EFFECT_SIZE="-0.23019079686434335" NO="1" P_CHI2="0.48031711852951564" P_Z="0.46380011309239444" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="149" WEIGHT="100.0" Z="0.7326038086667791">
<NAME>DPI</NAME>
<DICH_DATA CI_END="3.123898577516711" CI_START="0.035568091714244104" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4946969253525552" LOG_CI_START="-1.4489394347918803" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="4789" O_E="0.0" SE="1.141701619103992" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="67" VAR="1.3034825870646765" WEIGHT="59.571938168846614"/>
<DICH_DATA CI_END="6.688632338481282" CI_START="0.1391401698209774" EFFECT_SIZE="0.9647058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8253373242592293" LOG_CI_START="-0.8565474709203815" LOG_EFFECT_SIZE="-0.015605073330576038" ORDER="4790" O_E="0.0" SE="0.9879474541525108" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" VAR="0.9760401721664276" WEIGHT="40.42806183115339"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-011.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>High vs Low ICS Dose (Device)</NAME>
<CONT_OUTCOME CHI2="0.47957962686212796" CI_END="0.15824712397451318" CI_START="-0.5519871257736606" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.19687000089957368" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.01" NO="1" P_CHI2="0.4886128305196745" P_Q="0.4886128305196745" P_Z="0.27722877741232155" Q="0.47957962686212796" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="1.0865657676642473">
<NAME>FEV1</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.25112982880466106" CI_START="-0.5299888820138743" DF="0.0" EFFECT_SIZE="-0.13942952660460659" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.01" NO="1" P_CHI2="1.0" P_Z="0.48411073175601294" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="50" WEIGHT="100.0" Z="0.6997063231019803">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.25112982880466106" CI_START="-0.5299888820138743" EFFECT_SIZE="-0.13942952660460659" ESTIMABLE="YES" MEAN_1="88.3" MEAN_2="89.7" ORDER="4791" SD_1="9.3" SD_2="10.6" SE="0.199268638857627" STUDY_ID="STD-Tukiainen--2000" TOTAL_1="51" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6263380359126845E-32" CI_END="0.3821872948251185" CI_START="-1.3241029633789667" DF="0.0" EFFECT_SIZE="-0.47095783427692406" ESTIMABLE="YES" I2="100.0" ID="CMP-012.01.02" NO="2" P_CHI2="0.0" P_Z="0.2792747514598898" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="1.0819500246005034">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="0.38218729482511854" CI_START="-1.3241029633789665" EFFECT_SIZE="-0.470957834276924" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="3.09" ORDER="4792" SD_1="0.69" SD_2="0.7" SE="0.4352861255775833" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6006627985107081" CI_END="19.949593455634396" CI_START="-56.04269451338604" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.046550528875823" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" NO="2" P_CHI2="0.43832541588337126" P_Q="0.43832541588337126" P_Z="0.35190559627399653" Q="0.6006627985107081" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="200.0" Z="0.9308994380113496">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="35.352049019096704" CI_START="-53.352049019096704" DF="0.0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-012.02.01" NO="1" P_CHI2="1.0" P_Z="0.6908369444214122" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="0.39771952482432904">
<NAME>DPI</NAME>
<CONT_DATA CI_END="35.352049019096704" CI_START="-53.352049019096704" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="425.0" MEAN_2="434.0" ORDER="4793" SD_1="98.6" SD_2="94.7" SE="22.629012251725033" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="30.660977310090047" CI_START="-116.66097731009005" DF="0.0" EFFECT_SIZE="-43.0" ESTIMABLE="YES" I2="0.0" ID="CMP-012.02.02" NO="2" P_CHI2="1.0" P_Z="0.2525657088725335" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.00000000000001" Z="1.1441397387443828">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="30.660977310090047" CI_START="-116.66097731009005" EFFECT_SIZE="-43.0" ESTIMABLE="YES" MEAN_1="457.0" MEAN_2="500.0" ORDER="4794" SD_1="114.3" SD_2="56.9" SE="37.58282187382954" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" I2_Q="0.0" ID="CMP-012.03" NO="3" P_CHI2="0.15071704735946023" P_Q="1.0" P_Z="0.08146767927689498" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="136" UNITS="" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Figh Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" DF="1.0" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" ID="CMP-012.03.01" NO="1" P_CHI2="0.15071704735946023" P_Z="0.08146767927689498" STUDIES="2" TAU2="0.0" TOTAL_1="146" TOTAL_2="136" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>DPI</NAME>
<CONT_DATA CI_END="49.383191322099684" CI_START="2.616808677900316" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="45.0" ORDER="4795" SD_1="69.0" SD_2="60.0" SE="11.930418878379047" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="56" WEIGHT="33.351797424210346"/>
<CONT_DATA CI_END="21.54128271599394" CI_START="-11.54128271599394" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="37.5" ORDER="4796" SD_1="62.7" SD_2="44.7" SE="8.439585036495297" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" WEIGHT="66.64820257578967"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6737537845299415" CI_END="0.5585664838908377" CI_START="-0.6461874794450229" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0438104977770926" ESTIMABLE="YES" I2="62.59939842681495" I2_Q="62.59939842681495" ID="CMP-012.04" NO="4" P_CHI2="0.10201521524358914" P_Q="0.10201521524358914" P_Z="0.8866480021204945" Q="2.6737537845299415" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="200.0" Z="0.1425469438591681">
<NAME>Rescue Medications (no. of puffs)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7265554040177095" CI_START="-0.5265554040177095" DF="0.0" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-012.04.01" NO="1" P_CHI2="1.0" P_Z="0.754420649396242" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="0.3128157497281207">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.7265554040177095" CI_START="-0.5265554040177095" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.8" ORDER="4797" SD_1="1.54" SD_2="1.18" SE="0.31967699863869875" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3895248256254782" CI_START="-3.9895248256254785" DF="0.0" EFFECT_SIZE="-1.8" ESTIMABLE="YES" I2="0.0" ID="CMP-012.04.02" NO="2" P_CHI2="1.0" P_Z="0.1071189455955537" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="1.6112789089588322">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="0.3895248256254782" CI_START="-3.9895248256254785" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.6" ORDER="4798" SD_1="1.73" SD_2="3.16" SE="1.1171250303047253" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-012.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" I2_Q="0.0" ID="CMP-012.05" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" METHOD="MH" NO="5" P_CHI2="0.20416258909086904" P_Q="0.0" P_Z="0.42845627127583574" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="0.7918360754774336">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" DF="1.0" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" ID="CMP-012.05.01" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" NO="1" P_CHI2="0.20416258909086904" P_Z="0.42845627127583574" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="0.7918360754774336">
<NAME>DPI</NAME>
<DICH_DATA CI_END="2.0468258985652774" CI_START="0.026997938727846522" EFFECT_SIZE="0.23507462686567165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31108090347930123" LOG_CI_START="-1.5686693926297155" LOG_EFFECT_SIZE="-0.628794244575207" ORDER="4799" O_E="0.0" SE="1.1041746288484697" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="1.2192016109926558" WEIGHT="80.00723719920391"/>
<DICH_DATA CI_END="20.35820012661124" CI_START="0.174045474212828" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3087393792819173" LOG_CI_START="-0.7593372653986533" LOG_EFFECT_SIZE="0.27470105694163205" ORDER="4800" O_E="0.0" SE="1.214798458229861" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" VAR="1.4757352941176471" WEIGHT="19.992762800796093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-012.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-012.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Moderate vs Low ICS Dose (Device)</NAME>
<CONT_OUTCOME CHI2="3.8829016852751153" CI_END="0.2840817161698703" CI_START="-0.05573095452110606" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.11417538082438212" ESTIMABLE="YES" I2="0.0" I2_Q="36.73604936042791" ID="CMP-013.01" NO="1" P_CHI2="0.4220854290959357" P_Q="0.2086629583988907" P_Z="0.18781299736300916" Q="1.5806790279304694" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="268" TOTAL_2="268" UNITS="" WEIGHT="200.0" Z="1.317076457931364">
<NAME>FEV1 change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1062867780146273" CI_END="0.8081235873607749" CI_START="-0.06432333506696708" DF="1.0" EFFECT_SIZE="0.37190012614690393" ESTIMABLE="YES" I2="52.52308420496312" ID="CMP-013.01.01" NO="1" P_CHI2="0.1466949500364031" P_Z="0.09473007776219053" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="1.6709574745601894">
<NAME>DPI</NAME>
<CONT_DATA CI_END="2.2544040863311006" CI_START="0.015887887004713663" EFFECT_SIZE="1.135145986667907" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.0" ORDER="4801" SD_1="0.53" SD_2="0.28" SE="0.5710605442200767" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="15.189992061090038"/>
<CONT_DATA CI_END="0.7088785734083383" CI_START="-0.23848234131754717" EFFECT_SIZE="0.23519811604539556" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.14" ORDER="4802" SD_1="0.42" SD_2="0.33" SE="0.24167814362879814" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="35" TOTAL_2="34" WEIGHT="84.81000793890996"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.19593587933001846" CI_END="0.2525594260721742" CI_START="-0.11638947683913058" DF="2.0" EFFECT_SIZE="0.06808497461652181" ESTIMABLE="YES" I2="0.0" ID="CMP-013.01.02" NO="2" P_CHI2="0.9066780410020083" P_Z="0.4694498918286256" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="226" WEIGHT="100.00000000000001" Z="0.723374413550087">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="0.32119965731034755" CI_START="-0.18823753322396347" EFFECT_SIZE="0.06648106204319203" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.2" ORDER="4803" SD_1="12.98" SD_2="10.95" SE="0.1299608550342472" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="52.450683652526244"/>
<CONT_DATA CI_END="0.6740450407355303" CI_START="-0.33996335355591273" EFFECT_SIZE="0.1670408435898088" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.3" ORDER="4804" SD_1="0.55" SD_2="0.38" SE="0.25868036410102735" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.23882209451871"/>
<CONT_DATA CI_END="0.3472907387291552" CI_START="-0.2825818896783239" EFFECT_SIZE="0.032354424525415634" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="0.4" ORDER="4805" SD_1="0.62" SD_2="0.61" SE="0.16068474558099896" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="34.31049425295505"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5037226311746015" CI_END="20.933815511487794" CI_START="1.3387608045442079" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.136288158016" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" NO="2" P_CHI2="0.9731375802234453" P_Q="0.9296807950988805" P_Z="0.025895269370531142" Q="0.007787436992227614" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="209" TOTAL_2="202" UNITS="" WEIGHT="200.0" Z="2.2277787980287576">
<NAME>Morning PEF (L/min) change baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.19803137006976657" CI_END="26.951914095604497" CI_START="-5.864565353591441" DF="1.0" EFFECT_SIZE="10.543674371006528" ESTIMABLE="YES" I2="0.0" ID="CMP-013.02.01" NO="1" P_CHI2="0.6563145913240522" P_Z="0.20787084489666996" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="64" WEIGHT="100.0" Z="1.2594417426088125">
<NAME>DPI</NAME>
<CONT_DATA CI_END="45.09887700374776" CI_START="-13.098877003747763" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="20.0" ORDER="4806" SD_1="37.0" SD_2="14.1" SE="14.846638628707462" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="31.795929637581597"/>
<CONT_DATA CI_END="27.868123256247863" CI_START="-11.868123256247863" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="45.0" ORDER="4807" SD_1="46.0" SD_2="60.0" SE="10.136983849175333" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="68.2040703624184"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2979038241126073" CI_END="23.678598752800085" CI_START="-0.7492883205487111" DF="2.0" EFFECT_SIZE="11.464655216125687" ESTIMABLE="YES" I2="0.0" ID="CMP-013.02.02" NO="2" P_CHI2="0.8616105603349767" P_Z="0.06580845236497307" STUDIES="3" TAU2="0.0" TOTAL_1="147" TOTAL_2="138" WEIGHT="100.0" Z="1.839726149978078">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="34.60004411485052" CI_START="-12.600044114850519" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="36.0" ORDER="4808" SD_1="55.48" SD_2="45.25" SE="12.041060091412216" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="26.78466299207956"/>
<CONT_DATA CI_END="32.84374715781936" CI_START="-22.843747157819358" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="29.0" ORDER="4809" SD_1="49.3" SD_2="60.2" SE="14.206254491127021" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="19.242276601243617"/>
<CONT_DATA CI_END="30.62521941892898" CI_START="-2.6252194189289817" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="31.0" ORDER="4810" SD_1="53.3" SD_2="52.3" SE="8.482410671862642" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="53.97306040667683"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.477981893132649" CI_END="14.752780494942527" CI_START="-6.162564258825797" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.295108118058365" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.03" NO="3" P_CHI2="0.477595685290381" P_Q="0.5903998969973714" P_Z="0.42082901508280557" Q="0.2897203030870774" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="123" TOTAL_2="118" UNITS="" WEIGHT="200.0" Z="0.804983835572042">
<NAME>Evening PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.814036787541017" CI_START="-18.814036787541017" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-013.03.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="56" WEIGHT="100.0" Z="0.0">
<NAME>DPI</NAME>
<CONT_DATA CI_END="18.814036787541017" CI_START="-18.814036787541017" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="41.0" ORDER="4811" SD_1="42.0" SD_2="58.0" SE="9.599174748078912" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1882615900455715" CI_END="18.795556531493887" CI_START="-6.364655131535704" DF="1.0" EFFECT_SIZE="6.21545069997909" ESTIMABLE="YES" I2="15.843446562835664" ID="CMP-013.03.02" NO="2" P_CHI2="0.2756805538635543" P_Z="0.33286508812611104" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.9683590649234167">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="17.071234070417596" CI_START="-19.071234070417596" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.0" ORDER="4812" SD_1="36.99" SD_2="39.6" SE="9.220186805962346" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="48.461066428720784"/>
<CONT_DATA CI_END="30.523327618696882" CI_START="-4.523327618696882" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="16.0" ORDER="4813" SD_1="43.8" SD_2="21.9" SE="8.9406375611586" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="51.5389335712792"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" I2_Q="0.0" ID="CMP-013.04" NO="4" P_CHI2="0.2996611106850058" P_Q="1.0" P_Z="0.12015294096517" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="64" UNITS="" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>PEF Diurnal Variation change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" DF="1.0" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" ID="CMP-013.04.01" NO="1" P_CHI2="0.2996611106850058" P_Z="0.12015294096517" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="64" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.25578014000653204" CI_START="-1.8833514573756898" EFFECT_SIZE="-0.8137856586845789" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.4" ORDER="4814" SD_1="3.97" SD_2="3.68" SE="0.5457068635585701" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="10.852737797516065"/>
<CONT_DATA CI_END="0.1588467426680976" CI_START="-0.5875215012691248" EFFECT_SIZE="-0.21433737930051364" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-4.0" ORDER="4815" SD_1="27.0" SD_2="37.0" SE="0.19040356093899682" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="89.14726220248393"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>pMDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.975259928265272" CI_END="0.13224825732538276" CI_START="-0.21047048014087072" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.039111111407743995" ESTIMABLE="YES" I2="83.26432637232037" I2_Q="83.26432637232037" ID="CMP-013.05" NO="5" P_CHI2="0.014507992318637974" P_Q="0.014507992318637974" P_Z="0.6546276125075663" Q="5.975259928265272" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="38" UNITS="" WEIGHT="200.0" Z="0.44734274128831386">
<NAME>Symptom Score change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1430767548112396" CI_START="-1.2569232451887604" DF="0.0" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-013.05.01" NO="1" P_CHI2="1.0" P_Z="0.013759177221544818" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0" Z="2.463489899246401">
<NAME>DPI</NAME>
<CONT_DATA CI_END="-0.1430767548112396" CI_START="-1.2569232451887604" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.4" ORDER="4816" SD_1="0.53" SD_2="0.57" SE="0.2841497341694541" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21009641115078911" CI_START="-0.15009641115078912" DF="0.0" EFFECT_SIZE="0.03" ESTIMABLE="YES" I2="0.0" ID="CMP-013.05.02" NO="2" P_CHI2="1.0" P_Z="0.7440568373366976" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.32648579258456806">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="0.21009641115078911" CI_START="-0.15009641115078912" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.23" ORDER="4817" SD_1="0.33" SD_2="0.38" SE="0.0918876125129679" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.001652262246133" CI_END="-0.05962694869083568" CI_START="-0.5279432585579156" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.29378510362437565" ESTIMABLE="YES" I2="0.08254491937968925" I2_Q="0.0" ID="CMP-013.06" NO="6" P_CHI2="0.36757576228425937" P_Q="1.0" P_Z="0.013930254474781564" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="147" TOTAL_2="138" UNITS="" WEIGHT="100.00000000000001" Z="2.4590568817113074">
<NAME>Symptom (Night Waking) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.001652262246133" CI_END="-0.05962694869083568" CI_START="-0.5279432585579156" DF="2.0" EFFECT_SIZE="-0.29378510362437565" ESTIMABLE="YES" I2="0.08254491937968925" ID="CMP-013.06.02" NO="2" P_CHI2="0.36757576228425937" P_Z="0.013930254474781564" STUDIES="3" TAU2="0.0" TOTAL_1="147" TOTAL_2="138" WEIGHT="100.00000000000001" Z="2.4590568817113074">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="0.4702516451262082" CI_START="-0.4702516451262082" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" ORDER="4818" SD_1="0.62" SD_2="0.57" SE="0.23992871748434827" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="24.794646886093393"/>
<CONT_DATA CI_END="0.10123416745845132" CI_START="-0.9222319568228723" EFFECT_SIZE="-0.4104988946822105" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.01" ORDER="4819" SD_1="0.16" SD_2="0.22" SE="0.2610930946574258" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.93782767302575"/>
<CONT_DATA CI_END="-0.06512079875216148" CI_START="-0.7008457743231314" EFFECT_SIZE="-0.38298328653764646" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="-0.1" ORDER="4820" SD_1="0.27" SD_2="0.35" SE="0.16217771871970288" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="54.26752544088087"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.06.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03982061266901364" CI_END="0.2757419795110977" CI_START="-0.9762891845804921" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3502736025346972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.07" NO="7" P_CHI2="0.9979116736366878" P_Q="0.8581909699246646" P_Z="0.27279188348267214" Q="0.03192565399724933" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="234" UNITS="" WEIGHT="200.0" Z="1.0966558427500661">
<NAME>Rescue Medications (no. of puffs) change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.43031635091716447" CI_START="-1.2303163509171644" DF="0.0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-013.07.01" NO="1" P_CHI2="1.0" P_Z="0.345066915792426" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0" Z="0.9442010782396782">
<NAME>DPI</NAME>
<CONT_DATA CI_END="0.43031635091716447" CI_START="-1.2303163509171644" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.5" ORDER="4821" SD_1="0.79" SD_2="0.85" SE="0.4236385757425105" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.007894958671764311" CI_END="0.668159816570042" CI_START="-1.237711362110215" DF="2.0" EFFECT_SIZE="-0.28477577277008653" ESTIMABLE="YES" I2="0.0" ID="CMP-013.07.02" NO="2" P_CHI2="0.9960603017288723" P_Z="0.5580659340815031" STUDIES="3" TAU2="0.0" TOTAL_1="226" TOTAL_2="226" WEIGHT="100.00000000000001" Z="0.5857166680965601">
<NAME>pMDI</NAME>
<CONT_DATA CI_END="2.645586625714369" CI_START="-3.2855866257143687" EFFECT_SIZE="-0.31999999999999995" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-0.56" ORDER="4822" SD_1="2.16" SD_2="16.43" SE="1.5130822041152479" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="10.325375747231432"/>
<CONT_DATA CI_END="3.7765170490521847" CI_START="-4.696517049052185" EFFECT_SIZE="-0.45999999999999985" ESTIMABLE="YES" MEAN_1="-1.39" MEAN_2="-0.93" ORDER="4823" SD_1="11.7" SD_2="1.81" SE="2.1615280089171485" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="5.059518366563554"/>
<CONT_DATA CI_END="0.7659519106797645" CI_START="-1.3059519106797646" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.85" MEAN_2="-1.58" ORDER="4824" SD_1="2.8" SD_2="3.7" SE="0.528556605555623" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="84.61510588620503"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-013.07.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.39840228821690266" CI_END="2.4643517225494174" CI_START="0.40946152387386703" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0045183978784429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-013.08" LOG_CI_END="0.39170269223476323" LOG_CI_START="-0.3877869016064639" LOG_EFFECT_SIZE="0.0019578953141497087" METHOD="MH" NO="8" P_CHI2="0.8193851354593066" P_Q="0.0" P_Z="0.9921442025631493" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="260" TOTAL_2="263" WEIGHT="200.0" Z="0.009845941065929866">
<NAME>Withdrawal due to Adverse Event</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.027248350434825" CI_START="0.1642880478216715" DF="0.0" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-013.08.01" LOG_CI_END="0.48104805121725613" LOG_CI_START="-0.7843940309283456" LOG_EFFECT_SIZE="-0.1516729898555447" NO="1" P_CHI2="1.0" P_Z="0.6384739162380269" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="63" WEIGHT="100.0" Z="0.4698335889704865">
<NAME>DPI</NAME>
<DICH_DATA CI_END="3.0272483504348244" CI_START="0.16428804782167156" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.481048051217256" LOG_CI_START="-0.7843940309283454" LOG_EFFECT_SIZE="-0.1516729898555447" ORDER="4825" O_E="0.0" SE="0.743326943091658" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="0.552534944325989" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.025786434724834474" CI_END="4.000617185114615" CI_START="0.39504108744661814" DF="1.0" EFFECT_SIZE="1.2571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-013.08.02" LOG_CI_END="0.6021269961811931" LOG_CI_START="-0.4033577319093695" LOG_EFFECT_SIZE="0.09938463213591178" NO="2" P_CHI2="0.8724230066919081" P_Z="0.6984190156514023" STUDIES="2" TAU2="0.0" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0" Z="0.38745551108083">
<NAME>pMDI</NAME>
<DICH_DATA CI_END="4.7170692818842355" CI_START="0.3670291521278234" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6736722549862264" LOG_CI_START="-0.4352994395478091" LOG_EFFECT_SIZE="0.11918640771920867" ORDER="4826" O_E="0.0" SE="0.6514154628677139" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4243421052631579" WEIGHT="79.78737541528238"/>
<DICH_DATA CI_END="16.206354283559662" CI_START="0.06490907795006694" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096853286913705" LOG_CI_START="-1.1876945600884439" LOG_EFFECT_SIZE="0.010995384301463145" ORDER="4827" O_E="0.0" SE="1.4082328138911044" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="1.9831196581196582" WEIGHT="20.21262458471761"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5183178956499688" CI_END="1.1708833067993532" CI_START="0.9305743803910735" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0438361977509016" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="148" I2="0.0" I2_Q="0.0" ID="CMP-013.09" LOG_CI_END="0.06851361433927847" LOG_CI_START="-0.03124890818352177" LOG_EFFECT_SIZE="0.018632353077878375" METHOD="MH" NO="9" P_CHI2="0.7717003656253315" P_Q="0.0" P_Z="0.4640993465234754" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="262" WEIGHT="100.00000000000001" Z="0.732113424087276">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5183178956499688" CI_END="1.1708833067993532" CI_START="0.9305743803910735" DF="2.0" EFFECT_SIZE="1.0438361977509016" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="148" I2="0.0" ID="CMP-013.09.02" LOG_CI_END="0.06851361433927847" LOG_CI_START="-0.03124890818352177" LOG_EFFECT_SIZE="0.018632353077878375" NO="2" P_CHI2="0.7717003656253315" P_Z="0.4640993465234754" STUDIES="4" TAU2="0.0" TOTAL_1="261" TOTAL_2="262" WEIGHT="100.00000000000001" Z="0.732113424087276">
<NAME>pMDI</NAME>
<DICH_DATA CI_END="1.2421247758921332" CI_START="0.9205903412664099" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="63" LOG_CI_END="0.09416522447145745" LOG_CI_START="-0.03593358598854208" LOG_EFFECT_SIZE="0.029115819241457678" ORDER="4828" O_E="0.0" SE="0.07642068526370178" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.005840121136173767" WEIGHT="42.240611075747935"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4829" O_E="0.0" SE="0.0" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.195031195519736" CI_START="0.8594272876174881" EFFECT_SIZE="1.0134310134310134" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="84" LOG_CI_END="0.07737924240988739" LOG_CI_START="-0.0657908611785766" LOG_EFFECT_SIZE="0.005794190615655409" ORDER="4830" O_E="0.0" SE="0.08409882755130633" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.007072612795504361" WEIGHT="57.07125866863212"/>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="4831" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.6881302556199538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.907967776753731" CI_END="2.3857048546202426" CI_START="0.34106425463937723" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.902041378225299" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="74.4112526733606" I2_Q="0.0" ID="CMP-013.10" LOG_CI_END="0.3776167142973157" LOG_CI_START="-0.46716379459536894" LOG_EFFECT_SIZE="-0.04477354014902663" METHOD="MH" NO="10" P_CHI2="0.04805773694647619" P_Q="0.0" P_Z="0.8354187201061429" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.2077569859358535">
<NAME>Oral Candidiasis</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.907967776753731" CI_END="2.3857048546202426" CI_START="0.34106425463937723" DF="1.0" EFFECT_SIZE="0.902041378225299" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="74.4112526733606" ID="CMP-013.10.02" LOG_CI_END="0.3776167142973157" LOG_CI_START="-0.46716379459536894" LOG_EFFECT_SIZE="-0.04477354014902663" NO="2" P_CHI2="0.04805773694647619" P_Z="0.8354187201061429" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.2077569859358535">
<NAME>pMDI</NAME>
<DICH_DATA CI_END="1.4328858780172062" CI_START="0.10874360401321813" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.15621160245523724" LOG_CI_START="-0.9635962775774951" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="4832" O_E="0.0" SE="0.6577806918696316" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4326754385964912" WEIGHT="93.86406544996852"/>
<DICH_DATA CI_END="158.21294703008422" CI_START="0.4742905537037454" EFFECT_SIZE="8.6625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1992420202087515" LOG_CI_START="-0.32395552496902535" LOG_EFFECT_SIZE="0.9376432476198632" ORDER="4833" O_E="0.0" SE="1.4821387280667113" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" VAR="2.196735209235209" WEIGHT="6.1359345500314655"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5703993490512858" CI_END="1.426180986805702" CI_START="0.472745362488104" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8211092787084454" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-013.11" LOG_CI_END="0.15417464233450784" LOG_CI_START="-0.3253727227805531" LOG_EFFECT_SIZE="-0.08559904022302264" METHOD="MH" NO="11" P_CHI2="0.45010038935989527" P_Q="0.0" P_Z="0.4841110596104947" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0" Z="0.6997057982294007">
<NAME>Exacerbations</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5703993490512858" CI_END="1.426180986805702" CI_START="0.472745362488104" DF="1.0" EFFECT_SIZE="0.8211092787084454" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-013.11.02" LOG_CI_END="0.15417464233450784" LOG_CI_START="-0.3253727227805531" LOG_EFFECT_SIZE="-0.08559904022302264" NO="2" P_CHI2="0.45010038935989527" P_Z="0.4841110596104947" STUDIES="2" TAU2="0.0" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0" Z="0.6997057982294007">
<NAME>pMDI</NAME>
<DICH_DATA CI_END="1.347580365927445" CI_START="0.4195097349554893" EFFECT_SIZE="0.7518796992481203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.1295546747404524" LOG_CI_START="-0.37725795667462403" LOG_EFFECT_SIZE="-0.12385164096708583" ORDER="4834" O_E="0.0" SE="0.2977042484562022" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.08862781954887218" WEIGHT="91.19868067008072"/>
<DICH_DATA CI_END="9.040938856995785" CI_START="0.2617940396194572" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9562135321613053" LOG_CI_START="-0.5820402454470163" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="4835" O_E="0.0" SE="0.9035778834461319" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.8164529914529914" WEIGHT="8.801319329919279"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.11.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17122975367256682" CI_END="1.2712187758150482" CI_START="0.29980616043983177" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6173485403369258" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-013.12" LOG_CI_END="0.104220298746719" LOG_CI_START="-0.5231594474799434" LOG_EFFECT_SIZE="-0.2094695743666122" METHOD="MH" NO="12" P_CHI2="0.6790214714162608" P_Q="0.0" P_Z="0.19060695065167968" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" WEIGHT="200.0" Z="1.308785704622247">
<NAME>Plasma Cortisol below reference range</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.593272699972858E-32" CI_END="1.8840158732341867" CI_START="0.12630127082724826" DF="0.0" EFFECT_SIZE="0.48780487804878053" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="100.0" ID="CMP-013.12.01" LOG_CI_END="0.2750845574955937" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.31175386105575426" NO="1" P_CHI2="0.0" P_Z="0.29777470273847273" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="80" WEIGHT="99.99999999999999" Z="1.0412173443227255">
<NAME>DPI</NAME>
<DICH_DATA CI_END="1.8840158732341865" CI_START="0.12630127082724826" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27508455749559363" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.3117538610557543" ORDER="4836" O_E="0.0" SE="0.6894235839081664" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" VAR="0.47530487804878047" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4485744510283997E-31" CI_END="1.6119451793392632" CI_START="0.29004005759582824" DF="0.0" EFFECT_SIZE="0.6837606837606837" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="100.0" ID="CMP-013.12.02" LOG_CI_END="0.20735026779457044" LOG_CI_START="-0.5375420173030068" LOG_EFFECT_SIZE="-0.1650958747542181" NO="2" P_CHI2="0.0" P_Z="0.38495542610345057" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="120" WEIGHT="100.0" Z="0.8688020402091169">
<NAME>pMDI</NAME>
<DICH_DATA CI_END="1.6119451793392634" CI_START="0.2900400575958283" EFFECT_SIZE="0.6837606837606838" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2073502677945705" LOG_CI_START="-0.5375420173030067" LOG_EFFECT_SIZE="-0.16509587475421805" ORDER="4837" O_E="0.0" SE="0.4375534155425957" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.19145299145299144" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-013.12.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nebuliser</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Step down vs constant (Duration)</NAME>
<CONT_OUTCOME CHI2="0.011498839823517779" CI_END="24.303900679069244" CI_START="-26.12603337328808" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9110663471094177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.01" NO="1" P_CHI2="0.9146044202237349" P_Q="1.0" P_Z="0.943543120578758" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="0.0708173532809709">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.011498839823517779" CI_END="24.303900679069244" CI_START="-26.12603337328808" DF="1.0" EFFECT_SIZE="-0.9110663471094177" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.02" NO="2" P_CHI2="0.9146044202237349" P_Z="0.943543120578758" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="60" WEIGHT="100.0" Z="0.0708173532809709">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="42.7555762665847" CI_START="-48.7555762665847" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="420.0" MEAN_2="423.0" ORDER="4838" SD_1="98.6" SD_2="100.6" SE="23.345110740553828" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="30.368878236980596"/>
<CONT_DATA CI_END="30.217373222175407" CI_START="-30.217373222175407" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="269.0" MEAN_2="269.0" ORDER="4839" SD_1="62.7" SD_2="46.5" SE="15.417310450868582" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="69.63112176301941"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.02" NO="2" P_CHI2="0.7803864680435201" P_Q="1.0" P_Z="0.8632634359975946" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="315" TOTAL_2="328" UNITS="" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.07773805323828868" CI_END="10.257372718455942" CI_START="-8.600350242817031" DF="1.0" EFFECT_SIZE="0.8285112378194549" ESTIMABLE="YES" I2="0.0" ID="CMP-014.02.02" NO="2" P_CHI2="0.7803864680435201" P_Z="0.8632634359975946" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="328" WEIGHT="100.0" Z="0.17222144903153402">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="11.082585483794093" CI_START="-11.082585483794093" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="45.0" ORDER="4840" SD_1="60.9" SD_2="62.2" SE="5.654484251349572" STUDY_ID="STD-Campbell--1998" TOTAL_1="232" TOTAL_2="242" WEIGHT="72.38295873935151"/>
<CONT_DATA CI_END="20.94199292850359" CI_START="-14.941992928503591" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="58.0" ORDER="4841" SD_1="59.0" SD_2="60.0" SE="9.154246236169511" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="27.617041260648495"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.03" NO="3" P_CHI2="0.5545263699591919" P_Q="1.0" P_Z="0.17387926215134233" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="331" UNITS="" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>Diary Card Symptom Score (Day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.349270864371922" CI_END="0.028868571060292086" CI_START="-0.15969828519162096" DF="1.0" EFFECT_SIZE="-0.06541485706566444" ESTIMABLE="YES" I2="0.0" ID="CMP-014.03.02" NO="2" P_CHI2="0.5545263699591919" P_Z="0.17387926215134233" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="331" WEIGHT="100.0" Z="1.3598441046421919">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="0.02596715542399894" CI_START="-0.18596715542399886" EFFECT_SIZE="-0.07999999999999996" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="-0.49" ORDER="4842" SD_1="0.61" SD_2="0.57" SE="0.054065868689350566" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="245" WEIGHT="79.16408152237781"/>
<CONT_DATA CI_END="0.1965518267409323" CI_START="-0.21655182674093232" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.45" MEAN_2="-0.44" ORDER="4843" SD_1="0.67" SD_2="0.7" SE="0.10538552155559325" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="20.835918477622194"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" I2_Q="0.0" ID="CMP-014.04" NO="4" P_CHI2="0.30186300523143084" P_Q="1.0" P_Z="0.2404150545922351" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="329" UNITS="" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>Diary Card Symptom Score (Night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.065947497499029" CI_END="0.1519259797251912" CI_START="-0.038104407469701417" DF="1.0" EFFECT_SIZE="0.056910786127744896" ESTIMABLE="YES" I2="6.186749127302973" ID="CMP-014.04.02" NO="2" P_CHI2="0.30186300523143084" P_Z="0.2404150545922351" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="329" WEIGHT="100.0" Z="1.1739500486082222">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="0.1378782764578968" CI_START="-0.07787827645789676" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.45" ORDER="4844" SD_1="0.61" SD_2="0.59" SE="0.05504094835865703" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="243" WEIGHT="77.57434489354594"/>
<CONT_DATA CI_END="0.3506413716996898" CI_START="-0.05064137169968971" EFFECT_SIZE="0.15000000000000002" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.55" ORDER="4845" SD_1="0.63" SD_2="0.7" SE="0.10236992785700312" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="22.42565510645405"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" I2_Q="0.0" ID="CMP-014.05" NO="5" P_CHI2="0.24422826085037086" P_Q="1.0" P_Z="0.1820317738928679" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.356022016033215" CI_END="0.0848923439373292" CI_START="-0.44716916846925786" DF="1.0" EFFECT_SIZE="-0.18113841226596433" ESTIMABLE="YES" I2="26.254884642263395" ID="CMP-014.05.02" NO="2" P_CHI2="0.24422826085037086" P_Z="0.1820317738928679" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.0" Z="1.3345252606309856">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="0.03519162882360782" CI_START="-0.5751916288236079" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.13" ORDER="4846" SD_1="1.68" SD_2="1.71" SE="0.1557128759665588" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="75.98335466647684"/>
<CONT_DATA CI_END="0.6428447932693216" CI_START="-0.4428447932693219" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" ORDER="4847" SD_1="1.8" SD_2="1.8" SE="0.2769667185474898" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="24.016645333523154"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.06" NO="6" P_CHI2="0.835628835215149" P_Q="1.0" P_Z="0.42197702725394737" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="327" UNITS="" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-014.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04305129771415713" CI_END="0.054025461845844336" CI_START="-0.1290184340758569" DF="1.0" EFFECT_SIZE="-0.03749648611500628" ESTIMABLE="YES" I2="0.0" ID="CMP-014.06.02" NO="2" P_CHI2="0.835628835215149" P_Z="0.42197702725394737" STUDIES="2" TAU2="0.0" TOTAL_1="316" TOTAL_2="327" WEIGHT="100.00000000000001" Z="0.8029960459720037">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="0.054527890309513175" CI_START="-0.13452789030951318" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="-0.23" ORDER="4848" SD_1="0.52" SD_2="0.53" SE="0.04822940169061121" STUDY_ID="STD-Campbell--1998" TOTAL_1="233" TOTAL_2="241" WEIGHT="93.74121528751569"/>
<CONT_DATA CI_END="0.3658307846601671" CI_START="-0.3658307846601671" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.7" ORDER="4849" SD_1="1.0" SD_2="1.4" SE="0.18665178929092252" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.258784712484326"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-014.07" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" METHOD="MH" NO="7" P_CHI2="0.3183119887450464" P_Q="0.0" P_Z="0.2594456111978882" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>Withdrawal due to adverse event</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Step Down</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Constant</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9958707094556252" CI_END="3.235379197343334" CI_START="0.7287067633435613" DF="1.0" EFFECT_SIZE="1.5354617230934642" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-014.07.02" LOG_CI_END="0.5099251887644304" LOG_CI_START="-0.13744719964062904" LOG_EFFECT_SIZE="0.18623899456190063" NO="2" P_CHI2="0.3183119887450464" P_Z="0.2594456111978882" STUDIES="2" TAU2="0.0" TOTAL_1="426" TOTAL_2="424" WEIGHT="100.00000000000003" Z="1.1277024735564811">
<NAME>&gt; 12 weeks</NAME>
<DICH_DATA CI_END="2.8814196517478945" CI_START="0.5695414692728974" EFFECT_SIZE="1.2810495626822158" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4596065138049211" LOG_CI_START="-0.24447464872147914" LOG_EFFECT_SIZE="0.10756593254172103" ORDER="4850" O_E="0.0" SE="0.41358076012597156" STUDY_ID="STD-Campbell--1998" TOTAL_1="343" TOTAL_2="338" VAR="0.17104904514637642" WEIGHT="91.1154319522535"/>
<DICH_DATA CI_END="36.31589614749957" CI_START="0.4730030432105941" EFFECT_SIZE="4.144578313253012" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5600967654769557" LOG_CI_START="-0.32513606508604326" LOG_EFFECT_SIZE="0.6174803501954562" ORDER="4851" O_E="0.0" SE="1.1073950967257222" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" VAR="1.2263239002521715" WEIGHT="8.88456804774652"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" I2_Q="0.0" ID="CMP-014.08" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" METHOD="MH" NO="8" P_CHI2="0.4981586221009352" P_Q="0.0" P_Z="0.9532000313190644" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>Proportion Achieving Asthma Control</NAME>
<GROUP_LABEL_1>Step Down Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Constant Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Constant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Step Down</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-014.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&lt; = 12 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4588571051271233" CI_END="1.1606823069898766" CI_START="0.8690594523877175" DF="1.0" EFFECT_SIZE="1.0043415405671194" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="125" I2="0.0" ID="CMP-014.08.02" LOG_CI_END="0.06471336426753753" LOG_CI_START="-0.06095051243426409" LOG_EFFECT_SIZE="0.0018814259166367183" NO="2" P_CHI2="0.4981586221009352" P_Z="0.9532000313190644" STUDIES="2" TAU2="0.0" TOTAL_1="179" TOTAL_2="187" WEIGHT="100.0" Z="0.058688735903614855">
<NAME>&gt; 12 weeks</NAME>
<DICH_DATA CI_END="1.2033547105734104" CI_START="0.8755815859878481" EFFECT_SIZE="1.0264673526176147" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="101" LOG_CI_END="0.08039366236738556" LOG_CI_START="-0.05770338048459777" LOG_EFFECT_SIZE="0.011345140941393887" ORDER="4852" O_E="0.0" SE="0.08111888656264195" STUDY_ID="STD-Campbell--1998" TOTAL_1="153" TOTAL_2="154" VAR="0.006580273757162773" WEIGHT="82.63673813440649"/>
<DICH_DATA CI_END="1.2746520393518797" CI_START="0.6341104320018376" EFFECT_SIZE="0.8990384615384616" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" LOG_CI_END="0.10539164515123073" LOG_CI_START="-0.19783510200375598" LOG_EFFECT_SIZE="-0.04622172842626257" ORDER="4853" O_E="0.0" SE="0.17811689227544536" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="26" TOTAL_2="33" VAR="0.03172562731386261" WEIGHT="17.36326186559352"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" NO="15">
<NAME>High vs Moderate ICS Dose (Duration)</NAME>
<CONT_OUTCOME CHI2="2.7013430364302593" CI_END="9.985564020342643" CI_START="0.6464205052493579" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.315992262796001" ESTIMABLE="YES" I2="0.0" I2_Q="37.00652257588397" ID="CMP-015.01" NO="1" P_CHI2="0.4399991748897033" P_Q="0.20768860193191452" P_Z="0.02566214381797517" Q="1.5874659423344777" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="68" TOTAL_2="62" UNITS="" WEIGHT="200.0" Z="2.2312867042539875">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="21.953515815815052" CI_START="0.8464841841849573" DF="0.0" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.01" NO="1" P_CHI2="1.0" P_Z="0.03424540366490605" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="2.1171702221048916">
<NAME>&lt;= 12 weeks</NAME>
<CONT_DATA CI_END="21.953515815815052" CI_START="0.8464841841849573" EFFECT_SIZE="11.400000000000006" ESTIMABLE="YES" MEAN_1="81.4" MEAN_2="70.0" ORDER="4854" SD_1="8.6" SD_2="10.0" SE="5.3845457870960045" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1138770940957816" CI_END="9.041944497128668" CI_START="-1.3720795033571376" DF="2.0" EFFECT_SIZE="3.8349324968857648" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.02" NO="2" P_CHI2="0.5729606132430083" P_Z="0.14887925326760235" STUDIES="3" TAU2="0.0" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.0" Z="1.4435014892778686">
<NAME>&gt; 12 weeks</NAME>
<CONT_DATA CI_END="9.891911348796498" CI_START="-7.891911348796498" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="98.3" MEAN_2="97.3" ORDER="4855" SD_1="14.7" SD_2="6.6" SE="4.536772827937023" STUDY_ID="STD-Hofstra--2000" TOTAL_1="13" TOTAL_2="11" WEIGHT="34.29153364014944"/>
<CONT_DATA CI_END="20.903039713633156" CI_START="-2.903039713633154" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="82.5" MEAN_2="73.5" ORDER="4856" SD_1="20.6" SD_2="19.2" SE="6.073091040204214" STUDY_ID="STD-Pedersen-1996" TOTAL_1="23" TOTAL_2="20" WEIGHT="19.136450746345073"/>
<CONT_DATA CI_END="11.430026764541502" CI_START="-3.830026764541479" EFFECT_SIZE="3.8000000000000114" ESTIMABLE="YES" MEAN_1="106.4" MEAN_2="102.6" ORDER="4857" SD_1="14.3" SD_2="13.5" SE="3.892942331964346" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="46.572015613505485"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1459525699473343" CI_END="31.99730208753371" CI_START="-16.171224318684146" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.9130388844247825" ESTIMABLE="YES" I2="12.736353473516097" I2_Q="12.736353473516097" ID="CMP-015.02" NO="2" P_CHI2="0.2843980682563255" P_Q="0.2843980682563255" P_Z="0.5196022087669634" Q="1.1459525699473343" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="31" UNITS="" WEIGHT="200.0" Z="0.6439587165670719">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="78.70416958322528" CI_START="-228.70416958322528" DF="0.0" EFFECT_SIZE="-75.0" ESTIMABLE="YES" I2="0.0" ID="CMP-015.02.01" NO="1" P_CHI2="1.0" P_Z="0.33888783771392517" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.9563650695950074">
<NAME>&lt; =12 weeks</NAME>
<CONT_DATA CI_END="78.70416958322528" CI_START="-228.70416958322528" EFFECT_SIZE="-75.0" ESTIMABLE="YES" MEAN_1="375.0" MEAN_2="450.0" ORDER="4858" SD_1="120.0" SD_2="150.0" SE="78.4219357067906" STUDY_ID="STD-Majima-1993" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.38548575498966" CI_START="-14.385485754989656" DF="0.0" EFFECT_SIZE="10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-015.02.02" NO="2" P_CHI2="1.0" P_Z="0.421545981993972" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.8037420309082892">
<NAME>&gt;12 weeks</NAME>
<CONT_DATA CI_END="34.38548575498966" CI_START="-14.385485754989656" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="244.0" MEAN_2="234.0" ORDER="4859" SD_1="51.0" SD_2="37.0" SE="12.441802985840177" STUDY_ID="STD-Visser-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.18133654025803" CI_END="13.004971082457143" CI_START="-1.5644606590516892" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.720255211702727" ESTIMABLE="YES" I2="4.336808063931634" I2_Q="0.0" ID="CMP-015.03" NO="3" P_CHI2="0.3820205779981114" P_Q="0.6116157695591916" P_Z="0.12379369075052225" Q="0.25782881100524113" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="563" TOTAL_2="554" UNITS="" WEIGHT="200.0" Z="1.5390434433174138">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.426341675947398" CI_END="15.93265838889459" CI_START="-10.072780241852955" DF="2.0" EFFECT_SIZE="2.9299390735208166" ESTIMABLE="YES" I2="41.62870521524997" ID="CMP-015.03.01" NO="1" P_CHI2="0.18029348141902712" P_Z="0.6587467237856048" STUDIES="3" TAU2="0.0" TOTAL_1="166" TOTAL_2="154" WEIGHT="100.0" Z="0.4416441608646983">
<NAME>&lt; =12 weeks</NAME>
<CONT_DATA CI_END="39.1568927245098" CI_START="-3.156892724509806" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="53.0" ORDER="4860" SD_1="69.0" SD_2="46.0" SE="10.794531374756207" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="55" WEIGHT="37.7715326459212"/>
<CONT_DATA CI_END="35.95884107860774" CI_START="-31.95884107860774" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="68.0" MEAN_2="66.0" ORDER="4861" SD_1="53.7" SD_2="51.5" SE="17.326257699871398" STUDY_ID="STD-O_x0027_Byrne-1996" TOTAL_1="20" TOTAL_2="17" WEIGHT="14.660968285924614"/>
<CONT_DATA CI_END="10.102937532401661" CI_START="-27.60293753240166" EFFECT_SIZE="-8.75" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="51.25" ORDER="4862" SD_1="62.7" SD_2="61.6" SE="9.619022431591207" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" WEIGHT="47.567499068154184"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4971660533053912" CI_END="15.791212278651608" CI_START="-1.7977825737805073" DF="1.0" EFFECT_SIZE="6.9967148524355505" ESTIMABLE="YES" I2="0.0" ID="CMP-015.03.02" NO="2" P_CHI2="0.48074803813977085" P_Z="0.11892406599416842" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="400" WEIGHT="100.0" Z="1.5593056039781548">
<NAME>&gt;12 weeks</NAME>
<CONT_DATA CI_END="19.409209826058163" CI_START="-1.409209826058163" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="26.0" ORDER="4863" SD_1="70.8" SD_2="62.0" SE="5.310918929207211" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="314" WEIGHT="71.3816407490793"/>
<CONT_DATA CI_END="18.43950212106763" CI_START="-14.43950212106763" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="48.0" MEAN_2="46.0" ORDER="4864" SD_1="55.0" SD_2="54.0" SE="8.387655207310095" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="28.618359250920708"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.04" NO="4" P_CHI2="0.3193479923711562" P_Q="1.0" P_Z="0.6268056443156612" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="397" UNITS="" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>Diary Card Symptom Score (day) change baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.991615905877441" CI_END="0.10654003219793592" CI_START="-0.06418625744307979" DF="1.0" EFFECT_SIZE="0.021176887377428073" ESTIMABLE="YES" I2="0.0" ID="CMP-015.04.01" NO="1" P_CHI2="0.3193479923711562" P_Z="0.6268056443156612" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="397" WEIGHT="100.00000000000001" Z="0.486227828785994">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.0949956579110747" CI_START="-0.0949956579110747" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.42" MEAN_2="-0.42" ORDER="4865" SD_1="0.64" SD_2="0.57" SE="0.048468063015641265" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="311" WEIGHT="80.74828420233813"/>
<CONT_DATA CI_END="0.30455199359843693" CI_START="-0.08455199359843696" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.45" ORDER="4866" SD_1="0.65" SD_2="0.64" SE="0.09926304520544164" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="19.251715797661884"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.63874798732214" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="398" TOTAL_2="402" UNITS="" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>Diary Card Symptom Score (night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10350042844980463" CI_START="-0.0635004284498047" DF="1.0" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" I2="0.0" ID="CMP-015.05.01" NO="1" P_CHI2="1.0" P_Z="0.63874798732214" STUDIES="2" TAU2="0.0" TOTAL_1="398" TOTAL_2="402" WEIGHT="100.0" Z="0.46945004257511336">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.11212736432696213" CI_START="-0.0721273643269622" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="-0.36" ORDER="4867" SD_1="0.61" SD_2="0.57" SE="0.04700462103061641" STUDY_ID="STD-Campbell--1998" TOTAL_1="315" TOTAL_2="316" WEIGHT="82.14859018915008"/>
<CONT_DATA CI_END="0.2176298057826377" CI_START="-0.17762980578263776" EFFECT_SIZE="0.019999999999999962" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.42" ORDER="4868" SD_1="0.62" SD_2="0.69" SE="0.10083338639970754" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="17.851409810849916"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt;12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" I2_Q="0.0" ID="CMP-015.06" NO="6" P_CHI2="0.28244531465389533" P_Q="1.0" P_Z="0.4581819409042932" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>Rescue Medications (puffs per day) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1552863112264173" CI_END="0.17373790486312757" CI_START="-0.3853531620264975" DF="1.0" EFFECT_SIZE="-0.10580762858168496" ESTIMABLE="YES" I2="13.441370309457753" ID="CMP-015.06.01" NO="1" P_CHI2="0.28244531465389533" P_Z="0.4581819409042932" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.7418438733546564">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.12857546261999508" CI_START="-0.5685754626199953" EFFECT_SIZE="-0.22000000000000008" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.88" ORDER="4869" SD_1="1.95" SD_2="2.44" SE="0.17784789178245822" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="64.31488393177654"/>
<CONT_DATA CI_END="0.5679602891997918" CI_START="-0.36796028919979185" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.9" ORDER="4870" SD_1="1.6" SD_2="1.5" SE="0.23875963685608656" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="35.685116068223465"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt;12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.07" NO="7" P_CHI2="0.676104830152686" P_Q="1.0" P_Z="0.4135226426615982" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="391" UNITS="" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>Rescue Medications (puffs per night) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.17454407039284692" CI_END="0.048716937630219254" CI_START="-0.1184673637466245" DF="1.0" EFFECT_SIZE="-0.034875213058202625" ESTIMABLE="YES" I2="0.0" ID="CMP-015.07.01" NO="1" P_CHI2="0.676104830152686" P_Z="0.4135226426615982" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="391" WEIGHT="100.0" Z="0.8177102872017109">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.05666452505601076" CI_START="-0.11666452505601076" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.21" ORDER="4871" SD_1="0.55" SD_2="0.55" SE="0.04421740692156053" STUDY_ID="STD-Campbell--1998" TOTAL_1="314" TOTAL_2="305" WEIGHT="93.03540991685338"/>
<CONT_DATA CI_END="0.21675079895488042" CI_START="-0.4167507989548804" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.5" ORDER="4872" SD_1="1.0" SD_2="1.1" SE="0.16161052011841556" STUDY_ID="STD-Chanez-2001" TOTAL_1="83" TOTAL_2="86" WEIGHT="6.964590083146619"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-015.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt;12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.49814332460811017" CI_END="2.430232132656587" CI_START="0.1425511244648875" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5885850178359098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-015.08" LOG_CI_END="0.3856477588315893" LOG_CI_START="-0.846029352560276" LOG_EFFECT_SIZE="-0.23019079686434335" METHOD="MH" NO="8" P_CHI2="0.48031711852951564" P_Q="0.0" P_Z="0.46380011309239444" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="149" WEIGHT="100.0" Z="0.7326038086667791">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Mod Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.49814332460811017" CI_END="2.430232132656587" CI_START="0.1425511244648875" DF="1.0" EFFECT_SIZE="0.5885850178359098" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-015.08.01" LOG_CI_END="0.3856477588315893" LOG_CI_START="-0.846029352560276" LOG_EFFECT_SIZE="-0.23019079686434335" NO="1" P_CHI2="0.48031711852951564" P_Z="0.46380011309239444" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="149" WEIGHT="100.0" Z="0.7326038086667791">
<NAME>&lt; = 12 weeks</NAME>
<DICH_DATA CI_END="3.123898577516711" CI_START="0.035568091714244104" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4946969253525552" LOG_CI_START="-1.4489394347918803" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="4873" O_E="0.0" SE="1.141701619103992" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="67" VAR="1.3034825870646765" WEIGHT="59.571938168846614"/>
<DICH_DATA CI_END="6.688632338481282" CI_START="0.1391401698209774" EFFECT_SIZE="0.9647058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8253373242592293" LOG_CI_START="-0.8565474709203815" LOG_EFFECT_SIZE="-0.015605073330576038" ORDER="4874" O_E="0.0" SE="0.9879474541525108" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="82" VAR="0.9760401721664276" WEIGHT="40.42806183115339"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-015.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" NO="16">
<NAME>High vs Low ICS Dose (Duration)</NAME>
<CONT_OUTCOME CHI2="0.47957962686212796" CI_END="0.15824712397451318" CI_START="-0.5519871257736606" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.19687000089957368" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.01" NO="1" P_CHI2="0.4886128305196745" P_Q="1.0" P_Z="0.27722877741232155" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="60" UNITS="" WEIGHT="99.99999999999999" Z="1.0865657676642473">
<NAME>FEV1</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.47957962686212796" CI_END="0.15824712397451318" CI_START="-0.5519871257736606" DF="1.0" EFFECT_SIZE="-0.19687000089957368" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.01" NO="1" P_CHI2="0.4886128305196745" P_Z="0.27722877741232155" STUDIES="2" TAU2="0.0" TOTAL_1="63" TOTAL_2="60" WEIGHT="99.99999999999999" Z="1.0865657676642473">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.38218729482511854" CI_START="-1.3241029633789665" EFFECT_SIZE="-0.470957834276924" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="3.09" ORDER="4875" SD_1="0.69" SD_2="0.7" SE="0.4352861255775833" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="17.32596371581677"/>
<CONT_DATA CI_END="0.25112982880466106" CI_START="-0.5299888820138743" EFFECT_SIZE="-0.13942952660460659" ESTIMABLE="YES" MEAN_1="88.3" MEAN_2="89.7" ORDER="4876" SD_1="9.3" SD_2="10.6" SE="0.199268638857627" STUDY_ID="STD-Tukiainen--2000" TOTAL_1="51" TOTAL_2="50" WEIGHT="82.67403628418322"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6006627985107081" CI_END="19.949593455634396" CI_START="-56.04269451338604" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.046550528875823" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-016.02" NO="2" P_CHI2="0.43832541588337126" P_Q="1.0" P_Z="0.35190559627399653" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="100.00000000000001" Z="0.9308994380113496">
<NAME>Morning PEF (L/min)</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours High Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6006627985107081" CI_END="19.949593455634396" CI_START="-56.04269451338604" DF="1.0" EFFECT_SIZE="-18.046550528875823" ESTIMABLE="YES" I2="0.0" ID="CMP-016.02.01" NO="1" P_CHI2="0.43832541588337126" P_Z="0.35190559627399653" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.00000000000001" Z="0.9308994380113496">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="30.660977310090047" CI_START="-116.66097731009005" EFFECT_SIZE="-43.0" ESTIMABLE="YES" MEAN_1="457.0" MEAN_2="500.0" ORDER="4877" SD_1="114.3" SD_2="56.9" SE="37.58282187382954" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="26.60750155551713"/>
<CONT_DATA CI_END="35.352049019096704" CI_START="-53.352049019096704" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="425.0" MEAN_2="434.0" ORDER="4878" SD_1="98.6" SD_2="94.7" SE="22.629012251725033" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="73.39249844448288"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" I2_Q="0.0" ID="CMP-016.03" NO="3" P_CHI2="0.15071704735946023" P_Q="1.0" P_Z="0.08146767927689498" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="136" UNITS="" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>Morning PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Figh Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0649790352335953" CI_END="25.50790780498795" CI_START="-1.500152886819608" DF="1.0" EFFECT_SIZE="12.003877459084173" ESTIMABLE="YES" I2="51.57335823088017" ID="CMP-016.03.01" NO="1" P_CHI2="0.15071704735946023" P_Z="0.08146767927689498" STUDIES="2" TAU2="0.0" TOTAL_1="146" TOTAL_2="136" WEIGHT="100.00000000000001" Z="1.7422330142921907">
<NAME>&lt;= 12 weeks</NAME>
<CONT_DATA CI_END="49.383191322099684" CI_START="2.616808677900316" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="45.0" ORDER="4879" SD_1="69.0" SD_2="60.0" SE="11.930418878379047" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="61" TOTAL_2="56" WEIGHT="33.351797424210346"/>
<CONT_DATA CI_END="21.54128271599394" CI_START="-11.54128271599394" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="37.5" ORDER="4880" SD_1="62.7" SD_2="44.7" SE="8.439585036495297" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" WEIGHT="66.64820257578967"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 Weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6737537845299415" CI_END="0.5585664838908377" CI_START="-0.6461874794450229" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0438104977770926" ESTIMABLE="YES" I2="62.59939842681495" I2_Q="0.0" ID="CMP-016.04" NO="4" P_CHI2="0.10201521524358914" P_Q="1.0" P_Z="0.8866480021204945" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="45" UNITS="" WEIGHT="99.99999999999999" Z="0.1425469438591681">
<NAME>Rescue Medications (no. of puffs)</NAME>
<GROUP_LABEL_1>High Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.6737537845299415" CI_END="0.5585664838908377" CI_START="-0.6461874794450229" DF="1.0" EFFECT_SIZE="-0.0438104977770926" ESTIMABLE="YES" I2="62.59939842681495" ID="CMP-016.04.01" NO="1" P_CHI2="0.10201521524358914" P_Z="0.8866480021204945" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="99.99999999999999" Z="0.1425469438591681">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.3895248256254782" CI_START="-3.9895248256254785" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.6" ORDER="4881" SD_1="1.73" SD_2="3.16" SE="1.1171250303047253" STUDY_ID="STD-Gershman-2000" TOTAL_1="12" TOTAL_2="10" WEIGHT="7.568973567215399"/>
<CONT_DATA CI_END="0.7265554040177095" CI_START="-0.5265554040177095" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.8" ORDER="4882" SD_1="1.54" SD_2="1.18" SE="0.31967699863869875" STUDY_ID="STD-van-der-Molen--1998" TOTAL_1="38" TOTAL_2="35" WEIGHT="92.43102643278459"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" I2_Q="0.0" ID="CMP-016.05" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" METHOD="MH" NO="5" P_CHI2="0.20416258909086904" P_Q="0.0" P_Z="0.42845627127583574" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="0.7918360754774336">
<NAME>Withdrawal Due to Adverse Event</NAME>
<GROUP_LABEL_1>High Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours High Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6123446181421155" CI_END="2.3251438971151224" CI_START="0.13700651371472639" DF="1.0" EFFECT_SIZE="0.564411072914782" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="37.97851968195934" ID="CMP-016.05.01" LOG_CI_END="0.3664498354148899" LOG_CI_START="-0.8632587846456761" LOG_EFFECT_SIZE="-0.24840447461539306" NO="1" P_CHI2="0.20416258909086904" P_Z="0.42845627127583574" STUDIES="2" TAU2="0.0" TOTAL_1="152" TOTAL_2="143" WEIGHT="100.0" Z="0.7918360754774336">
<NAME>&lt; = 12 weeks</NAME>
<DICH_DATA CI_END="2.0468258985652774" CI_START="0.026997938727846522" EFFECT_SIZE="0.23507462686567165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.31108090347930123" LOG_CI_START="-1.5686693926297155" LOG_EFFECT_SIZE="-0.628794244575207" ORDER="4883" O_E="0.0" SE="1.1041746288484697" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="1.2192016109926558" WEIGHT="80.00723719920391"/>
<DICH_DATA CI_END="20.35820012661124" CI_START="0.174045474212828" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3087393792819173" LOG_CI_START="-0.7593372653986533" LOG_EFFECT_SIZE="0.27470105694163205" ORDER="4884" O_E="0.0" SE="1.214798458229861" STUDY_ID="STD-Wasserman-1996" TOTAL_1="85" TOTAL_2="80" VAR="1.4757352941176471" WEIGHT="19.992762800796093"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-016.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt;12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" NO="17">
<NAME>Moderate vs Low ICS Dose (Duration)</NAME>
<CONT_OUTCOME CHI2="3.8829016852751153" CI_END="0.28408171616987027" CI_START="-0.05573095452110606" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1141753808243821" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.01" NO="1" P_CHI2="0.4220854290959357" P_Q="1.0" P_Z="0.18781299736300916" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="268" TOTAL_2="268" UNITS="" WEIGHT="100.0" Z="1.317076457931364">
<NAME>FEV1 change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.8829016852751153" CI_END="0.28408171616987027" CI_START="-0.05573095452110606" DF="4.0" EFFECT_SIZE="0.1141753808243821" ESTIMABLE="YES" I2="0.0" ID="CMP-017.01.01" NO="1" P_CHI2="0.4220854290959357" P_Z="0.18781299736300916" STUDIES="5" TAU2="0.0" TOTAL_1="268" TOTAL_2="268" WEIGHT="100.0" Z="1.317076457931364">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="2.2544040863311006" CI_START="0.015887887004713663" EFFECT_SIZE="1.135145986667907" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.0" ORDER="4885" SD_1="0.53" SD_2="0.28" SE="0.5710605442200767" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="2.3044041775507043"/>
<CONT_DATA CI_END="0.7088785734083383" CI_START="-0.23848234131754717" EFFECT_SIZE="0.23519811604539556" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.14" ORDER="4886" SD_1="0.42" SD_2="0.33" SE="0.24167814362879814" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="35" TOTAL_2="34" WEIGHT="12.866138165611913"/>
<CONT_DATA CI_END="0.32119965731034755" CI_START="-0.18823753322396347" EFFECT_SIZE="0.06648106204319203" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.2" ORDER="4887" SD_1="12.98" SD_2="10.95" SE="0.1299608550342472" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="44.49363047974147"/>
<CONT_DATA CI_END="0.6740450407355303" CI_START="-0.33996335355591273" EFFECT_SIZE="0.1670408435898088" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.3" ORDER="4888" SD_1="0.55" SD_2="0.38" SE="0.25868036410102735" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="11.230420982933778"/>
<CONT_DATA CI_END="0.3472907387291552" CI_START="-0.2825818896783239" EFFECT_SIZE="0.032354424525415634" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="0.4" ORDER="4889" SD_1="0.62" SD_2="0.61" SE="0.16068474558099896" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="29.105406194162125"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-017.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5037226311746014" CI_END="20.933815511487794" CI_START="1.3387608045442079" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="11.136288158016" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.02" NO="2" P_CHI2="0.9731375802234453" P_Q="1.0" P_Z="0.025895269370531142" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="209" TOTAL_2="202" UNITS="" WEIGHT="100.0" Z="2.2277787980287576">
<NAME>Morning PEF (L/min) change baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5037226311746014" CI_END="20.933815511487794" CI_START="1.3387608045442079" DF="4.0" EFFECT_SIZE="11.136288158016" ESTIMABLE="YES" I2="0.0" ID="CMP-017.02.01" NO="1" P_CHI2="0.9731375802234453" P_Z="0.025895269370531142" STUDIES="5" TAU2="0.0" TOTAL_1="209" TOTAL_2="202" WEIGHT="100.0" Z="2.2277787980287576">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="45.09887700374776" CI_START="-13.098877003747763" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="20.0" ORDER="4890" SD_1="37.0" SD_2="14.1" SE="14.846638628707462" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="11.33653965800383"/>
<CONT_DATA CI_END="34.60004411485052" CI_START="-12.600044114850519" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="36.0" ORDER="4891" SD_1="55.48" SD_2="45.25" SE="12.041060091412216" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="17.2348433234299"/>
<CONT_DATA CI_END="27.868123256247863" CI_START="-11.868123256247863" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="45.0" ORDER="4892" SD_1="46.0" SD_2="60.0" SE="10.136983849175333" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="24.3175197993566"/>
<CONT_DATA CI_END="32.84374715781936" CI_START="-22.843747157819358" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="29.0" ORDER="4893" SD_1="49.3" SD_2="60.2" SE="14.206254491127021" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="12.381623860886464"/>
<CONT_DATA CI_END="30.62521941892898" CI_START="-2.6252194189289817" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="31.0" ORDER="4894" SD_1="53.3" SD_2="52.3" SE="8.482410671862642" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="34.72947335832321"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-017.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.477981893132649" CI_END="14.752780494942527" CI_START="-6.162564258825797" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.295108118058365" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.03" NO="3" P_CHI2="0.477595685290381" P_Q="1.0" P_Z="0.42082901508280557" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="123" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="0.804983835572042">
<NAME>Evening PEF (L/min) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.477981893132649" CI_END="14.752780494942527" CI_START="-6.162564258825797" DF="2.0" EFFECT_SIZE="4.295108118058365" ESTIMABLE="YES" I2="0.0" ID="CMP-017.03.01" NO="1" P_CHI2="0.477595685290381" P_Z="0.42082901508280557" STUDIES="3" TAU2="0.0" TOTAL_1="123" TOTAL_2="118" WEIGHT="100.0" Z="0.804983835572042">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="17.071234070417596" CI_START="-19.071234070417596" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.0" ORDER="4895" SD_1="36.99" SD_2="39.6" SE="9.220186805962346" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="33.48840331538059"/>
<CONT_DATA CI_END="18.814036787541017" CI_START="-18.814036787541017" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="41.0" MEAN_2="41.0" ORDER="4896" SD_1="42.0" SD_2="58.0" SE="9.599174748078912" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="30.8962724445258"/>
<CONT_DATA CI_END="30.523327618696882" CI_START="-4.523327618696882" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="29.0" MEAN_2="16.0" ORDER="4897" SD_1="43.8" SD_2="21.9" SE="8.9406375611586" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="35.61532424009362"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-017.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" I2_Q="0.0" ID="CMP-017.04" NO="4" P_CHI2="0.2996611106850058" P_Q="1.0" P_Z="0.12015294096517" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="64" UNITS="" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>PEF Diurnal Variation change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.075703579661066" CI_END="0.0729584126357623" CI_START="-0.6317462712233379" DF="1.0" EFFECT_SIZE="-0.2793939292937878" ESTIMABLE="YES" I2="7.037587407203635" ID="CMP-017.04.01" NO="1" P_CHI2="0.2996611106850058" P_Z="0.12015294096517" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="64" WEIGHT="100.0" Z="1.5541319689154867">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.25578014000653204" CI_START="-1.8833514573756898" EFFECT_SIZE="-0.8137856586845789" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-1.4" ORDER="4898" SD_1="3.97" SD_2="3.68" SE="0.5457068635585701" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="10.852737797516065"/>
<CONT_DATA CI_END="0.1588467426680976" CI_START="-0.5875215012691248" EFFECT_SIZE="-0.21433737930051364" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-4.0" ORDER="4899" SD_1="27.0" SD_2="37.0" SE="0.19040356093899682" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="55" TOTAL_2="56" WEIGHT="89.14726220248393"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-017.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.975259928265272" CI_END="0.13224825732538276" CI_START="-0.21047048014087072" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.039111111407743995" ESTIMABLE="YES" I2="83.26432637232037" I2_Q="0.0" ID="CMP-017.05" NO="5" P_CHI2="0.014507992318637974" P_Q="1.0" P_Z="0.6546276125075663" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="0.44734274128831386">
<NAME>Symptom Score change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.975259928265272" CI_END="0.13224825732538276" CI_START="-0.21047048014087072" DF="1.0" EFFECT_SIZE="-0.039111111407743995" ESTIMABLE="YES" I2="83.26432637232037" ID="CMP-017.05.01" NO="1" P_CHI2="0.014507992318637974" P_Z="0.6546276125075663" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="38" WEIGHT="100.0" Z="0.44734274128831386">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="-0.1430767548112396" CI_START="-1.2569232451887604" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.4" ORDER="4900" SD_1="0.53" SD_2="0.57" SE="0.2841497341694541" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="9.467275535307396"/>
<CONT_DATA CI_END="0.21009641115078911" CI_START="-0.15009641115078912" EFFECT_SIZE="0.03" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.23" ORDER="4901" SD_1="0.33" SD_2="0.38" SE="0.0918876125129679" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="90.5327244646926"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-017.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.001652262246133" CI_END="-0.05962694869083568" CI_START="-0.5279432585579156" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.29378510362437565" ESTIMABLE="YES" I2="0.08254491937968925" I2_Q="0.0" ID="CMP-017.06" NO="6" P_CHI2="0.36757576228425937" P_Q="1.0" P_Z="0.013930254474781564" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="147" TOTAL_2="138" UNITS="" WEIGHT="100.0" Z="2.4590568817113074">
<NAME>Symptom (Night Waking) change from baseline</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.001652262246133" CI_END="-0.05962694869083568" CI_START="-0.5279432585579156" DF="2.0" EFFECT_SIZE="-0.29378510362437565" ESTIMABLE="YES" I2="0.08254491937968925" ID="CMP-017.06.01" NO="1" P_CHI2="0.36757576228425937" P_Z="0.013930254474781564" STUDIES="3" TAU2="0.0" TOTAL_1="147" TOTAL_2="138" WEIGHT="100.0" Z="2.4590568817113074">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.4702516451262082" CI_START="-0.4702516451262082" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.4" ORDER="4902" SD_1="0.62" SD_2="0.57" SE="0.23992871748434827" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" WEIGHT="24.794646886093393"/>
<CONT_DATA CI_END="0.10123416745845132" CI_START="-0.9222319568228723" EFFECT_SIZE="-0.4104988946822105" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="-0.01" ORDER="4903" SD_1="0.16" SD_2="0.22" SE="0.2610930946574258" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.93782767302575"/>
<CONT_DATA CI_END="-0.06512079875216148" CI_START="-0.7008457743231314" EFFECT_SIZE="-0.38298328653764646" ESTIMABLE="YES" MEAN_1="-0.22" MEAN_2="-0.1" ORDER="4904" SD_1="0.27" SD_2="0.35" SE="0.16217771871970288" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="54.26752544088087"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-017.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03982061266901365" CI_END="0.2757419795110977" CI_START="-0.9762891845804921" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3502736025346972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.07" NO="7" P_CHI2="0.9979116736366878" P_Q="1.0" P_Z="0.27279188348267214" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="234" UNITS="" WEIGHT="100.0" Z="1.0966558427500661">
<NAME>Rescue Medications (n0. of puffs change baseline</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.03982061266901365" CI_END="0.2757419795110977" CI_START="-0.9762891845804921" DF="3.0" EFFECT_SIZE="-0.3502736025346972" ESTIMABLE="YES" I2="0.0" ID="CMP-017.07.01" NO="1" P_CHI2="0.9979116736366878" P_Z="0.27279188348267214" STUDIES="4" TAU2="0.0" TOTAL_1="233" TOTAL_2="234" WEIGHT="100.0" Z="1.0966558427500661">
<NAME>&lt; = 12 weeks</NAME>
<CONT_DATA CI_END="0.43031635091716447" CI_START="-1.2303163509171644" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.5" ORDER="4905" SD_1="0.79" SD_2="0.85" SE="0.4236385757425105" STUDY_ID="STD-Jatakanon-1999" TOTAL_1="7" TOTAL_2="8" WEIGHT="56.843800422214244"/>
<CONT_DATA CI_END="2.645586625714369" CI_START="-3.2855866257143687" EFFECT_SIZE="-0.31999999999999995" ESTIMABLE="YES" MEAN_1="-0.88" MEAN_2="-0.56" ORDER="4906" SD_1="2.16" SD_2="16.43" SE="1.5130822041152479" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" WEIGHT="4.456039764631482"/>
<CONT_DATA CI_END="3.7765170490521847" CI_START="-4.696517049052185" EFFECT_SIZE="-0.45999999999999985" ESTIMABLE="YES" MEAN_1="-1.39" MEAN_2="-0.93" ORDER="4907" SD_1="11.7" SD_2="1.81" SE="2.1615280089171485" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="2.1834958439488927"/>
<CONT_DATA CI_END="0.7659519106797645" CI_START="-1.3059519106797646" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="-1.85" MEAN_2="-1.58" ORDER="4908" SD_1="2.8" SD_2="3.7" SE="0.528556605555623" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" WEIGHT="36.516663969205375"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-017.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.39840228821690266" CI_END="2.4643517225494174" CI_START="0.40946152387386703" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0045183978784429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-017.08" LOG_CI_END="0.39170269223476323" LOG_CI_START="-0.3877869016064639" LOG_EFFECT_SIZE="0.0019578953141497087" METHOD="MH" NO="8" P_CHI2="0.8193851354593066" P_Q="0.0" P_Z="0.9921442025631493" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="260" TOTAL_2="263" WEIGHT="99.99999999999999" Z="0.009845941065929866">
<NAME>Withdrawal due to Adverse Event</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.39840228821690266" CI_END="2.4643517225494174" CI_START="0.40946152387386703" DF="2.0" EFFECT_SIZE="1.0045183978784429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-017.08.01" LOG_CI_END="0.39170269223476323" LOG_CI_START="-0.3877869016064639" LOG_EFFECT_SIZE="0.0019578953141497087" NO="1" P_CHI2="0.8193851354593066" P_Z="0.9921442025631493" STUDIES="3" TAU2="0.0" TOTAL_1="260" TOTAL_2="263" WEIGHT="99.99999999999999" Z="0.009845941065929866">
<NAME>&lt; = 12 weeks</NAME>
<DICH_DATA CI_END="4.7170692818842355" CI_START="0.3670291521278234" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6736722549862264" LOG_CI_START="-0.4352994395478091" LOG_EFFECT_SIZE="0.11918640771920867" ORDER="4909" O_E="0.0" SE="0.6514154628677139" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4243421052631579" WEIGHT="43.26708271478604"/>
<DICH_DATA CI_END="3.0272483504348244" CI_START="0.16428804782167156" EFFECT_SIZE="0.7052238805970149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.481048051217256" LOG_CI_START="-0.7843940309283454" LOG_EFFECT_SIZE="-0.1516729898555447" ORDER="4910" O_E="0.0" SE="0.743326943091658" STUDY_ID="STD-Miyamoto-2000" TOTAL_1="67" TOTAL_2="63" VAR="0.552534944325989" WEIGHT="45.77201908248417"/>
<DICH_DATA CI_END="16.206354283559662" CI_START="0.06490907795006694" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096853286913705" LOG_CI_START="-1.1876945600884439" LOG_EFFECT_SIZE="0.010995384301463145" ORDER="4911" O_E="0.0" SE="1.4082328138911044" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="1.9831196581196582" WEIGHT="10.960898202729775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt;12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5183178956499688" CI_END="1.1708833067993532" CI_START="0.9305743803910735" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0438361977509016" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="148" I2="0.0" I2_Q="0.0" ID="CMP-017.09" LOG_CI_END="0.06851361433927847" LOG_CI_START="-0.03124890818352177" LOG_EFFECT_SIZE="0.018632353077878375" METHOD="MH" NO="9" P_CHI2="0.7717003656253315" P_Q="0.0" P_Z="0.4640993465234754" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="261" TOTAL_2="262" WEIGHT="100.0" Z="0.732113424087276">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5183178956499688" CI_END="1.1708833067993532" CI_START="0.9305743803910735" DF="2.0" EFFECT_SIZE="1.0438361977509016" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="148" I2="0.0" ID="CMP-017.09.01" LOG_CI_END="0.06851361433927847" LOG_CI_START="-0.03124890818352177" LOG_EFFECT_SIZE="0.018632353077878375" NO="1" P_CHI2="0.7717003656253315" P_Z="0.4640993465234754" STUDIES="4" TAU2="0.0" TOTAL_1="261" TOTAL_2="262" WEIGHT="100.0" Z="0.732113424087276">
<NAME>&lt; = 12 weeks</NAME>
<DICH_DATA CI_END="1.2421247758921332" CI_START="0.9205903412664099" EFFECT_SIZE="1.0693400167084377" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="63" LOG_CI_END="0.09416522447145745" LOG_CI_START="-0.03593358598854208" LOG_EFFECT_SIZE="0.029115819241457678" ORDER="4912" O_E="0.0" SE="0.07642068526370178" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.005840121136173767" WEIGHT="42.240611075747935"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4913" O_E="0.0" SE="0.0" STUDY_ID="STD-Lorentzson-1990" TOTAL_1="38" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.195031195519736" CI_START="0.8594272876174881" EFFECT_SIZE="1.0134310134310134" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="84" LOG_CI_END="0.07737924240988739" LOG_CI_START="-0.0657908611785766" LOG_EFFECT_SIZE="0.005794190615655409" ORDER="4914" O_E="0.0" SE="0.08409882755130633" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.007072612795504361" WEIGHT="57.07125866863212"/>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="4915" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Noonan-1998" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="0.6881302556199538"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.907967776753731" CI_END="2.3857048546202426" CI_START="0.34106425463937723" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.902041378225299" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="74.4112526733606" I2_Q="0.0" ID="CMP-017.10" LOG_CI_END="0.3776167142973157" LOG_CI_START="-0.46716379459536894" LOG_EFFECT_SIZE="-0.04477354014902663" METHOD="MH" NO="10" P_CHI2="0.04805773694647619" P_Q="0.0" P_Z="0.8354187201061429" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.2077569859358535">
<NAME>Oral Candidiasis</NAME>
<GROUP_LABEL_1>Mod Dose ICS</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose ICS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.907967776753731" CI_END="2.3857048546202426" CI_START="0.34106425463937723" DF="1.0" EFFECT_SIZE="0.902041378225299" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="74.4112526733606" ID="CMP-017.10.01" LOG_CI_END="0.3776167142973157" LOG_CI_START="-0.46716379459536894" LOG_EFFECT_SIZE="-0.04477354014902663" NO="1" P_CHI2="0.04805773694647619" P_Z="0.8354187201061429" STUDIES="2" TAU2="0.0" TOTAL_1="155" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.2077569859358535">
<NAME>&lt; = 12 weeks</NAME>
<DICH_DATA CI_END="1.4328858780172062" CI_START="0.10874360401321813" EFFECT_SIZE="0.39473684210526316" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.15621160245523724" LOG_CI_START="-0.9635962775774951" LOG_EFFECT_SIZE="-0.40369233756112893" ORDER="4916" O_E="0.0" SE="0.6577806918696316" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.4326754385964912" WEIGHT="93.86406544996852"/>
<DICH_DATA CI_END="158.21294703008422" CI_START="0.4742905537037454" EFFECT_SIZE="8.6625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1992420202087515" LOG_CI_START="-0.32395552496902535" LOG_EFFECT_SIZE="0.9376432476198632" ORDER="4917" O_E="0.0" SE="1.4821387280667113" STUDY_ID="STD-Sheffer-1996" TOTAL_1="79" TOTAL_2="76" VAR="2.196735209235209" WEIGHT="6.1359345500314655"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5703993490512858" CI_END="1.426180986805702" CI_START="0.472745362488104" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8211092787084454" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-017.11" LOG_CI_END="0.15417464233450784" LOG_CI_START="-0.3253727227805531" LOG_EFFECT_SIZE="-0.08559904022302264" METHOD="MH" NO="11" P_CHI2="0.45010038935989527" P_Q="0.0" P_Z="0.4841110596104947" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0" Z="0.6997057982294007">
<NAME>Exacerbations</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Mod Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Low Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5703993490512858" CI_END="1.426180986805702" CI_START="0.472745362488104" DF="1.0" EFFECT_SIZE="0.8211092787084454" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" ID="CMP-017.11.01" LOG_CI_END="0.15417464233450784" LOG_CI_START="-0.3253727227805531" LOG_EFFECT_SIZE="-0.08559904022302264" NO="1" P_CHI2="0.45010038935989527" P_Z="0.4841110596104947" STUDIES="2" TAU2="0.0" TOTAL_1="193" TOTAL_2="200" WEIGHT="100.0" Z="0.6997057982294007">
<NAME>&lt; = 12 weeks</NAME>
<DICH_DATA CI_END="1.347580365927445" CI_START="0.4195097349554893" EFFECT_SIZE="0.7518796992481203" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.1295546747404524" LOG_CI_START="-0.37725795667462403" LOG_EFFECT_SIZE="-0.12385164096708583" ORDER="4918" O_E="0.0" SE="0.2977042484562022" STUDY_ID="STD-Bisgaard-1999" TOTAL_1="76" TOTAL_2="80" VAR="0.08862781954887218" WEIGHT="91.19868067008072"/>
<DICH_DATA CI_END="9.040938856995785" CI_START="0.2617940396194572" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9562135321613053" LOG_CI_START="-0.5820402454470163" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="4919" O_E="0.0" SE="0.9035778834461319" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.8164529914529914" WEIGHT="8.801319329919279"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt; 12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17122975367256682" CI_END="1.2712187758150482" CI_START="0.29980616043983177" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6173485403369258" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-017.12" LOG_CI_END="0.104220298746719" LOG_CI_START="-0.5231594474799434" LOG_EFFECT_SIZE="-0.2094695743666122" METHOD="MH" NO="12" P_CHI2="0.6790214714162608" P_Q="0.0" P_Z="0.19060695065167968" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="1.308785704622247">
<NAME>Plasma Cortisol below reference range</NAME>
<GROUP_LABEL_1>Mod Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Low Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Mod Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.17122975367256682" CI_END="1.2712187758150482" CI_START="0.29980616043983177" DF="1.0" EFFECT_SIZE="0.6173485403369258" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" ID="CMP-017.12.01" LOG_CI_END="0.104220298746719" LOG_CI_START="-0.5231594474799434" LOG_EFFECT_SIZE="-0.2094695743666122" NO="1" P_CHI2="0.6790214714162608" P_Z="0.19060695065167968" STUDIES="2" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="1.308785704622247">
<NAME>&lt; = 12 weeks</NAME>
<DICH_DATA CI_END="1.6119451793392634" CI_START="0.2900400575958283" EFFECT_SIZE="0.6837606837606838" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2073502677945705" LOG_CI_START="-0.5375420173030067" LOG_EFFECT_SIZE="-0.16509587475421805" ORDER="4920" O_E="0.0" SE="0.4375534155425957" STUDY_ID="STD-Nayak-2002" TOTAL_1="117" TOTAL_2="120" VAR="0.19145299145299144" WEIGHT="66.10861148896096"/>
<DICH_DATA CI_END="1.8840158732341865" CI_START="0.12630127082724826" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27508455749559363" LOG_CI_START="-0.8985922796071022" LOG_EFFECT_SIZE="-0.3117538610557543" ORDER="4921" O_E="0.0" SE="0.6894235839081664" STUDY_ID="STD-Wasserman-1996" TOTAL_1="82" TOTAL_2="80" VAR="0.47530487804878047" WEIGHT="33.89138851103903"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-017.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>&gt;12 weeks</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>